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Abstract
Combined tumour treatment by coupling conventional radiotherapy to an
additional dose contribution from thermal neutrons
by Katia ALIKANIOTIS
iv
Aim: To employ the thermal neutron background in conventional X-rays radiother-
apy treatments in order to add a localized neutron dose boost to the patient, enhanc-
ing the treatment effectiveness.
Background: Conventional linear accelerators for radiotherapy produce fast secondary
neutrons with a mean energy of about 1 MeV due to (g, n) reaction. This neutron
field, isotropically distributed, is considered as an extra unaccounted dose during
the treatment. Moreover, considering the moderating effect of human body, a ther-
mal neutron field is localized in the tumour area: this neutron background could be
employed for Boron Neutron Capture Therapy (BNCT) by previously administering
a boron (10B enriched) carrier to the patient, acting as a localized radiosensitizer. The
thermal neutron absorption in the 10B enriched tissue will improve radiotherapy ef-
fectiveness.
Materials and Methods: The feasibility of the proposed method was investigated by
using simplified tissue-equivalent phantoms with cavities in correspondence of rele-
vant tissues or organs, suited for dosimetric measurements. A 10 cm⇥ 10 cm square
photon field with different energies was delivered to the phantoms. Additional ex-
posures were implemented, using a compact neutron photo-converter-moderator
assembly, with the purpose of modifying the mixed photon-neutron field in the
treatment region. Doses due to photons and neutrons were both measured by using
radiochromic films and superheated bubble detectors, respectively, and simulated
with Monte Carlo codes.
Results: For a 10 cm ⇥ 10 cm square photon field with accelerating potentials 6
MV, 10 MV and 15 MV, the neutron dose equivalent in phantom was measured and
its values was 0.07 mGy/Gy (neutron dose equivalent / photon absorbed dose at
isocentre), 0.99 mGy/Gy and 2.22 mGy/Gy, respectively.
For a 18 MV treatment, simulations and measurements quantified the thermal neu-
tron field in the treatment zone in 1.55 ⇥ 107 cm 2 Gy 1. Assuming a BNCT-
standard 10B concentration in tumour tissue, the calculated additional BNCT dose at
4 cm depth in phantom would be 1.5 mGy-eq/Gy. This ratio would reach 43 mGy-
eq/Gy for an intensity modulated radiotherapy treatment (IMRT).
When a specifically designed compact neutron photo-converter-moderator assem-
bly is applied to the LINAC to enhance the thermal neutron field, the photon field is
modified. Particularly, a 15 MV photon field produces a dose profile very similar to
that would be produced by a 6MVfield in absence of the photo-converter-moderator
assembly. As far as the thermal neutron field is concerned, more thermal neutrons
are present, and thermal neutrons per photon increase of a factor 3 to 12 according to
the depth in phantom and to different photoconverter geometries. By contrast, the
photo-converter-moderator assembly was found to reduce fast neutrons of a factor
16 in the direction of the incident beam.
Conclusions: The parasitic thermal neutron component during conventional high-
energy radiotherapy could be exploited to produce additional therapeutic doses if
the 10B-carrier was administered to the patient. This radiosensitization effect could
be increased by modifying the treatment field by using the specifically designed
neutron photo-converter-moderator assembly.
vAcknowledgements
A conclusione di questo ciclo di studi di Dottorato sento il dovere e il piacere di
ringraziare tutti coloro che mi hanno sostenuto e accompagnato durante questo per-
corso con i loro consigli, la loro saggezza e il loro affetto.
Il mio supervisore per avermi dato la possibilita’ e la spinta di condurre un per-
corso di studi e ricerca in proseguimento agli anni di laurea.
Il mio co-supervisore per essere stato anche un amico, dandomi consigli quando
credevo di non farcela.
La dottoressaMara Severgnini, sempre gentile e disponibile nel permettermi di effet-
tuare le misure sperimentali in ospedale anche dopo l’orario lavorativo o di sabato.
Lo staff dell’officina, non solo per aver contribuito alla realizzazione della parte sper-
imentale del lavoro, ma anche per le lunghe chiaccherate e il fatto di esserci quando
avevo bisogno di aiuto nella vita quotidiana. Soprattutto grazie a Stefano e la moglie
Elena, che sono diventati i miei genitori triestini.
Non potro’ mai dimenticare gli appuntamenti del mercoledi’ a pranzo all’ICTP e
quelli del giovedi’ in Area di Ricerca con tutti i miei colleghi-amici.
Un grazie speciale a Laura, che e’ stata con me ogni giorno in questi tre anni, e a
Valeria, che dalla laurea magistrale rimane la mia compagna di viaggi di studio e la-
voro, ai miei amici della piscina e della ginnastica per lo svago serale post-lavorativo,
in particolare a Chiaretta con cui si e’ creato un forte legame.
...mi avete ben accolto a Trieste e fatto sentire in famiglia.
Grazie alla mia famiglia che continua a credere in me, a sostenermi in ogni mia
decisione e a starmi vicino.
Infine, vorrei ringraziare anche i miei revisori, che con molto impegno e dedizione
hanno letto ogni singola parola scritta in questa lunga tesi.
Grazie di cuore a tutti,
Katia

vii
Contents
Abstract iv
Acknowledgements v
Introduction i
1 Cancer treatment techniques 1
1.1 Types of cancer treatment . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.1 Radiation modalities . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.1.2 Treatment techniques . . . . . . . . . . . . . . . . . . . . . . . . . 3
Radiotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Hadrontherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
2 Elements of Radiobiology and Dosimetry 5
2.1 Introductory remarks on the interactions of ionizing particles with
matter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.2 Radiobiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.2.1 The cell cycle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.2.2 Ionizing radiation and biological organisms . . . . . . . . . . . 8
2.2.3 Radiation damage to DNA . . . . . . . . . . . . . . . . . . . . . 9
2.2.4 Linear energy transfer and relative biological effectiveness . . . 11
2.2.5 Fractionation of radiation dose . . . . . . . . . . . . . . . . . . . 12
2.3 Radiation-induced effects . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.3.1 Deterministic and stochastic effects . . . . . . . . . . . . . . . . 14
2.3.2 Equivalent and effective dose . . . . . . . . . . . . . . . . . . . . 15
Equivalent dose and dose equivalent . . . . . . . . . . . . . . . 16
3 Electron linear accelerators for radiotherapy 19
3.1 Principles of linear accelerators . . . . . . . . . . . . . . . . . . . . . . . 19
3.1.1 Components of modern LINACs . . . . . . . . . . . . . . . . . . 20
3.1.2 The LINAC treatment head . . . . . . . . . . . . . . . . . . . . . 24
3.2 Radiation treatment parameters . . . . . . . . . . . . . . . . . . . . . . . 27
3.2.1 Central axis depth doses: source to surface distance set-up . . . 27
Percentage depth dose . . . . . . . . . . . . . . . . . . . . . . . . 27
Tissue-phantom ratio or tissue-maximum ratio . . . . . . . . . . 27
Relationship between TPR and PDD . . . . . . . . . . . . . . . . 29
4 Neutron contamination from medical accelerators 31
4.1 General aspects of photon interactions with matter . . . . . . . . . . . . 31
4.1.1 Classification of photon interactions with absorber atoms . . . . 32
4.2 Photonuclear reactions (Photodisintegration) . . . . . . . . . . . . . . . 36
Cross section and threshold energy for photonuclear reaction . 36
4.3 Interactions of neutrons with matter . . . . . . . . . . . . . . . . . . . . 39
viii
4.3.1 General aspects of neutron interactions with absorbers . . . . . 39
4.3.2 Neutron interactions with nuclei of the absorber . . . . . . . . . 40
Elastic scattering . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
Inelastic scattering . . . . . . . . . . . . . . . . . . . . . . . . . . 42
Neutron capture . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Spallation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
4.4 Neutron dosimetry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
4.4.1 Neutron riskiness for human tissues and organs . . . . . . . . . 43
4.4.2 Characteristics of neutron dosimeters . . . . . . . . . . . . . . . 45
4.5 Neutron photoproduction consequences . . . . . . . . . . . . . . . . . . 46
4.5.1 Unaccounted neutron dose during radiotherapy . . . . . . . . . 46
4.5.2 Relationship between monitor units and unaccounted neutron
dose . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
5 The Boron Neutron Capture Therapy 49
5.1 Therapy of the neutron capture on boron-10 . . . . . . . . . . . . . . . . 49
The nuclear reaction . . . . . . . . . . . . . . . . . . . . . . . . . 49
Radiobiological considerations . . . . . . . . . . . . . . . . . . . 51
Boron delivery agents . . . . . . . . . . . . . . . . . . . . . . . . 52
5.2 Overview of BNCT dosimetry . . . . . . . . . . . . . . . . . . . . . . . . 52
5.2.1 Dose components . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
5.2.2 Dose calculation . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
5.3 Considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
6 Radiosensitizers in the treatment of cancer 57
6.1 Combining two agents together: additivity and synergy . . . . . . . . . 58
6.2 Drugs and radiation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
6.2.1 BNCT as radiosensitizer in radiotherapy . . . . . . . . . . . . . 61
7 Materials:
The experimental detection system 63
7.1 Gafchromic EBT3 films . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
7.1.1 Description . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
7.1.2 Principle of operation and use . . . . . . . . . . . . . . . . . . . 65
7.1.3 Calibration and sensitivity . . . . . . . . . . . . . . . . . . . . . . 65
7.2 Superheated Drop (Bubble) detectors . . . . . . . . . . . . . . . . . . . . 67
7.2.1 Description . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
7.2.2 Principle of operation and use . . . . . . . . . . . . . . . . . . . 68
7.2.3 Calibration and sensitivity . . . . . . . . . . . . . . . . . . . . . . 69
7.2.4 Longevity of bubble dosimeters . . . . . . . . . . . . . . . . . . 70
7.3 The anthropomorphic phantoms . . . . . . . . . . . . . . . . . . . . . . 70
7.3.1 The Trieste anthropomorphic phantom . . . . . . . . . . . . . . 70
7.3.2 The Torino anthropomorphic phantom . . . . . . . . . . . . . . 76
8 Simulation methods: the Monte Carlo codes 81
8.1 Monte Carlo simulations: the MCNP4B code . . . . . . . . . . . . . . . 82
8.1.1 The MCNP4B-GN code . . . . . . . . . . . . . . . . . . . . . . . 83
Evaporation model . . . . . . . . . . . . . . . . . . . . . . . . . . 83
Direct model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
Photonuclear reactions on light elements . . . . . . . . . . . . . 85
8.2 Monte Carlo simulations: the GEANT4 code . . . . . . . . . . . . . . . 87
ix
8.2.1 How to built a GEANT4 input file . . . . . . . . . . . . . . . . . 87
1. Detector construction . . . . . . . . . . . . . . . . . . . . . . . 88
2. Physics implementation . . . . . . . . . . . . . . . . . . . . . . 90
3. Primary generator action . . . . . . . . . . . . . . . . . . . . . 90
9 PART 1:
Measurements of the secondary neutron radiation in radiotherapy 91
9.1 Materials and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
The experimental method . . . . . . . . . . . . . . . . . . . . . . 92
9.2 Results and discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
The patient surface plane neutron dose equivalent . . . . . . . . 92
The parasitic neutron dose equivalent at organs . . . . . . . . . 93
9.3 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
10 PART 2:
The BNCT contribution in radiotherapy 99
10.1 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
10.1.1 Simulation of the experimental set-up . . . . . . . . . . . . . . . 100
The 18 MV Varian 2300CD LINAC . . . . . . . . . . . . . . . . . 100
The Torino anthropomorphic phantom . . . . . . . . . . . . . . 102
10.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
Neutron spectrum at patient plane . . . . . . . . . . . . . . . . . 104
Neutron spectrum in depth in tissue . . . . . . . . . . . . . . . . 105
Neutron equivalent dose at organs . . . . . . . . . . . . . . . . . 107
The additional BNCT equivalent dose . . . . . . . . . . . . . . . 107
10.3 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
11 PART 3:
Development of a compact neutron photo-converter-moderator 111
11.1 Performance of the neutron photo-converter-moderator assembly . . . 111
11.1.1 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . 112
11.1.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
The photon absorbed dose in depth in phantom . . . . . . . . . 113
The neutron dose equivalent in depth in phantom . . . . . . . . 116
11.2 The angular neutron dose distribution . . . . . . . . . . . . . . . . . . . 117
11.2.1 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . 117
11.2.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
11.3 GEANT4 simulations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
11.3.1 Simulation of the experimental set-up . . . . . . . . . . . . . . . 121
The 15 MV Elekta Synergy Agility LINAC . . . . . . . . . . . . 121
The photo-converter-moderator . . . . . . . . . . . . . . . . . . 122
The simplified phantom . . . . . . . . . . . . . . . . . . . . . . . 122
11.3.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
1. Simulation of the X-ray energy spectrum . . . . . . . . . . . . 123
2. Simulation of the neutron dose equivalent in depth in phan-
tom and comparison with experimental results . . . . 124
11.4 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
12 Conclusions 129
A Superheated Drop (Bubble) detectors: Features provided by BTI 131
xB New RGB algorithm for dose measurements with EBT3 films tested in 15
MV X-ray beams 135
C MCNP: Variance reduction techniques 143
Bibliography 145
xi
List of Figures
1.1 Characteristic percentage depth dose curves (PDD) of different types
of radiation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.2 Illustration of the differences between different radiotherapy beams . . 4
2.1 Schematic of the cell cycle . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.2 Direct and indirect action of radiation . . . . . . . . . . . . . . . . . . . 9
2.3 Schematic representation of several types of DNA damage . . . . . . . 10
2.4 Microscopic energy deposition pattern of charged particles . . . . . . . 11
2.5 LET vs RBE in cell killing . . . . . . . . . . . . . . . . . . . . . . . . . . 13
2.6 Schematic illustration of different possible extrapolations of stochastic
effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
3.1 Electron-beam depth-dose curves . . . . . . . . . . . . . . . . . . . . . . 21
3.2 Design configurations for isocentric medical LINACs in photon mode 21
3.3 Schematic representation of a typical medical linear accelerator . . . . 22
3.4 Schematic representation of a typical LINAC head operating in pho-
ton mode . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
3.5 Detail of the multileaf collimator. . . . . . . . . . . . . . . . . . . . . . . 26
3.6 Reference parameters used in radiotherapy . . . . . . . . . . . . . . . . 26
3.7 Geometry for PDD measurement and definition. . . . . . . . . . . . . . 28
3.8 PDD curves in water for various megavoltage photon beams . . . . . . 28
3.9 Geometry for the measurement of TPR . . . . . . . . . . . . . . . . . . . 29
3.10 Geometry for derivation of the relationship between PDD and TPR . . 30
4.1 Representation of the relative predominance of the three main pro-
cesses of photon interaction with absorber atom . . . . . . . . . . . . . 35
4.2 Cross sections of the different types of radiation interaction with mat-
ter for Pb-208 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
4.3 Electric dipole oscillation of the nucleus . . . . . . . . . . . . . . . . . . 37
4.4 Cross section of the photoneutron production reaction or two differ-
ent nuclides, with high and low atomic number. . . . . . . . . . . . . . 38
4.5 Schematic diagram of an elastic collision . . . . . . . . . . . . . . . . . . 41
4.6 Cross section both of elastic scattering on hydrogen and of radiative
capture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
5.1 Nuclear reaction in BNCT . . . . . . . . . . . . . . . . . . . . . . . . . . 50
5.2 Schematic representation of the boron fission reaction inside the cell . 51
6.1 The effect of combining two cytotoxic agents together . . . . . . . . . . 58
6.2 Possibile outcomes of drug treatment on the relationship between the
radiation dose and cell survival . . . . . . . . . . . . . . . . . . . . . . . 59
6.3 Radiotherapy plus Cetuximab for locoregionally advanced head and
neck cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
xii
7.1 Gafchromic EBT3 films . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
7.2 Gafchromic EBT3 film structure . . . . . . . . . . . . . . . . . . . . . . . 64
7.3 Typical response of the Gafchromic EBT3 film . . . . . . . . . . . . . . . 66
7.4 BTI: Bubble dosimeters representation . . . . . . . . . . . . . . . . . . . 67
7.5 How a bubble detector works . . . . . . . . . . . . . . . . . . . . . . . . 68
7.6 A representation of the Trieste anthropomorphic phantom . . . . . . . 71
7.7 Study of the body proportions to build the Trireste phantom . . . . . . 72
7.8 3-D representation of the Trieste anthropomorphic phantom with its
external dimensions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
7.9 Representation of the drawer with arrays for the Trieste phantom . . . 74
7.10 Front and back projection of the human body . . . . . . . . . . . . . . . 75
7.11 Representation of the Torino anthropomorphic phantom . . . . . . . . 77
7.12 The reference system for determining the organ positions in the Torino
anthropomorphic phantom . . . . . . . . . . . . . . . . . . . . . . . . . 77
8.1 Fraction of neutrons emitted by the direct process as a function of the
energy available for the emission itself . . . . . . . . . . . . . . . . . . . 85
8.2 Block diagram representing the relationships between action classes
in GEANT4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
8.3 The geometry management in GEANT4 . . . . . . . . . . . . . . . . . . 89
8.4 Block diagram representing the sensitive detector classes in GEANT4 . 89
9.1 The Trieste anthropomorphic phantom undergoing the single-field ra-
diotherapy session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
9.2 The Trieste anthropomorphic phantom undergoing the single-field ra-
diotherapy session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
9.3 Neutron dose equivalent per 100 MU at organs for the LINAC oper-
ating at 15 MV and 10 MV . . . . . . . . . . . . . . . . . . . . . . . . . . 95
9.4 Neutron dose equivalent per 100 MU at organs for the LINAC oper-
ating at 6 MV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
9.5 Total neutron dose equivalent per 100 MU at organs provided by a 15,
10 and 6 MV LINAC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
10.1 The Torino anthropomorphic phantom undergoing the single-field ra-
diotherapy session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
10.2 Representation of the Varian 2300 LINAChead simulated byMCNP4B-
GN code. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
10.3 Reference system for determining organs position. . . . . . . . . . . . . 102
10.4 Neutron fluence per Gy at the patient plane during a direct single-
field 18 MV radiotherapy treatment . . . . . . . . . . . . . . . . . . . . 104
10.5 Neutron fluence per Gy in tissue during a direct single-field 18 MV
radiotherapy treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
10.6 Neutron spectrum, and details of its components, at different depth
in tissue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
10.7 Fluence to dose conversion coefficients trend as a function of energy,
for different types of radiation . . . . . . . . . . . . . . . . . . . . . . . . 107
10.8 Neutron fluence per Gy and thermal neutron equivalent dose at or-
gans for the 18 MV treatment. . . . . . . . . . . . . . . . . . . . . . . . . 108
10.9 BNCT equivalent dose profiles in depth in tissue and its different
physical dose components . . . . . . . . . . . . . . . . . . . . . . . . . . 109
11.1 Plot of the photo-converter-moderator assembly . . . . . . . . . . . . . 112
xiii
11.2 Experimental set-ups for assessing the photo-converter-moderator per-
formance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
11.3 Percentage depth dose curves of the photon beam. Configuration
without the photoconverter assembly, and with the photoconverter
with 5 cm and 10 cm thick lead. . . . . . . . . . . . . . . . . . . . . . . . 115
11.4 Photon beam cross profile at different depth in phantom. Configura-
tion with the photoconverter assembly by using 10 cm thick lead. . . . 115
11.5 Ratio between thermal and fast neutrons dose equivalent, in absence
and with the photoconverter assembly. . . . . . . . . . . . . . . . . . . . 116
11.6 Thermal neutron dose equivalent per unit photon absorbed dose, in
absence and with the photoconverter . . . . . . . . . . . . . . . . . . . . 117
11.7 3-D representation of the alveolar polycarbonate structure upon the
photoconverter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
11.8 Experimental set-up for or the angular neutron dose distribution with
the photoconverter. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
11.9 Graphical representation of the angular neutron doses distribution
around the photoconverter . . . . . . . . . . . . . . . . . . . . . . . . . . 119
11.10Fast neutrons dose equivalent angular distribution. Comparison be-
tween the configuration with and without the photoconverter assem-
bly at f = 0 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
11.11Simulation plot of the experimental set-up: linac + photoconverter +
phantom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
11.12X-ray energy spectrum provided by the 15 MV Elekta Synergy Agility
LINAC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
11.13Spatial distribution of the X-ray beam incidents the photoconverter
lead block. Geant4 calculations. . . . . . . . . . . . . . . . . . . . . . . . 125
11.14Thermal and Fast neutron dose equivalent in depth in phantom, by
using the photonconverter. Simulation results. . . . . . . . . . . . . . . 126
11.15Thermal and fast neutron dose equivalent in depth in tissue, by using
the photoconverter. Comparison between experimental and simula-
tion results. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
A.1 Temperature response of BD-PND dosimeters . . . . . . . . . . . . . . 131
A.2 Dynamic range for BD-PND dosimeter - with recompression . . . . . . 132
A.3 Dynamic range for BD-PND dosimeter - without recompression . . . . 132
A.4 Energy response of BD-PND dosimeters . . . . . . . . . . . . . . . . . . 133
B.1 EBT3 dose response curves . . . . . . . . . . . . . . . . . . . . . . . . . 139
B.2 Calculated weighted absorbed dose and residuals . . . . . . . . . . . . 139

xv
List of Tables
1.1 Some radionuclides commonly used in brachyterapy . . . . . . . . . . 4
2.1 Comparison of deterministic and stochastic effects of ionizing radiation 15
2.2 Radiation weighting factors wR . . . . . . . . . . . . . . . . . . . . . . . 16
2.3 Tissue weighting factors wT . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.4 Summary of different dosimetric quantities . . . . . . . . . . . . . . . . 18
3.1 Photon beam quality: depth-dose . . . . . . . . . . . . . . . . . . . . . . 30
4.1 Photon interactions with matter . . . . . . . . . . . . . . . . . . . . . . . 33
4.2 Types of targets in photon interactions with atoms . . . . . . . . . . . . 33
4.3 Types of photon-atom interactions . . . . . . . . . . . . . . . . . . . . . 34
4.4 Release and production of charged particles in photon interactions . . 34
4.5 Photonuclear (g,n) giant resonance cross section parameters for se-
lected absorbers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
4.6 Monitor units in different kinds of radiotherapy treatments . . . . . . . 48
6.1 Mechanisms of Chemotherapy and Radiotherapy interaction . . . . . . 60
7.1 The human body versus the Trieste anthropomorphic phantom . . . . 71
7.2 External dimensions of the Trieste anthropomorphic phantom . . . . . 74
7.3 Organ positions in the Trieste anthropomorphic phantom . . . . . . . 74
7.4 Chemical composition and density ofmaterials constituting the Torino
phantom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
7.5 External dimensions of the Torino phantom . . . . . . . . . . . . . . . . 78
7.6 Organ positions in the Torino phantom . . . . . . . . . . . . . . . . . . 78
7.7 Phantoms tissue substitutes . . . . . . . . . . . . . . . . . . . . . . . . . 79
8.1 Light elements considered in the MCNP4B-GN code, photonuclear
reactions and corresponding threshold energies . . . . . . . . . . . . . 86
9.1 Patient surface plane neutron dose equivalent per 100 MU for the
LINAC operating at 15, 10 and 6 MV . . . . . . . . . . . . . . . . . . . . 93
10.1 Summary table of the Varian LINAC head components . . . . . . . . . 101
10.2 Beam parameters for the 18 MV Varian 2300CD LINAC . . . . . . . . . 102
10.3 Organs positions inside the Torino anthropomorphic phantom, fol-
lowing the simulation reference system . . . . . . . . . . . . . . . . . . 103
10.4 Elemental composition of organs according to ICRU 44 . . . . . . . . . 103
11.1 Summary table of the Elekta Synergy Agility LINAC head components 121

xvii
List of Abbreviations
3D-CRT 3 Dimensional - Conformal Radiation Therapy
BBB Blood Brain Barrier
BDT Bubble Detector for Thermal neutrons
BD-PND Bubble Detector - Personal Neutron Dosimeter
BNCT Boron Neutron Capture Therapy
BPA Boron Phenyl Alanine
BTI Bubble Technology Industries
DNA DeoxyriboNucleic Acid
DSB Double Strand Break
GDR Giant Dipole Resonance
GEANT GEometry ANd Tracking
e-LiBANS electron LiNAC Based Actively monitoredNeutron Source
ICRP International Commission on Radiological Protection
ICRU International Commission on Radiation Units and Measurements
IMRT IntensityModulated Radiation Therapy
INFN Istituto Nazionale di Fisica Nucleare (National Institute of Nuclear Physics)
LET Linear Energy Transfer
LINAC LINear ACcelerator
LNT Linear NonThreshold model
LQ Linear Quadratic model
MCNP Monte Carlo N-Particle
MLC MultiLeaf Collimator
MU Monitor Units
PDD Percentage Depth Dose
PhoNeS Photo Neutron Source
xviii
RBE Relative Biological Effectiveness
RGB Red Green Blue
ROI Region Of Interest
ROS Reactive Oxygen Species
SSB Single Strand Break
SSD Source to Surface Distance
TPR Tissue Phantom Ratio
TMR TissueMaximum Ratio
VMAT VolumetricModulatec Arc Therapy
xix
List of Symbols
Am Americium nucleus
B Boron nucleus
Be Beryllium nucleus
C Carbon nucleus
Ca Calcium nucleus
Co Cobalt nucleus
H Hydrogen nucleus
He Helium nucleus
I Iodine nucleus
Ir Iridium nucleus
Li Lithium nucleus
N Nitrogen nucleus
O Oxygen nucleus
P Phosphorus nucleus
wR Radiation weighting factor
wT Tissue weighting factor
D Absorbed dose [Gy] = [joule/kg]
E Effective dose [Sv] = [joule/kg]
HT Equivalent dose [Sv] = [joule/kg]

iIntroduction
Three are the methods to fight cancer, namely surgery, chemotherapy and radiother-
apy. Although these treatment modalities are generally used in combination, almost
two-thirds of cancer patients (that is more than 15 millions per year, worldwide) re-
ceive some form of radiation therapy during their treatment. Considering the ten
most frequent cancer pathologies (prostate, female breast, lung, colorectal, bladder,
non-Hodgkin lymphoma, skin melanoma, kidney, ovarian, and uterine), it has been
estimated that at least 50% of them are treated with radiotherapy as a part or the
totality of the treatment. Although the number of patients treated with protons or
carbon ions is increasing (from 8000 patients worldwide in 2007 to 20000 in 2016), the
conventional radiotherapy with electron linear accelerators (LINACs) still remains
the option for the large majority of these patients.
Thanks to modern treatment techniques (IMRT, tomotherapy, VMAT...), the effec-
tiveness of conventional radiotherapy improved in last two decades. However, there
are still tumours with high fatality rate. This is the case of the Glioblastoma Multi-
forme, characterized by high radioresistance and extensive hypoxia, for which only
27% of the patients are expected to survive more than two years [1]. Consequently,
the need exists for alternative treatment modalities and new radiosensitizers, "in-
tended to enhance tumour cell killing while having much less effect on normal tis-
sues" (deterministic or second cancers) [2].
BoronNeutron Capture Therapy (BNCT) is a highly selective radiotherapy [3]. BNCT
selectively targets tumour cells with high-LET (LET = Linear Energy Transfer) heavy
charged particles. The conditions to achieve this selective treatment are:
- Load the tumour tissue with a 10B-rich compound, also called tumour-seeking
compound, usually 10-Boron-Phenyl-Alanine, 10BPA.
- Expose the tissue to a thermal neutron field.
Due to the very large 10B(n, a)7Li neutron capture cross section at slow energies
(3843 barns at 0.025 eV) [4], the tumour tissue will be exposed to a field of a parti-
cles (energy 1.5 MeV) and 7Li nuclei (0.8 MeV). Owing on the short range in tissue,
comparable with the cell size, these particles selectively destroy tumour cells [5].
BNCT is usually performed at dedicated facilities like nuclear reactors or 7Li(p, n)7Be
based particle accelerators, not in conventional medical electron LINACs. Neverthe-
less, the parasitic neutron field produced in these machines (when operating at 10
MV or more) could be used to deliver a BNCT-boost to the tumour, in addition and
simultaneously, to the conventional treatment.
Photo-neutrons, produced inmedical LINACs through giant dipole resonance (GDR)
g-n reactions, are a parasitic effect in conventional radiotherapy, as they expose the
patient to an extra neutron dose, potentially leading to second cancers [6].
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The photo-neutron field, especially generated in heavy elements (such as lead, tung-
sten, iron) in the LINAC target and surrounding materials, is almost isotropically
produced at an average energy of about 1 MeV [7]. Due to the moderation effect
of the patient [8], a large fraction of these neutrons get thermalized before reaching
internal organs/tissues.
If this neutron field was adequately shaped in intensity and spatial distribution, and
a 10B-carrier was administered to the patient, an additional BNCT therapeutic dose
could be delivered in addition to the therapeutic photons. BNCT could thus act as a
localized radiosensitizer, improving the radiotherapy effectiveness.
The subject of this researchwork, developed in the framework of the INFN e-LiBANS
project, is to study this in-phantom neutron field and possible field modifications,
oriented to improve the thermal field at the tumour place. The work includes a nu-
merical part, aimed at simulating the in-phantom field and dosimetric quantities, as
well as an experimental one, where in-phantom measurements were performed by
using photon (radiochromic films) and neutron (superheated drop dosimeters) de-
tectors.
The chapters from 1 to 6 give basic elements of radiotherapy, radiobiology, BNCT,
cancer radiosensitizers, medical linear accelerators and neutron contamination in ra-
diotherapy.
Chapters 7 and 8 describes the experimental and computational framework.
Chapter 9 report neutronmeasurements performed in a radiotherapy treatment room
by using a tissue-equivalent anthropomorphic phantom.
Chapter 10 describes, via MCNP simulations, the potential BNCT dose contribution
in a direct single-field conventional radiotherapy treatment.
Chapter 11 treats the case of a simplified photon/neutron treatment, where the radi-
ation field was modified with a compact neutron photo-converter-moderator assem-
bly (device specially designed to improve the thermal field in the treatment region,
without compromising the therapeutic photon beam).
1Chapter 1
Cancer treatment techniques
The meaning of the word cancer refers to an abnormal growth of cells which tend to
proliferate in an uncontrolled way and, in some cases, to metastasize. Cancer can
involve any tissue of the body and have many different forms in each body area.
Cancer is not one disease: it is a group of more than 100 different and distinctive dis-
eases, named in different ways based on the type of cell or organ in which it starts.
Giving a brief biological introduction, in normal cells the cell cycle (2.2.1) is tightly
regulated by a number of proteins. However, if a critical number of DNAmutations
in the corresponding genes has accumulated in a single cell, these control mecha-
nisms can fail. The resulting cancer cells usually proliferate at a much higher rate
and have lost the ability to eliminate themselves by apoptosis. They take up nutri-
ents and space that normal cells need. This uncontrolled growth can damage tissues
and organs, disseminate over the entire body by formingmetastases, and finally lead
to death.
Almost every second, people (in western countries) dealt with a cancer diagnosis
during their lifetime [9]. On the one hand, this is a consequence of the increase of
life expectancy during the last century - many types of cancer are "disease of age",
since a longer life span increases the time over which random mutations in normal
stem cells can accumulate and eventually lead to carcinogenesis [10]. On the other
hand, the incidence of many cancer types is correlated with habits like smoking and
alcohol abuse or exposition to certain environmental factors (e.g., ultraviolet radia-
tion, some chemicals like asbestos...). Behind cardiovascular diseases, cancer ranks
second in the causes of death.
The main cancer treatment techniques are here described.
1.1 Types of cancer treatment
There are many types of cancer treatment, that depend on the kind of tumour and
how advanced it is.
Currently, more than 50% of cancer patients receive radiotherapy, making it one of
the three cornerstones of cancer treatment along with surgery and chemotherapy.
- Surgery: Cancer surgery removes the tumor and nearby tissue during an op-
eration. It is a localized treatment, it can thus lead to recovery when a solid
tumor is confined to a single site and anatomical area. If the tumour can be
completely removed, surgery is the unique needed treatment; otherwise, it
may be combined with chemotherapy and/or radiation therapy to increase
the possibility of a complete neoplastic cells removal.
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- Chemotherapy: It is a type of cancer treatment that uses drugs to kill cancer
cells, administered as primary treatment or together with other treatments.
In case of non-localized tumours, chemotherapy becomes the main treatment
because the drug can reach all parts of the body.
- Radiotherapy: The goal of radiotherapy treatment is to kill all tumour cells
(curative treatment) or at least reduce symptoms such as pain (palliative treat-
ment). This must go along with a tolerable level of damage to the surrounding
normal tissue, which inevitably receives some dose.
The different radiationmodalities and techniques used in radiotherapy are described
in the next sections.
1.1.1 Radiation modalities
A first classification of the different techniques used in radiotherapy can be made
according to the type of radiation (photons, charged particle, neutrons), as well as
the nature of the radiation source and its location relative to the patient:
- Teletherapy (or external beam radiation therapy): The prefix tele means far
from, that is the radiation source is well separated from the patient.
The workhorse of contemporary radiation therapy is the linear accelerator
(LINAC), in which electrons reach energies of several MeV before hit a target
and generate bremsstrahlung, which shows a pronounced dose build-up1 ef-
fect and it is only slightly attenuated by typical patient dimensions (Figure 1.1,
blue and pink curves). The distance of the source (where electrons hit the tar-
get) and the center of rotation of the LINAC (where the patient is positioned) is
usually 100 cm. By moving the target from the beam, electrons can be directly
used for the treatment of superficial regions due to their different depth dose
characteristics (Figure 1.1 red curve). With dimensions of few meters, medical
LINACs can be installed in every hospital. They have largely superseded the
60Co machines, which use large amounts of this radioisotope (Figure 1.1, green
dashed curve).
Protons can be advantageous in many cases due to the narrow maximum of
their percentage depth dose (PDD) curve2 (Figure 1.1, black curve), but require
considerably higher technical effort [11], and they are currently only available
at a few facilities worldwide. This applies even more to heavy ion therapy
(e.g., with carbon ions), which has an even sharper Bragg peak.
- Brachytherapy (or internal beam radiation therapy): In contrast, the prefix
brachy means short or close. Radioactive sources contained in a protective cap-
sule are placed either very close to or even within the tumour. Radiation can
escape from the capsule, but the radioisotope itself remains separated from the
organism. The energy of the emitted radiation is usually considerably lower
compared to teletherapy, which allows good sparing of healthy tissue. Due to
the small distances between source and irradiated tissue, dose gradients are
steeper and dose inhomogeneity is higher compared to teletherapy. Some iso-
topes commonly used in brachyterapy are given in Table 1.1.
1Build-up: The maximum point of the deposited energy as a function of distance in depth from the
patient surface.
2Percentage depth dose: it relates the absorbed dose deposited by a radiation beam into a medium as
it varies with depth along the beam axis. The dose values are divided by the maximum dose, referred
to as dmax, yielding a plot in terms of percentage of the maximum dose.
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FIGURE 1.1: Characteristic percentage depth dose (PDD) curves of
different types of radiation. Location and extent of the tumour de-
termine which type of radiation at which energy is suited best. In
addition, high LET radiation like protons, carbon ions or neutrons
can be advantageous for radiobiological reasons. Electrons have got
a short path in tissue, therefore they are used for skin tumours; X-rays
penetrate deeper, but the dose absorbed by the tissue shows a typi-
cal exponential decay as the thickness increases. Instead, for protons
and heavy ions the dose increases as the thickness increase up to the
Bragg peak, that is at the path end of the particle where the treatment
target is; after the Bragg peak the dose drops down to zero.
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Radiotherapy
Teletherapy with photon radiation from a linear accelerator, which outnumbers all
other form of radiotherapy, achieves high conformality (i.e., spatial agreement of
the high dose region and the target volume to be irradiated) by superimposition of
radiation beams from several directions.
It can be further subdivided into four different techniques:
- Conventional radiotherapy: each beamhas a simple rectangular shape (Figure
1.2a). For a long time, furthermodulation could only be achieved by additional
devices like blocks, wedges or compensators.
- 3D conformal radiotherapy (3D-CRT): The shape of each beam is adapted to
the contour of the tumor by a multileaf collimator (MLC) (Figure 1.2b). This
yields better spatial agreement of the resulting dose distributionwith the target
volume, which is called conformality.
- Intensity modulated radiotherapy (IMRT): The intensity within each beam is
modulated using MLC (figure 1.2c). This allows to achieve even better dose
conformality, also for concave and very complex target volume shapes.
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TABLE 1.1: Some radionuclides commonly used in brachyterapy.
Only the emitted g radiation can pass through the encapsulation and
generate a dose distribution to treat the patient.
Isotope Half-life time Energy Eg
T1/2 [MeV]
Co-60 5.27 y 1.173 - 1.332
Ir-192 73.82 d 0.296 - 0.612
I-125 59.41 d 0.035
FIGURE 1.2: Illustration of the differences between different ra-
diotherapy beams: (a) conventional radiotherapy beams (rectan-
gular shape, constant photon fluence), (b) conformal radiotherapy
beams (fields shaped by an MLC matching the target volume region,
constant photon fluence) and (c) intensity modulated radiotherapy
beams (IMRT, conformal fields with additional variation of photon
fluence across the field).
Hadrontherapy
Hadrontherapy is a specific type of oncological teletherapy which makes use of fast
hadrons to obtain better dose depositions when compared with the ones of X-rays
used in conventional radiotherapy. It increases the local tumour control, safeguard-
ing the surrounding healthy tissues and reducing the occurrence of late complica-
tions, thus enhancing the quality of life during and after cancer treatment.
Today only two types of hadrons are used to treat solid tumours - protons and fully
stripped carbon ions - but other hadrons such as neutrons, charged pions, alpha par-
ticles and other light ions nuclei (like lithium, oxygen, up to silicon ions) have been
either used or planned to be used for the treatment of cancer [12].
The strength of hadrontherapy lies in the unique physical and radiobiological prop-
erties of these particles, sometimes allowing to destroy radioresistant tumours.
Hadrons can penetrate the tissues with little diffusion and deposit the maximum en-
ergy just before stopping (as seen in Figure 1.1). This allows a precise definition of
the specific region to be irradiated. The peaked shape of the hadron energy deposi-
tion is called Bragg peak and it has become the symbol of hadrontherapy.
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Elements of Radiobiology and
Dosimetry
Ionizing radiation can cause considerable harm to living cells and tissues. The main
target for radiation causing biological effects is the carrier of the genetic information,
deoxyribonucleic acid (DNA), which in eukaryotic organisms it is located within the
nucleus of cells. Radiation induced DNA damage can kill cells, induce mutations
and cause carcinogenesis. Since the human body is constantly exposed to radiation
of cosmic and terrestrial origin, a variety of DNA repair mechanisms to cope with
radiation damage have evolved.
The medical use of X-rays has become the most important source of man made ra-
diation exposure, therefore the risks of ionizing radiation must be carefully assessed
and balanced against its possible benefits. This requires precise knowledge about
the biological response of different tissues to ionizing radiation, as well as the abil-
ity to conform a dose distribution inside the patient body that closely matches the
tumour, while healthy and normal tissue is spared.
This chapter addresses some fundamental physics principles required for a quanti-
tative description of these processes.
2.1 Introductory remarks on the interactions of ionizing par-
ticles with matter
This section gives some introductory remarks on the photon interactions with mat-
ter.
Typical photon energies used in X-ray imaging are on the order of about 10 keV, in
medical diagnostics of about 100 keV and in radiotherapy of few MeV. In contrast,
only few eV are usually required for ionization of the low Z elements of biological
tissues.
The energy transfer from high energy photons to matter (e.g., a patient’s body) is a
two step procedure:
1. The primary photon interactions with matter - photoelectric effect, Compton
effect and pair production - trigger secondary charged particles.
2. These are much more likely to interact with matter (per unit path length) since
they are subject to the Coulomb force and lose their kinetic energy in numerous
collision events, foremost with atomic electrons of the absorber.
In addition, the emission of secondary charged particles can produce photons again
in the form of bremsstrahlung, fluorescence and annihilation radiation.
At energies used in diagnostic radiology, the range of secondary electrons is below
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1 mm, while it can reach several cm in the MeV range used in radiotherapy. Since
the energy of high energy photons is transferred to an absorbing medium almost ex-
clusively by secondary charged particles, photon radiation is classified as indirectly
ionizing radiation. Charged particle radiation, in contrast, is called directly ionizing
radiation.
It can be assumed that the effects of radiation to a certain volume element dV of an
irradiated absorbing medium, for example, the fraction of cells killed if the medium
is living tissue, are determined by the amount of energy de deposited per mass
dm = r · dV. This leads to the definition of the absorbed dose, which is the cen-
tral quantity in radiobiology, as well as in radiotherapy:
D =
de¯
dm
=
1
r
de¯
dV
(2.1)
While the energy deposited per unit mass de/dm in a small volume is subject to sta-
tistical fluctuations due to the discrete character of photons and charged particles,
the absorbed dose is a nonstochastic quantity and it is defined as the correspond-
ing expectation value, as denoted by the bar. The unit of absorbed dose is 1 J/kg =
1 Gray [Gy], in honor of L.H. Gray, who estalbished the field of radiobiology. An
older unit is the radiation absorbed dose [rad], where 1 rad = 0.01 Gy.
Only if the range of secondary electron is negligibly small, the distribution of ab-
sorbed dose can be assumed to be proportional to the primary photon fluence. In
the MeV range used in radiotherapy, however, this is no longer possible, since sec-
ondary electrons travel macroscopic distances of several cm from the site of the pri-
mary interaction. Therefore, to calculate the dose distribution resulting from high
energy X-rays must include not only the primary interactions, but also the subse-
quent interaction of secondary charged particles and matter, as well as photons re-
sulting from the Compton effect, electron-positron annihilation, bremsstrahlung and
fluorescence.
2.2 Radiobiology
In radiotherapy and radiation protection, it is important to know about the effects of
ionizing radiation on living organisms. The main references for the following brief
account of radiobiology are [13], [14], and [15].
2.2.1 The cell cycle
Most cells in our body do not exist over our entire lifetime, but are replaced with
a characteristic period ranging from a few days to several years [16]. I Each tissue
contains a small fraction of stem cells, which are able to undergo, under special
conditions, an unlimited number of cell divisions and provide replacement for old,
worn out cells as long as the organism is still alive.
Cell division proceeds by the so called cell cycle, a sequence of molecular processes
(see Figure 2.1). Five phases are distinguished:
• G1: After cell division, each daughter cell is concerned with protein synthesis
and growth to perform its specific task and prepare for replication of the DNA,
the carrier of all genetic information.
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• S: DNA replication leads to chromosomes consisting of two sister chromatids
with identical base sequence that are held together in a region called centromere.
• G2: Proteins that are required to perform the subsequent cell division are syn-
thesized. Complex mechanisms check if complete DNA replication has been
achieved and repair possible errors.
• M: The cell division, i.e. the formation of two nuclei each one containing the
full genetic information, is known as the mitosis phase. It can be further subdi-
vided into prophase, metaphase, anaphase and telophase. Only in the metaphase,
the chromosomes are fully condensed and show the typical X like shape. Mi-
tosis is usually followed by cytokinesis, the division of the cell body, resulting
in two separate and genetically identical daughter cells.
• G0: Cells can leave the cell cycle and enter a quiescent phase, in which they
continue their specific tasks with no proliferation.
FIGURE 2.1: Schematic of the cell cycle. The interphase comprises G1,
S, and G2 phases, in which the cell grows, replicates its DNA and pre-
pares for division. Subsequently, in the M phase, the cell divides into
two genetically identical daughter cells. For different mammalian cell
types, the length of the phase G1 can vary considerably, while the du-
ration of the other phases show only little variation. Typical durations
for human cells are indicated. Cells that do not show any proliferative
activity are said to be in the G0 phase. In cancerous cells, the molec-
ular mechanisms controlling the cell cycle are insufficient, leading to
an autonomous proliferation. Radiosensitivity is highest during M
phase, followed by the G2 phase: cells that proliferate quickly are
thus typically more sensitive to radiation.
In normal and healthy tissue, the cell cycle is tightly controlled to maintain the cell
number at a constant level adjusted to the requirements of the organism. the ra-
diation sensitivity of cells shows some characteristic variations with the cell cycle
phases, as will be discussed in chapter 6.
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2.2.2 Ionizing radiation and biological organisms
The events in a biological organism that follow irradiation with high energy photons
or charged particles can be divided into three stages:
1. The physical stage (time scale about 10 16 s to 10 13 s) comprises the excitation
and ionization events in which energy is transferred from the incident radia-
tion to the molecules of the biological organism. Note that the energy of a
single photon with a energy range between 10 keV to 10 MeV, as used in radio-
logical diagnostics or radiotherapy, is several orders of magnitude higher than
the typical excitation and ionization energies of biomolecules.
2. In the chemical stage (time scale about 10 13 s to 10 2 s), the absorbed energy
leads to changes in the structure of the four classes of biomolecules - nucleic
acids (DNA and RNA), proteins, carbohydrates and lipids. The result can be
ionization, formation of radicals, disruption of covalent or hydrogen bonds,
etc. However, since approximately the 80% of a cell’s content is water, the
most frequent event is the radiolysis of water:
H2O! H ·+OH·
H2O! H2O+ + e  (2.2)
This is immediately followed by further reactions, like:
H2O+ ! H+ +OH·
OH ·+OH·! H2O2
O2 + e  ! O 2
O 2 + H2O! H2O2 + 2OH  +O2
(2.3)
which produce so called reactive oxygen species (ROS). The hydroxyl radical
OH· with an unpaired electron, hydrogen peroxide H2O2 and the superox-
ide anion O 2 are chemically highly reactive and can cause modifications of
biomolecules, including several types of DNA damage.
In irradiation with photons and electrons, the indirect action of radiation via
radicals and ROS created fromwater andmolecular oxygen accounts for about
70% of radiation induced cell death, whereas with direct action of radiation,
the immediate damage of DNA by the primary radiation or secondary elec-
trons dominates in the case of massive charged particles (protons, a-particle,
heavy ions). The two different mechanisms are sketched in Figure 2.2.
3. In the biological stage (10 2 s to years), the chemical modifications of
biomolecules result in a cellular response by stopping the cell cycle and the
DNA repair processes, by changing the cellular metabolism or, if the damage
is severe, by leading the cell to death. If a proliferating cell survives despite
damage to its DNA, the DNA mutations are passed on to subsequent cell gen-
erations. When a certain number of mutations has accumulated, this can lead
to the transformation into a cancer cell (carcinogenesis).
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FIGURE 2.2: Direct and indirect action of radiation. A secondary
electron released by an energy rich photon, for example, can (a) di-
rectly cause DNA damage or (b) create ROS, here a hydroxyl radical
OH·, which subsequently reacts with DNA and thus indirectly leads
to DNA damage.
2.2.3 Radiation damage to DNA
Different types of DNA damage can be caused by ionizing radiation (Figure 2.3):
• base or sugar (deoxyribose) damage
• covalent cross links between two DNA strands or DNA and proteins
• single strand breaks (SSBs)
• double strand breaks (DSBs)
• clustered lesions, i.e. combinations of the above types in close proximity
It has been estimated that an X-ray dose of 1Gy causes about 1000 base damages,
1000 SSBs and 20-40 DSBs in a typical, sufficiently oxygenated mammalian cell [17].
Several DNA repair mechanisms, each one specialized for a certain type of dam-
age, have evolved to cope with the inevitable natural levels of ionizing radiation,
warranting the genetic material integrity. In brief, base damage and SSBs can be re-
pairedmore reliably andwith fewer error thanDSBs, since the intact complementary
DNA strand can be used as a template. Therefore, it is generally accepted that only
DSBs are the principal lesions leading to the following radiation induced biological
effects:
• Genomic instability and carcinogenesis: If repair mechanisms fail, but the
cell survives, radiation damage can modify the DNA base sequence and cause
thus genetic mutations. With regard to cancer, mutations in DNA regions that
encode for proteins involved in cell cycle control or DNA repair are critical. If
sufficiently many of these mutations (the exact number depends on the type of
cancer) have accumulated in a single (stem) cell, the result can be unrestricted
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FIGURE 2.3: Schematic representation of several types of damage that
can be inflicted on DNA by ionizing radiation, either by direct hit or
indirectly by ROS. A number of highly efficient repair mechanisms
exist. The biological effects of ionizing radiation are attributed to
DSBs.
cell proliferation and invasive growth: the cell has transformed into a malig-
nant cancer cell [18].
• Cell death: Ionizing radiation can kill cells. Different pathways are distin-
guished:
1. Mitotic or clonogenic cell death: if DNA repair mechanisms fail, that can
lead to errors in next of the subsequent cell divisions, triggering the cell
death. This is considered the most important form of cell death from irra-
diation.
2. Apoptosis: A "programmed cell death" triggered by a failure of DNA re-
pair mechanism; a cell senses that something has seriously gone wrong
with its DNA and, as a safeguard to protect the entire organism, it un-
dergoes a defined sequence of morphological changes and finally dies.
Note that one of the main characteristics of cancer cells is their increased
resistance to pro-apoptotic signals, which promotes the tumour growth
[18].
3. Necrosis: High radiation doses can cause a massive loss of the function
many proteins and damage membranes, leading to immediate cell death.
In contrast to apoptosis, where the cell content remains separated from
the extracellular space, here the cell leaks into the extracellular space caus-
ing an inflammatory reaction.
In summary, ionizing radiation is a sort of "double edged sword" [17] can both cause
and cure cancer. On the one hand, it can induce genetic mutations leading to un-
restricted cell division and tumor growth; on the other hand, large radiation doses
targeted at tumour cells can kill these by inducing massive DNA damage, especially
DSBs. The former effect is the reason for measures of radiation protection, while the
latter is applied in radiotherapy.
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2.2.4 Linear energy transfer and relative biological effectiveness
On the microscopic scale, the energy imparted to a biological system by ionizing ra-
diation is not deposited uniformly. Energy transfer takes place in discrete ionization
events, which are associated to the tracks of charged particles. For example: In two
volume elements of equal size, the same absorbed dose D (total energy deposited
in the volume divided by its mass) is deposited either by several ionizing particles
tracks, or by a single track of a different particle that produces more ion pairs per
unit path length1, as shown in Figure 2.4.
Therefore, the absorbed dose D alone is not sufficient to characterize the effect of
different types of ionizing radiation on living organisms. In fact, the probability of
the generation of DNA DSBs also depends on the spatial distribution of ionization
events, since one DSB requires two ionization events in close proximity and within
a sufficiently short period of time. This is quantify by the relative biological effec-
tiveness (RBE), defined as the radio between the dose of a reference spectrum (often
250 kV X-rays) and the dose of the test radiation that produces the same biological
effect (e.g., the same survival probability of cells):
RBE =
D(re f   radiation)
D(test  radiation) (2.4)
FIGURE 2.4: Microscopic energy deposition pattern of two different
types of charged particles. Each black dot symbolizes an ionization
event. In both volume elements DV, the same absorbed dose D is
generated. On the left, D results from several incident charged par-
ticles with low ionization density along their track. On the right, an
identical value D is created by a single charged particle that produces
considerably more ionization event per unit path length (e.g., a pro-
ton or carbon ion).
The higher RBE, themore efficient the test radiation in production of DSBs compared
to the reference radiation.
A frequently used quantity to characterize the microscopic pattern of dose depo-
sition is the so called linear energy transfer (LET), which is usually given in units
of [keV/µm]. It is defined as a fraction of the electronic stopping power2 Sel due to
1The theoretical and experimental methods to quantify such dose inhomogeneities on the micro-
scopic level is know as microdosimetry.
2When the term LET is used to characterize photon radiation, it actually refers to the secondary
electrons released by the photons. The same applies to the case of neutrons, where LET refers to recoil
protons released in collisions with atomic nuclei.
12 Chapter 2. Elements of Radiobiology and Dosimetry
ionization events in which the kinetic energy transferred to an atomic electron of the
medium is below a cutoff value D [19]:
LETD = Sel,D = Sel   dEk.e.<Ddl (2.5)
This way, energy rich knock on electrons that lead to energy dissipation away from
the primary particle track are excluded. For given D, a high LET implies that ion-
ization events resulting from a primary particle are "densely concentrated" along its
track. Thus, LETD can be interpreted as a measure of how "dense" the ionization
track of a given type of radiation is.
In radiobiology, the LET concept is often used to distinguish between two categories
of ionizing radiation:
- Densely ionizing radiation or high-LET radiation: Two subsequent events of
a single incident particle are often close enough to induce DNA DBSs. Protons
and heavy ions (i.e., a particles) usually are into this category, especially to-
wards the end of their track in the region of Bragg peak. Also neutrons (which
interact with atomic nuclei and produce recoil protons) belong to this class.
- Sparsely ionizing radiation or low-LET radiation: The typical distance between
two interaction events is much larger than the diameter of the DNA molecule
(2 nm). Creation of DSBs usually requires that two different particle tracks
happen to cross the same DNA region. This category comprises photons and
electrons.
The LET of a given type of radiation is fully characterized only if its spectral dis-
tribution is known [20]. However, values averaged over the track of known initial
energy (or initial energy spectrum) are usually used as an approximation. The bor-
der line between the two categories is fixed around (30 - 50) keV/µm.
In general, for a given type of radiation, LET increases if the kinetic energy of charged
particles decreases. In the case of photon radiation, LET refers to the released sec-
ondary electrons; while, for neutrons it refers to recoil protons.
Note that LET and RBE are related each other, as shown in Figure 2.5. It has been
demonstrated that the maximum RBE for mammalian cells is reached around LET
⇠ 100 keV/µm. This "optimal" LET corresponds to a mean distance between ioniza-
tion events along a charged particle’s track which is on the order of the diameter of a
DNA molecule, i.e., the energy is spent most efficiently for DBS production. At still
higher LET, energy is deposited inefficiently in ionization events that are too close
together, and RBE decreases again.
In radiation protection (see Section 2.3), LET is used to determine quality factors for
the risk assessment of different types of radiation.
2.2.5 Fractionation of radiation dose
In most cases, the total dose D that is considered sufficient to achieve tumour control
(i.e., eradicate all tumour cells) at an accetable level of damage to normal tissue is
not given in a single treatment, but in smaller portions called fractions. Standard ra-
diation therapy thus delivers a dose of 2 Gy to the tumour at each fraction, 5 times a
week during several weeks. This traditional fractionation regimen is aimed at maxi-
mizing the local control of the tumour while minimizing the toxicity to other healthy
tissues based on radiobiology models. However, such fractionation regimen might
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FIGURE 2.5: Plot of (average) LET vs RBE in cell killing. The curve
reaches a peak at about 100 keV/µm, where the energy deposited in
the medium is used most efficiently to induce DNA DSBs. Note that
the absolute value of RBE is not unique, but it depends on the chosen
biological effect [14].
not be beneficial for all tumours, in which case the dose per fraction can be increased
without lowering the quality of the treatment [21]. Hypofractionated radiotherapy
is increasingly being used to treat cancer. For this radiation treatment, the total dose
of radiation is divided into large doses and treatments are given once a day or less
often.
Research nowadays is ongoing to work out how low the fractions can go, but still
be effective and safe, taking always into account the so called 4 R’s of radiobiology
[14]
- Repopulation
- Redistribution
- Repair of sublethal damage
- Reoxygenation
both for tumoral and healthy cells, including also the new member of R’s: the Ra-
diosensitivity, which reminds that there is an intrinsic radiosensitivity or radioresis-
tance in different cell types.
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2.3 Radiation-induced effects
2.3.1 Deterministic and stochastic effects
Ionizing radiation has detrimental effects on living organisms, especially by damag-
ing DNA, the carrier of the genetic information, as said in par. 2.2.2.
Based on the relation ship between dose and effect, the biological effects of radiation
can be categorized as follows [22], [14], [23]:
- Deterministic effects (or tissue reactions) results from radiation induced cell
killing. The loss of a small fraction of cells in an organ or tissue does not usu-
ally effect its function. However, if this fraction increases further, a clinically
observable impairment of organ function will occur. The corresponding dose
is called the threshold dose: above it, the probability of damage to an organ
rapidly increases to 100%. In radiotherapy planning, dose limits to organs at
risk are used to avoid these deterministic effects. The threshold doses are usu-
ally on the order of several tens of Gy for a fractionated treatment (as reporter
in a recent summary [24]).
- Stochastic effects, in contrast, are not due to loss of cells, but result from radi-
ation induced DNA mutations. It is custom that there is no threshold dose for
stochastic effects, but different approaches are recently taken into account by
the scientific community [25].
The differences between determinist and stochastic effects are summarized in Ta-
ble 2.1. Their probability increases with the total dose an individual has received.
However, in contrast to determinist effects, the severity for stochastic effects is dose
independent: a malignant cancer resulting from mutations induced by a few high
energy photons is as severe as if it was induced by a much higher radiation dose.
It is thus very important to quantify the exact functional dependence of low doses
of ionizing radiation and stochastic effects. Examples are the limits for occupational
dose exposure, or screening tests like mammography, etc. Even if the risk may ap-
pear small, a large number of cases of, for example, carcinogenesis can result if large
numbers of healthy individuals are deliberately exposed to ionizing radiation [26].
The so called linear nonthreshold (LNT) model assumes strict proportionality be-
tween dose and incidence of stochastic effects of radiation, without a threshold dose
(Figure 2.6). Various other types of extrapolation from measured risks down to very
small doses are represented also in Figure 2.6. Based on biophysical arguments, the
LNT model is considered a conservative choice and it is, therefore, used as the basis
of radiation protection.
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TABLE 2.1: Comparison of deterministic and stochastic effects of ion-
izing radiation [14].
Deterministic effects Stochastic effects
Mechanism cell killing DNA mutation
Threshold dose yes no
Probability increases with dose increases with dose
Severity increases with dose independent of dose
Mathematical model LQ model LNT model
FIGURE 2.6: Schematic illustration of different possible extrapola-
tions of the probability of stochastic radiation effects down to very
low doses. The LNT model is considered as a plausible choice and
used as the basis of radiation protection. However other models can-
not be ruled out [26].
2.3.2 Equivalent and effective dose
The number of cells in an organ or tissue T that may be affected by radiation induced
mutations is proportional to the absorbed dose D¯T averaged over T. In addition, as
discussed in par. 2.2.4, not only the absorbed dose alone, but also the RBE of the ra-
diation determines the probability of radiation induced DNAmutations, depending
on the type and energy spectrum of the chosen radiation.
For the purpose of radiation protection, approximative values, the radiationweight-
ing factors wR (Tab. 2.2) are used to determine the radiation weighted equivalent
dose:
HT = wR · D¯T (2.6)
generated by radiation of type R in an organ or tissue T. The unit of the equivalent
dose is 1 J · kg 1, which is called 1 Sievert [Sv] in demarcation to the absorbed dose
D = de¯/mmeasured in Gray [Gy].
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If an individual is exposed to different types of radiation, the equivalent dose for
organ or tissue T is given by the sum:
HT =Â
R
wR · D¯T,R. (2.7)
The central quantity in radiation protection is the effective dose, which is given by
the weighted sum of the equivalent doses of all organs and tissues in the human
body:
E =Â
T
wT · HT =Â
T
wT[Â
R
wR · D¯T,R]. (2.8)
Like the equivalent dose, also the effective dose is given in units of Sv. The weights
wT are called the tissue weighting factors3 (Tab. 2.3).
TABLE 2.2: Radiation weighting factors wR according to current rec-
ommendations of the ICRP 103 [22]. The values are based on the RBE
(par. 2.2.4). Except for the case of neutrons, energy independent val-
ues are used as an approximation.
Radiation wR
Photons 1
Electrons and Muons 1
Protons and charged pions 2
Neutrons continuous function of kinetic energy *
a particles, heavy ions, fission fragment 20
* The radiation weighting factor for neutrons with kinetic energy E is given by the
continuous function:
wR(E) =
8><>:
2.5+ 18.2exp[  16 ln2(E)], E < 1 MeV
5.0+ 17.0exp[  16 ln2(2E)], 1 MeV < E < 50 MeV
2.5+ 3.25exp[  16 ln2(0.04E)], E > 50 MeV
(2.9)
Finally, the different dose concepts used in dosimetry and in radiation protection are
summarized in Tab. 2.4.
Equivalent dose and dose equivalent
"Equivalent dose" and "Dose equivalent" are not the same quantities. Equivalent
dose was introduced the first time in ICRP 60 [27] (1990), replacing the Dose Equiva-
lent of ICRU concept as the quantity to be adopted in radiation protection activities.
But there is still confusions and misuses in applying them.
The dose equivalent is evaluated at a specific point in the tissue-equivalent phantom;
the equivalent dose is determined by averaging dose over the mass of a receptor
tissue of interest in the medium of interest [28].
3Each wT factor used in the calculation of the effective dose is based on the nominal risk coefficients
RT (cases per 10000 persons per Sv), which are weighted by the lethality fraction kT , the relative life
lost lT and the reduction in file quality, as deeper described in [22]
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TABLE 2.3: Tissue weighting factors wT according to current recom-
mendations of the ICRP 103 [22].
Organ / Tissue T wT
Gonads 0.08
Bone marrow 0.12
Colon 0.12
Lung 0.12
Stomach 0.12
Breast 0.12
Other solid 0.12
Bladder 0.04
Liver 0.04
Oesophagus 0.04
Thyroid 0.04
Skin 0.01
Bone 0.01
Brain 0.01
Salivary glands 0.01
S 1.00
However, the current ICRP recommends evaluating only equivalent doses in a tissue
HT from the absorbed dose in this tissue DT and the radiation weighting factors wR.
Unfortunately, experimentally, the absorbed dose is extremely difficult in practice to
measure in some cases, like when dealing with neutron irradiation, because of the
complexity of neutrons interaction mechanisms with matter: all secondary charged
particles originating around the volume of interest would have to be considered and
their energy deposition inside the region of interest would have to be evaluated. A
paper by Sanchez-Doblado et al. [29] tried to establish a methodology to correlate
the readings of the detectors to the neutron equivalent doses in specific organs of
patients undergoing external photon beam radiotherapy. From the work it emerges
that, for experimental measurements, equivalent dose is a good estimator of the dose
equivalent, with an overall uncertainty of the order of 30%.
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TABLE 2.4: Summary of different dosimetric quantities.
The absorbed dose is the fundamental physical quantity in dosimetry
and in radiotherapy; equivalent and effective dose are mainly used in
the context of radiation protection.
Quantity Definition Used in
absorbed dose energy deposited per mass element dosimetry, radiotherapy
of a medium (usually water)
D = de¯dm =
1
r
de¯
dV
[D] = 1 Jkg = [1 Gy] (Gray)
equivalent dose mean absorbed dose in a certain radiation protection
organ/tissue T multiplied by
radiation weighting factor (Tab. 2.2)
HT = wR · D¯T = ÂR wRD¯T,R
[HT] = 1 Jkg = [1 Sv] (Sievert)
effective dose sum of equivalent doses weighted radiation protection
according to risk of
stochastic effects (Tab. 2.3)
E = ÂT wT · HT = ÂT wT[ÂR wRD¯T,R]
[E] = 1 Jkg = [1 Sv] (Sievert)
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Chapter 3
Electron linear accelerators for
radiotherapy
Medical electron linear accelerators (LINAC) have been started to be employed in
clinical applications since the fifties. In contrast to LINACs used for high-energy
physics research, medical LINACs are compact machines mounted isocentrically so
to allow practical radiation treatment aiming the beam toward the patient from var-
ious directions to concentrate the dose in the tumor and spare healthy tissues as
much as possible. In fact, the main goal of modern oncological radiotherapy is to
increase the treatment therapeutic index, intended as a progressive increase in the
total radiation dose to the target volume safeguarding healthy surrounding tissues,
by intensifying the beam energy and by diversifying its section.
Medical LINACs accelerate electrons to kinetic energies from 4 MeV to 22 MeV.
Then, the electron beam can be converted to X-rays or can alternatively be directly
used for the treatment.
Various types of LINACs are available for clinical use: a typical modern high-energy
LINAC provide photon with accelerating potentials of 6 MV, 10 MV, 15 MV and/or
18 MV, and several electron energies in the range from 4 MeV to 22 MeV.
This chapter describes the structure of a typical medical linear accelerator and the
different types of collimation and beam shaping systems for the control of the tu-
mour. Moreover, the last section gives a brief overview of the radiation treatment
parameters.
3.1 Principles of linear accelerators
In a linear accelerator (LINAC) designed for radiotherapy, electrons are generated
by thermionic effect in the gun. Bunches of these electrons are injected into an ac-
celerating structure, in synchronism with the pulsed microwave radiation inside it,
gaining thus energy by interacting with the synchronised radio-frequency electro-
magnetic field (typical value 3 GHz). The accelerating waveguide (the accelerator
structure) consists of a long cylindrical tube, containing a series of circular baffles.
These are designed so that speed of propagation of the microwaves increases in the
first part of the accelerating tube until it eventually reaches velocities close to the
light speed.
The microwaves are generated by a magnetron or klystron, by applying high voltage
pulses (about 50 kV), lasting only a few microseconds, coming from a modulator.
The electron gun and the accelerating waveguide are kept at low pressure, so that
the mean free path of electrons for atomic collisions is long.
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The energy an electron can acquire from the radio-frequency field in the waveguide
depends on the electric field amplitude, which in turn depends on the instantaneous
power of the microwave generator. The required power is a fewmegawatts. The mi-
crowave generators, for thermal reasons, cannot work continuously at these power
levels: that’s why the electrons are produced in bunches.
The accelerated electrons tend to diverge, both by the mutual repulsion due to the
Coulomb’s force and because the electric field in the waveguide has also a radial
component. For this reason, a coaxial magnetic field in the waveguide is used to
focus the beam. Moreover, at the exit of the accelerating area, other coils (the steering
coils) are present to direct the beam, so that it has the desired position and direction.
The LINACs can work in two different modalities:
1. Electron mode: the high energy electron beams, typically from 6MeV to 22MeV,
can be directly used for therapy. Their depth dose curves are characterized by
initial skin sparing followed by several centimeters of uniform dose (depend-
ing on energy) and then a rapid fall-off in dose as shown in Figure 3.1. Electron
beams from linear accelerators are useful for the treatment of tumours up to
about 7 cm deep, due to their low penetrating power being low-LET parti-
cles (par. 2.2.4); thus, for more deep-seated tumours, it is better to use photon
beams.
2. Photon mode: the electrons are focused onto a high-atomic-number thick tar-
get, and their energy loss is converted into bremsstrahlung radiation in order
to have a more penetrating beam in tissue, reaching deeper-seated tumours
(see depth dose curves, Fig. 3.8). At megavoltage energies, like the ones used
in radiotherapy, the principal direction of bremsstrahlung emission is in the
forward direction. In the simplest accelerators, the target is fixed and the ac-
celerating structure is coaxial with the emerging X-ray beam (i.e. it is parallel
to the direction of travel of the electrons so that no bending of the electrons
takes place) and it is perpendicular to the cranio-caudal1 axis of the patient.
However, for energies above 6 MeV, the length of the accelerator tube is such
that it makes this impracticable. In order for the radiation beam to be brought
in to irradiate the patient from any angle, it becomes necessary to bend the
beam: electrons are easily deflected through a magnetic field, bending them
of 270 . A schematic representation of a LINAC working in photon mode is
shown in Figure 3.2.
The challenge for accelerator design is to produce a stable monoenergetic high cur-
rent electron beam concentrated onto a small focal spot that will ensure that a sharply
focussed X-ray beam can be produced. The X-ray beam must be modified to allow
uniform irradiation of the intended treatment area of the patient, which can vary
from a very small area up to a maximum of about (40 ⇥ 40) cm2. Moreover, it’s
possible to choose the beam energy to suit the tumour being treated.
3.1.1 Components of modern LINACs
A schematic diagram of a typical modern medical LINAC is shown in Figure 3.3.
Also shown are the connections and relationships among the various LINAC com-
ponents; however, there are significant variations from one commercial machine to
1Cranio-caudal: direction from head to foot. The X-ray beam enters at the cranial end of the part
being examined and exits at the caudal end.
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FIGURE 3.1: Electron-beam depth-dose curves. Representative cen-
tral axis percentage depth-dose curves for electron beam energies
from 5 MeV to 20 MeV. (Picture from [30]).
FIGURE 3.2: Design configurations for isocentric medical LINACs
working in photonmode. The acceleratingwaveguide is in the gantry
parallel to the isocenter axis; electrons are brought to the movable tar-
get through a beam transport system; the RF-power generator is lo-
cated in the gantry stand; the machine produce megavoltage X-rays.
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(A) Outer view.
(B) Inner view. (Reproduced from [31])
FIGURE 3.3: Schematic representation of a typical medical linear ac-
celerator: inner and outer view.
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another, depending on the final electron beam kinetic energy as well as on the par-
ticular design used by the manufacturer: for example, the length of the accelerating
waveguide depends on the final electron kinetic energy, and ranges from ⇠30 cm at
4 MeV to ⇠150 cm at 22 MeV.
The beam-forming components of medical LINACs are usually grouped into six
classes:
1. Injection system
2. RF power generation system
3. Accelerating waveguide
4. Auxiliary system
5. Beam transport system
6. Beam collimation and beam monitoring system.
1. The injection system is the source of electrons, essentially a simple electrostatic ac-
celerator called "electron gun". Electrons are thermionically emitted from the heated
cathode, focused into a pencil beam and accelerated toward the perforated anode
through which they drift into the accelerating waveguide.
2. The radiofrequency (RF) power generating system produces the high power mi-
crowave radiation used for electron acceleration in the accelerating waveguide and
consists of two components: the RF power source and the pulsed modulator. The RF
power source is either a magnetron or a klystron in conjunction with a low power
RF oscillator. Both devices use electron acceleration and deceleration in vacuum for
production of the high power RF fields. The pulsed modulator produces the high
voltage, high current, short duration pulses required by the RF power source and
the electron injection system.
3. Electrons are accelerated in the accelerating waveguide by means of an energy trans-
fer from the high power RF field which is set up in the accelerating waveguide and
produced by the RF power generator. The accelerating waveguide is in principle
obtained from a cylindrical uniform waveguide by adding a series of disks with cir-
cular holes at the center, positioned at equal distances along the tube.
4. The auxiliary system consists of several basic systems that are not directly involved
with electron acceleration, yet they make the acceleration possible and the LINAC
viable for clinical operation. These systems are: the vacuum-pumping system, the
water-cooling system, the air-pressure system, and the shielding against leakage ra-
diation.
5. The electron beam transport system brings the pulsed high-energy electron beam
from the accelerating waveguide onto the target in the X-ray therapy mode and onto
the scattering foil in the electron therapy mode.
6. The beam monitoring system and the beam collimation system ensure that the radia-
tion dose is delivered to the patient as prescribed, with a high numerical and spatial
accuracy.
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3.1.2 The LINAC treatment head
The LINAC head contains several components, which influence the production,
shaping, localizing, and monitoring of the clinical photon and electron beams.
Electrons, originating in the electron gun, are accelerated in the accelerating waveg-
uide to the desired kinetic energy and then brought, in the form of a pencil beam,
through the beam transport system into the LINAC treatment head, where the clin-
ical photon and electron beams are produced.
The important components found in a typical head of a modern LINAC (see Fig.
3.4) operating in photon mode include:
1. X-ray targets
2. Flattening filters and electron scattering foils
3. Primary and secondary collimators
4. Dual transmission ionization chambers
5. Field defining light and range finder
6. Optional retractable wedges or full dynamic wedges
7. Optional multileaf collimator (MLC).
FIGURE 3.4: Schematic representation of a typical LINAC head oper-
ating in photon mode. The z-axis is directed downward.
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1 + 2. Clinical photon beams are produced in an X-ray target and flattened with a
flattening filter. Each clinical photon beam has its own target-flattening filter
combination. Optimal targets have a high atomic number Z and the flattening
filters are mounted on a rotating carousel for ease of mechanical positioning
into the beam. The photon maximum energy is equal to the energy of the
electrons striking on the target, and its mean energy is equal to 1/3 of the
maximum one. Since the clinical photon beam is not a monoenergetic beam,
it’s usual to refer to it giving the electron accelerating potential rather than an
energy value.
3. The primary collimator defines the largest available circular field size and is a
conical opening machined into a tungsten shielding block, with the sides of
the conical opening projecting on to edges of the target on one end of the block
and on to the flattening filter on the other end.
The secondary beam defining collimators consist of four blocks, two forming the
upper and two forming the lower jaws of the collimator. They can provide
rectangular or square fields with a maximum dimension of (40 ⇥ 40) cm2 at
the LINAC isocentre.
4. Dual transmission ionization chambers are used for monitoring the photon radi-
ation beam output as well as the radial and transverse beam flatness. The cus-
tomary position of the dose monitor chambers is between the flattening filter
or scattering foil and the photon beam secondary collimator. For patient safety,
the linac dosimetry system usually consists of two separately sealed ionization
chambers with completely independent biasing power supplies: if the primary
chamber fails during patient treatment, the secondary chamber will terminate
the irradiation.
The primary ionization chamber measures theMonitor Units (MUs). Typically,
the sensitivity of the chamber is adjusted in such a way that 1 MU corresponds
to a dose of 1 cGy delivered in a water phantom at the depth of dose maximum
(buid-up) on the central beam axis when irradiated in standard conditions2.
5. The field defining light and the range finder provide convenient visual methods
for correctly positioning the patient for treatment using reference marks. The
field light illuminates an area that coincides with the radiation treatment field
on the patient’s skin, while the range finder is used to place the patient at the
correct treatment distance by projecting a centimeter scale whose image on the
patient’s skin indicates the vertical distance from the LINAC isocentre.
6. Wedges are accessories placed on the proper support below the secondary colli-
mators. The wedge are used to make the dose distribution at the target volume
more homogeneous. They induce a beam attenuation and a hardening of the
spectrum, cutting the low energy component and thus increasing the main
photon energy.
7. Multileaf collimators (MLCs), represented in Figure 3.5, are a relatively recent
addition to LINAC dose delivery technology. The number of leaves in com-
mercial MLCs is steadily increasing, and models with 120 leaves (60 pairs) are
currently available. This system allows to contour the photon field, personal-
izing its shape according to the target volume shape. The customary position
of MLC is below the secondary collimators.
2Irradiation in standard conditions: irradiation set-up with a field size of (10 ⇥ 10) cm2 at isocentre
and a source to surface distance SSD of 100 cm
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Notice that:
• the LINAC head can rotate in the orizzontal plane of 360  in order to irradiate
the patient in all the directions;
• the isocentre is the intersection point between the couch and gantry axes;
• the distance from the beam source to isocentre is called SAD (Source to Axis
Distance);
• the distance from the beam source to the patient surface is called SSD (Source
to Surface Distance).
These reference radiation treatment parameters are shown in Figure 3.6.
FIGURE 3.5: Detail of the multileaf collimator.
FIGURE 3.6: Reference parameters used in radiotherapy. The isocen-
tre, the field size, the source to axis (SAD) and source to surface (SSD)
distances are shown.
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3.2 Radiation treatment parameters
The main parameters in external beam dose delivery with photon beams are:
- the depth of treatment;
- the field size:
- the SSD in SSD set- ups (or SAD in SAD isocentric set-ups);
- the photon beam energy.
All these parameters are given before starting a treatment.
In this work all measurements and simulations were carried out in SSD set-ups, and
the radiation treatment parameters are always reported.
3.2.1 Central axis depth doses: source to surface distance set-up
Percentage depth dose
Central axis dose distributions inside the patient or phantom are usually normalized
to Dmax = 100% at the depth of dose maximum zmax and then referred to as the PDD
distributions (Percentage Depth Dose).
The PDD is thus defined as follows:
PDD(z, A, f , hn) = 100
DQ
DP
(3.1)
where DQ is the dose at point Q at depth z on the central axis of the phantom and
DP is the dose at point P at zmax on the central axis of the phantom.
The geometry for PDD definition is shown in Figure 3.7. Point Q is an arbitrary
point at depth z on the beam central axis; point P represents the specific dose refer-
ence point at z = zmax on the beam central axis.
The PDD depends on four parameters: depth in a phantom z, field size A, SSD (often
designated with f ) and photon beam energy hn. The PDD ranges in value from 0 at
z! • to 100 at z = zmax.
An example of PDD distributions for (10 ⇥ 10) cm2 fields and various megavoltage
photon beams is given in Figure 3.8. The size of the build-up region increases with
beam energy and the surface dose decreases with beam energy.
Tissue-phantom ratio or tissue-maximum ratio
Tissue-phantom ratio (TPR) is defined as follows:
TPR(z, AQ, hn) =
DQ
DQre f
(3.2)
where DQ is the dose in a phantom at arbitrary point Q on the beam central axis,
and DQre f is the dose in a phantom at a reference depth zre f (typically 10 cm) on the
beam central axis.
The geometry for the measurement of doses DQ and DQre f is shown in Figure 3.9.
A special TPR is defined for the reference depth zre f equal to the depth of dose
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FIGURE 3.7: Geometry for PDD measurement and definition . Point
Q is an arbitrary point on the beam central axis at depth z, point P is
the point at zmax on the beam central axis. The field size A is defined
on the surface of the phantom.
FIGURE 3.8: PDD curves in water for a (10 ⇥ 10) cm2 field at an SSD
of 100 cm for various megavoltage photon beams ranging from 60Co
g-rays to 25 MV X-rays (Picture from [30]).
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maximum zmax, which is referred to as the tissue-maximum ratio (TMR), defined
as follows:
TMR(z, AQ, hn) =
DQ
DQmax
(3.3)
where DQ is the dose in a phantom at point Q at a depth z in a phantom DQmax is the
dose at point Q at zmax.
The geometry for the definition of TMR is the same as in Figure 3.9, except that zre f
is now zmax.
FIGURE 3.9: Geometry for the measurement of TPR. (a) Geometry for
the measurement of DQ at depth z in a phantom; (b) the geometry for
the measurement of DQre f at depth zre f in a phantom. The distance
between the source and the point of measurement, as well as the field
size at the point of measurement, is the same for (a) and (b).
Relationship between TPR and PDD
As shown in Figure 3.10 a relationship may be derived between TPR and the corre-
sponding PDD from the definitions governing the two functions.
In the first approximation:
TPR(z, AQ, hn) ⇡ PDD(z, A, f , hn)100 (
f + z
f + zmax
)2 (3.4)
where, remembering, z is the depth in a phantom, A the field size, f the SSD and hn
the photon beam energy.
However, an analytical expression is more often used in clinical application for
speed up the calculations. Knowing the value of the PDD at 20 cm and 10 cm, it’s
possible to found the corresponding TPR as:
TPR20,10 = 1, 2661⇥ (D20D10 )  0, 0595 (3.5)
All the relationships between depth-doses at different megavoltage photon beam are
reported inTable 3.1.
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FIGURE 3.10: Geometry for derivation of the relationship between
PDD and TPR.
TABLE 3.1: Photon beam quality: relationship between depth-doses
at different megavoltage photon beam [32].
Beam z-max PDD(10cm) TPR20/10
[cm]
6 MV 1.7 67.8 0.679
10 MV 2.5 73.2 0.713
18 MV 3.5 78.8 0.774
25 MV 4.0 81.9 0.801
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Neutron contamination from
medical accelerators
Medical LINACs for radiotherapy produce fast secondary neutrons due to photonu-
clear (g, n) reactions. Neutron production can result in doses to patients and to oper-
ating personnel from direct exposure both to neutrons and to the resulting residual
radioactivity.
The minimum energy required to remove one neutron from a nucleus lies between 6
and 20MeV for most stable nuclei heavier than carbon. A nucleus can absorb energy
from high-energy photon and it can emit a neutron if the photon energy exceed the
minimum energy.
Above the neutron separation energy, the cross section for neutron production in-
creases with the photon energy Eg, reaches a maximum value, and then decreases
with further increases of Eg. The shape of this peak is characteristic of resonance
reactions and it is called giant dipole resonance (GDR).
In summary, the potential sources of neutron contamination are any materials on
which the X-ray beam is incident, such as target, scattering foils, collimators, jaws,
etc., in addition to being produced in the bunker walls, floor and ceiling or directly
inside the human body; while, the potential sources of residual radioactivity are any
places where neutrons are produced or absorbed.
Before starting to discuss the physics of photoneutrons and their consequences in
radiotherapy, it’s important to give a general description of the photon interactions
with matter.
4.1 General aspects of photon interactions with matter
Photons are indirectly ionizing radiation and they deposit energy in thematter through
a two-step process:
1. in the first step energy is transferred to an energetic light charged particle;
2. in the second step energy is deposited in the absorbingmedium by the charged
particle.
The energy transferred to charged particles from the interacting photon generally
exceeds the energy subsequently deposited in the absorbing medium by the charged
particles, because some of the transferred energy may be radiated from the charged
particles in the form of photons.
Depending on their energy and the atomic number of the absorber, photons may
interact with an absorber atom as a whole, with the nucleus of an absorber atom, or
with an orbital electron of the absorber atom.
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As far as the photon fate after the interaction with an atom is concerned there are
two possible outcomes:
1. Photon disappears (i.e., is absorbed completely) and a portion of its energy is
transferred to light charged particles (electrons and positrons).
2. Photon is scattered and two outcomes are possible:
a The resulting photon has the same energy as the incident photon and no
light charged particles are released in the interaction.
b The resulting scattered photon has a lower energy than the incident pho-
ton and the energy excess is transferred to a light charged particle (elec-
tron).
The light charged particles (electrons and positrons) released or produced in the
absorbing medium through photon interactions will:
1. Either deposit their energy to the medium through Coulomb interactions with
orbital electrons of the absorbing medium (collision loss also referred to as
ionization loss)
2. Or radiate their kinetic energy away in the form of photons through Coulomb
interactions with the nuclei of the absorbing medium (radiation loss)
The probability of a particular interaction to occur depends on the photon energy,
as well as on the density and atomic number of the absorber, and it is generally ex-
pressed in the form of a cross section.
In penetrating an absorbing medium, photons may experience various interactions
with the atoms of the medium. These interactions involve either the nuclei of the
absorbing medium or the orbital electrons of the absorbing medium:
• The interactions with nuclei may be direct photon-nucleus interactions (photo-
disintegration) or interactions between the photon and the electrostatic field of
the nucleus (pair production).
• The photon - orbital electron interactions are characterized as interactions be-
tween the photon and either (1) a loosely bound electron1 (Thomson scattering,
Compton effect, triplet production) or (2) a tightly bound electron2 (photoelectric
effect, Rayleigh scattering).
4.1.1 Classification of photon interactions with absorber atoms
As seen in the above section, photons with energy in the ionizing radiation category
have several options for interacting with matter. The seven interactions of impor-
tance in medical physics and radiation dosimetry are summarized in Table 4.1, and
they can be classified according to:
- Type of target (orbital electron or nucleus), as shown in Table 4.2.
1Loosely bound electron: It is an electronwhose binding energy EB is small in comparisonwith photon
energy hn, i.e., EB << hn. An interaction between a photon and a loosely bound electron is considered
as an interaction between a photon and a "free" (i.e., unbound) electron.
2Tightly bound electron is an electron whose binding energy EB is comparable to, or larger than the
photon energy hn, i.e., EB ' hn. An interaction between a photon and a tightly bound electron is
considered an interaction between a photon and the atom as a whole.
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- Type of interaction (photon disappearance or photon scattering), as shown in
Table 4.3.
- Type of particle released (electron or positron), as shown in Table 4.4.
TABLE 4.1: Most important photon interactions with atoms of the
absorber.
Interaction
1. Thomson scattering
2. Rayleigh scattering
3. Compton scattering
4. Photoelectric effect
5. Nuclear pair production
6. Triplet production
7. Photodisintegration
TABLE 4.2: Types of targets in photon interactions with atoms (orbital
electrons or nuclei).
Photon-orbital electron interactions Photon-nucleus interactions
With bound electrons: With nucleus directly:
- Photoelectric effect - Photodisintegration
- Rayleigh scattering
With "free electrons" With Coulomb field of nucleus
- Thomson scattering - Nuclear pair production
- Rayleigh scattering
With Coulomb field of electron
- Triplet productions
As far as importance to medical physics and radiation dosimetry is concerned, pho-
ton interactions with atom of absorber are classified into four categories:
1. Interactions of major importance:
- Photoelectric effect
- Compton scattering by "free" electron
- Pair production in the field of nucleus
2. Interactions of moderate importance:
- Rayleigh scattering
3. Interactions of minor importance:
- Photonuclear reaction (also known as photonuclear effect)
- Thomson scattering by "free" electron
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TABLE 4.3: Types of photon-atom interactions (complete photon ab-
sorption or photon scattering).
Complete absorption of photon Photon scattering
Photoelectric effect Thomson scattering
Nuclear pair production Rayleigh scattering
Triplet production Compton scattering
Photodisintegration
TABLE 4.4: Release and production of charged particles in photon
interactions with absorber atoms.
Result of interaction Interaction event
1. No charged particles released or produced Thomson scattering
Rayleigh scattering
2. Only electrons released Photoelectric effect
Compton scattering
3. Electrons and positrons produced and released Nuclear pair production
Triplet production
4. Negligible interactions:
- Thomson scattering by the nucleus
- Compton scattering by the nucleus
Regarding the interactions of major importance (photoelectric effect, Compton scat-
tering and pair produtcion), the relative importance between these three different
mechanisms depends both on the energy of the incident photon E and on the atomic
number Z of the absorber, as shown in Figure 4.1. In the photoelectric effect, the
cross section is characterized by a strong dependence on the atomic number Z, and
it mainly contributes to the total cross section for energies smaller than 300 keV. The
Compton cross section, instead, depends linearly on Z and it became relevant in the
energy range between 0.1 MeV and 2 MeV. By increasing the photon energy, for en-
ergies higher than 10 MeV, the emission of electron-positron pairs becomes possible:
in this case the cross section is proportional to the square of the atomic number of
the absorber medium.
The other types of radiation interaction with matter are characterized by cross sec-
tions much smaller than those of the three dominant effects mentioned above, of
about two order of magnitude (see Figure 4.2), and they became relevant at higher
photon energies.
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FIGURE 4.1: Representation of the relative predominance of the three
main processes of photon interaction with absorber atom: photoelec-
tric effect, Compton scattering and pair production (from [33]). The
two curves connect points where photoelectric and Compton cross
sections are equally probable shown by the curve on the left, and
Compton and pair production cross sections are equally probable
shown by the curve on the right. The photoelectric effect is dominant
for low photon energies (region A), the Compton effect is dominant in
the central area (region B), while pair production becomes important
at higher energies (region C).
FIGURE 4.2: Cross sections of the different types of radiation inter-
action with matter for Pb-208 (from [34]). The photonuclear cross
section, green line, is about two orders of magnitude lower than the
dominant ones.
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4.2 Photonuclear reactions (Photodisintegration)
Photonuclear reaction occurs in a direct interaction between an energetic photon and
an absorber nucleus causing nuclear disintegration:
A⇤(Z,N)! A1(Z  x,N   y) + A2(x, y) (4.1)
Two other names are often used for the effect: "photodisintegration" and "nuclear
photoelectric effect".
In photonuclear reaction the nucleus absorbs a photon and the most likely result of
such an interaction is the emission of:
• a single neutron through a (g, n) reaction
• charged particles, such as protons or alpha particles
• gamma rays
• more than one neutron, or fission fragments (photofission), but much less
likely to occur.
Neutrons produced in photonuclear reactions are referred to as photoneutrons.
Photonuclear reactions are endothermic3, thus for the reaction to occur the incident
photon must possess minimum or threshold energy to be able to trigger the reaction:
Eth = (MA1c
2 + MA2c
2) MAc2 (4.2)
The threshold energy represents the separation energy of a neutron from the nucleus
that is of the order of 8 MeV or more for most nuclei, except for the deuteron (2H)
and berillium-9 (9Be) where it is at 2.225 MeV and 1.665 MeV, respectively [35].
Cross section and threshold energy for photonuclear reaction
The cross sections for photonuclear reactions vary as a function of photon energy as
well as the absorber nucleus, as described by the Levinger and Bethe formula [36]:Z •
0
s(E)dE =
2p2e2h¯
Mc
NZ
A
= 60
NZ
A
(4.3)
where s is the cross section expressed in [mbarn]; E is the incident photon energy in
[MeV]; h¯ is the reduced Planck’s constant [eV s];M is the mean nucleon mass (Mc2=
938.926 MeV); c is the speed of light [cm s 1]; N the neutron number; Z the proton
number; A=N+Z is the number of nucleons in a nuclide.
The most notable features of the cross section for nuclear absorption of energetic
photons are the reaction threshold and the so-called "giant resonance", both depend-
ing on the absorbing material.
The giant resonance is due to the acquisition of an electric dipole moment induced at
high frequency by the nucleus. This dipole is generated by the absorption of photons
with energies range between 10 MeV and 30 MeV, inducing a relative displacement
of protons and neutrons enclosed in the nucleus itself, as shown in Figure 4.3.
3A collision is termed endothermic if the so-called Q-value of the reaction is < 0. To take place, the
collision requires an energy transfer from the projectile to the target.
Notice that if the neutron energy En ⌧ Q, the momentum of the produced particle is p1 ⇡ -p2 and
E1+E2 ⇠ Q.
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FIGURE 4.3: Electric dipole oscillation of the nucleus. The neutron
and the proton oscillate relative to each other translationally (a) or
rotationally (b).
For heavy nuclei, the giant resonance decays predominantly with the emission of a
neutron; for higher incident photon energies it is also possible the (g, 2n) reaction.
The (g, p) is instead strongly depressed due to the high value of the Coulomb bar-
rier, which exceeds the giant resonance threshold of heavy nuclei.
For light nuclei, on the other hand, the (g, p) and the (g, n) reactions are equally
probable: this is due to the compensation between the reduction of the Coulomb
barrier and the partial increase of the neutron separation energy.
Neutrons from giant resonance are isotropically emitted, they have a mean energy
of about 1 MeV and a maximum energy of the order of 10 MeV [37].
The photonuclear absorption cross section is proportional to the atomic number Z
of the target nucleus, as seen in equation 4.3. Above the photon threshold energy
the cross section gradually increases, reaches a broad peak referred to as giant res-
onance, and then decreases with a further increase in photon energy. The giant res-
onance peak is centered at about 23 MeV for low atomic number Z absorbers and
at about 12 MeV for high Z absorbers. Figure 4.4 shows the cross section trend of
the reaction (g, n) on two different materials, with high and low atomic number,
Tungsten-186 (a) and Carbon-12 (b), respectively [38].
The full-width-at-half-maximum (FWHM) in the giant resonance cross sections typ-
ically ranges from about 3 MeV to 9 MeV and it depends on the detailed properties
of absorber nuclei.
Table 4.5 provides various parameters of the "giant (g, n) resonance" cross section
for selected absorbers, for those of interest in radiotherapy.
The threshold energy for the photoneutron reaction is lower for heavy elements, the
giant resonance peak is reached at lower energies and it is about twenty times higher
than light elements. The (g, n) reaction is thereforemore important for high-Z nuclei.
38 Chapter 4. Neutron contamination from medical accelerators
(A) Photoneutron cross section for 12C. The gi-
ant dipole resonance is at 23 MeV, in which the
resonance peak value is 20 mb. The vertical
small arrows point out the threshold energies
for the (g, n) and (g, 2n) reactions, respectively.
The threshold energy for the (g, n) reaction is
18.7 MeV.
(B) Photoneutron cross section for 186W. The giant dipole
resonance is at 13.5 MeV, in which the resonance peak
value is 400 mb. The vertical small arrows point out the
threshold energies for the (g, n), (g, 2n) and (g, 3n) re-
actions, respectively. The threshold energy for the (g, n)
reaction is 7.42 MeV.
FIGURE 4.4: Cross section of the photoneutron production reaction
for two different nuclides: Carbon-12 and Tungsten-186. [38]. The
threshold energy for the photonuclear reaction is lower for heavy nu-
clei, and the resonance peak is about twenty times higher than light
elements, and it is reached at lower energies: the photonuclear reac-
tion is more relevant for high atomic number of absorbers.
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TABLE 4.5: Photonuclear (g,n) giant resonance cross section parame-
ters for selected absorbers [39].
High-Z absorber Threshold energy Low-Z absorber Threshold energy
smax ⇠400 mb [MeV] smax ⇠ 20 mb [MeV]
Pb-208 7.41 C-12 18.7
W-184 7.42 O-16 15.7
Cu-63 9.00 Ca-40 15.6
Fe-56 10.9 P-31 12.3
4.3 Interactions of neutrons with matter
Neutrons are indirectly ionizing radiation exhibiting a quasi-exponential penetra-
tion into an absorber and depositing energy in the absorber through a two-step pro-
cess:
1. energy transfer to heavy charged particle
2. energy deposition in the absorber throughCoulomb interactions of these charged
particles with atoms of the absorber.
As they penetrate into matter, neutrons may undergo elastic and inelastic scattering
as well as trigger nuclear reactions, such as neutron capture, spallation, and fission.
4.3.1 General aspects of neutron interactions with absorbers
Neutrons, similarly to photons, may penetrate an absorber without interacting or
they may undergo various interactions with the absorber. In contrast to photons,
however, neutrons interact mostly with the nuclei of the absorber and have only mi-
nor interactions with orbital electrons of the absorber.
Neutron beams, similarly to photon beams, belong to the category of indirectly ion-
izing radiation beams, both types transferring energy to absorbing medium through
an intermediate step in which energy is transferred to a charged particle (protons
and heavier nuclei in the case of neutrons; electrons and positrons in the case of
photons).
The secondary heavy charged particles released in a medium traversed by neutrons
have a very short range in the medium.
In terms of their kinetic energy EK, neutrons are classified into several categories:
1. Ultracold neutronswith EK < 2⇥ 10 7 eV
2. Very cold neutronswith 2 ⇥10 7 eV  EK  5⇥ 10 5 eV
3. Cold neutronswith 5⇥10 5 eV  EK  0.025 eV
4. Thermal neutronswith EK ⇡ 0.025 eV
5. Epithermal neutronswith 1 eV < EK <1 keV
6. Intermediate neutronswith 1 keV< EK < 1 MeV
7. Fast neutronswith EK > 1 MeV.
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Of the seven categories listed above, only thermal, epithermal, and fast neutrons are
used in medicine and are thus of interest in medical physics4.
In this work, neutrons are named:
• THERMAL if their energy is up to 0.4 eV;
• EPITHERMAL if 0.4 eV < E <100 keV;
• FAST for energies greater than 100 keV.
4.3.2 Neutron interactions with nuclei of the absorber
Neutrons can approach a target nucleus without any interference from a Coulomb
repulsive or attractive force, since they, unlike protons and electrons, are not affected
by electric charge. Once in close proximity to the target nucleus, neutrons can inter-
act with it through the short range attractive nuclear potential and trigger various
nuclear reactions.
There are five principal processes by which neutrons interact with the nuclei of the
absorber:
1. Elastic scattering
2. Inelastic scattering
3. Neutron capture
4. Nuclear spallation
5. Nuclear fission
In general, it is possible to describe the interaction of a neutron with a nucleus A(Z,
n) like the formation of an excited nucleus A⇤(Z, N + 1):
A(Z,N) + n! A⇤(Z,N + 1) (4.4)
After a typical time of the order of (10 12 - 10 13) s the nucleus A⇤(Z, N + 1) is de-
energized by the emission of one or more particles.
The probability (cross section) for these different types of interactions varies with
the kinetic energy of the neutron and with the physical properties of the nuclei of
the absorber.
Elastic scattering
In elastic scattering a neutron collides with a nucleus of mass M that recoils with an
angle f with respect to the neutron initial direction of motion, as shown schemat-
ically in Figure 4.5 for general two-particle elastic scattering. Kinetic energy and
momentum are conserved in the interaction.
4Note that the velocity of an ultracold neutron with a kinetic energy of 2 ⇥10 7 eV is ⇠ 6 m/s; of a
thermal neutron with a kinetic energy of 0.025 eV it is ⇠ 2200 m/s; and of a fast neutron it is 1.4 ⇥107
m/s.
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FIGURE 4.5: Schematic diagram of an elastic collision between a pro-
jectile with mass m1 and velocity v1 striking a stationary target m2.
The projectile is scattered with a scattering angle q; the target recoils
with a recoil angle f. The impact parameter is b. After the collision
the velocity of the projectile m1 is u1; the velocity of the target m2 is
u2.
For a neutron with mass mn and initial kinetic energy (EK)i, the kinetic energy DEK
transferred to the nucleus is in general given by:
(DEK)max = EK
4mnM
(mn + M)2
cos2 f (4.5)
The maximum possible energy transfer (DEK) is attained in a head-on collision for
which f = 0 C
(DEK)max = |DEK|f=0 = (EK)i
4mnM
(mn + M)2
(4.6)
The average kinetic energy ¯DEK transferred to the recoil nucleus is
D¯EK =
1
2
(DEK)max =
1
2
(EK)i
4mnM
(mn + M)2
= 2(EK)i
mnM
(mn + M)2
(4.7)
The kinetic energy of the scattered neutron, (EK) f , in a head-on collision is equal to
(EK) f = (EK)i   (DEK)max = (EK)i(mn  Mmn + M )
2 (4.8)
while (E¯K) f , the average energy attained by the scattered neutron, is
(E¯K) f = (EK)i   (D¯EK)max = (EK)i m
2
n + M2
(mn + M)2
(4.9)
Thus, for example, if the target nucleus is hydrogen (nucleus is a proton with mass
mp), then M = mp ⇡ mn and the neutron will transfer on the average one half of its
initial kinetic energy to the proton [see Eq. 4.6], while the maximum energy trans-
ferred to the proton equals to the initial neutron energy (EK)i [see Eq. 4.9]. The recoil
proton will then travel a short distance through the absorbing medium and rapidly
transfer its kinetic energy to the medium through Coulomb interactions with the
nuclei and orbital electrons of the medium. This interaction could thus be used for
moderating fast neutron.
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The transfer of neutron energy to the absorbing medium is much less efficient when
mn ⌧ M; the larger is M, the less efficient is the energy transfer, as evident from
Eq. 4.6. For example, Eq. 4.6 predicts an only 2% fractional energy transfer from a
neutron colliding head-on with a lead nucleus, compared to a 100% energy transfer
in a head-on neutron-proton collision.
Except for some resonance peaks, at low energies the cross sections decrease rapidly
as the energy of the neutrons increases, while they decrease more slowly at higher
neutron energies, as shown for example in Figure 4.6, green solid curve, for hydro-
gen.
FIGURE 4.6: Cross section of the 1H(n, n0)1H reaction (green solid
curve) and of the 1H(n,g)2H reaction (red dashed curve) [38].
Inelastic scattering
In inelastic scattering the neutron n is first captured by the nucleus and then re-
emitted as neutron n’ with a lower energy and in a direction that is different from
the incident neutron direction. The nucleus is left in an excited state and will de-
excite by emitting high-energy g rays. This process is illustrated by the following
relationship
n+ AZX ! A+1Z X⇤ ! AZX⇤ + n0 ) A+1Z X⇤ + g (4.10)
where:
A
ZX is the stable target nucleus
A+1
Z X
⇤ is an unstable compound nucleus
A
ZX
⇤ is an excited target nucleus.
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Neutron capture
Neutron capture is a term used to describe a nuclear reaction in which a thermal
neutron bombards a nucleus leading to the emission of a proton, g ray, as well as
deuterons, tritons, 3He, alphas... Two of these interactions are of particular impor-
tance in tissue: 14N(n, p)14C and1H(n,g)2H, in which the last one emits gs at 2.2
MeV.
In Figure 4.6 it is also shown the neutron capture cross section trend as a function of
the incident neutron energy (red curve). Decreasing the energy, the cross section is
inversely proportional to the neutron velocity.
Spallation
Spallation is in general defined as fragmentation of a target into many smaller com-
ponents as a result of impact or stress. Consequently, nuclear spallation is defined
as disintegration of a target nucleus into many small residual components such as
aparticles and nucleons (protons and neutrons) upon bombardment with a suitable
projectile such as light or heavy ion beams or neutrons.
An example of spallation is as follows
16
8 O+ n! 3a+ 2p+ 3n (4.11)
Most of the energy released from the spallation process is carried away by the heav-
ier fragments that deposit their energy in the absorber locally. On the other hand,
neutrons and de-excitation g rays produced in spallation carry their energy to a
remote location. Spallation can be used for production of radionuclides and for gen-
eration of neutron beams in spallation neutron generators.
This process becomes important at neutron energies higher than 20 MeV. Consider-
ing that in radiotherapy the neutron spectrum for giant resonance does not exceed
energies of 10 MeV (see par. 4.2), it is here reported only for completeness.
4.4 Neutron dosimetry
Neutron dosimetry is a particularly challenging pursuit and it is important in many
exposures of human health, both in the medical and environmental fields. The most
important interactions of neutrons with elements that mainly constitute the human
body (H, C, N, O) are described here, in order to evaluate the risk patients are ex-
posed during radiotherapy.
4.4.1 Neutron riskiness for human tissues and organs
The fundamental interaction for neutrons with energies range between 100 keV and
20 MeV is the elastic scattering with hydrogen nuclei.
Soft tissues consist of 0.10 hydrogen mass fraction. The dominant reaction is
1H(n, n)1H, contributing for the 97% to the neutron dose with initial energy of 10
keV, for the 87% to 8 MeV and for the 70% to 18 MeV. The involved processes, in
order of importance, are the elastic scattering with oxygen, carbon and nitrogen nu-
clei. The inelastic and capture processes equal these ones in importance only when
neutrons reach energies of about 10 MeV.
The emitted charged particles by the interaction of neutrons have a high LET. For
example, the mean energy of a recoil proton produced by a 20 MeV neutron is worth
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about 10 MeV, and its mean path in water is 1.2 mm: the energy transferred from the
initial neutron will be absorbed very close to the interaction point when compared
to typical cells sizes (a few tens of µm). The neutron interactions with matter thus
regulate energy depositions in small volumes of tissue.
Diffuse neutrons suffer multiple collisions with the human body, and they are ther-
malized at the end. Once they are moderated the capture reaction on nitrogen
14N(n, p)14C occurs, emitting a 0.62 MeV proton.
Another important low-energy reaction is 1H(n,g)2H, that emits a 2.2 MeV photon.
This is to be added to the gammas of de-energization resulting from inelastic scat-
tering and capture reaction produced by high energy neutrons. With considerable
tissue thicknesses like those in humans, g rays tend to be absorbed.
Water-rich tissues are very sensitive to neutron action. Hydrogen nuclei, elastically
diffused by the incident neutron, acquire a certain kinetic energy causing an intense
ionization. This implicates a production of free radicals5.
Free radicals, with high chemical aggressiveness, react with others stable molecules
of the organism and increase the presence of hydrogen peroxide, which is also par-
ticularly reactive, so that its presence inside tissues is deleterious.
The incident radiation alters the molecules by activating an interaction process chain
with other molecules.
The events that contribute to the damage of biological system are essentially:
• the breakdown of molecular bonds;
• the transport of energy;
• the transmission tomacromolecules of the damage suffered by small molecules.
Moreover, for the biological effectiveness, it’s important the spatial distribution of
the produced ions: a higher ionization density implies a greater biological damage.
Therefore, it is of crucial importance to estimate the neutron dose which patients
are exposed, in order to achieve radiation protection. Radiation protection problems
related to neutron production are many:
• Neutrons are generally accompanied by intense photon fields, and it is so nec-
essary to use detectors that discriminate between the two types of radiation.
• The intense electromagnetic field provided by accelerators imply off-line and
passive measurements.
• The neutron energy spectrum covers several orders of magnitude, from 0.025
eV (thermal neutrons) to tens of MeV (fast neutrons): different interaction
mechanisms occur and, thus, different detectors for different energies are nec-
essary.
• The relative biological effectiveness, RBE, strongly depends on the neutron
energy: it is so necessary to know the neutron spectrum in order to use the
5Free radicals are atoms or groups of atoms with an odd (unpaired) number of electrons and they
can be formed when oxygen interacts with certain molecules. Once formed, these highly reactive
radicals can start a chain reaction. Their chief danger comes from the damage they can do when they
react with important cellular components such as DNA, or the cell membrane. Cells may function
poorly or die if this occurs.
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correct fluence - dose conversion factors, tabulated in ICRP 116 [40] for the
ambient dose equivalent, and in NCRP 38 for the dose equivalent in tissue
[41].
4.4.2 Characteristics of neutron dosimeters
As mentioned in the previous section, it is essential to understand the properties of
not only the detector, but also the neutron field being measured in order to perform
neutron dosimetry correctly. Most importantly, neutron detectors are sensitive to
neutrons only in a particular energy range. Because detector responses to different
neutron energies often varies by several orders of magnitude, it is critical to know
the detector response function and how it is related to the neutron spectrum being
measured. Moreover, because the primary photon beam is pulsed, passive detectors
are generally preferred for measurements [42]
Basic features of a good dosimeter, taking into account the issues concerning neu-
tron dosimetry listed above, are:
• dose-response linearity;
• independence from the incident radiation energy;
• high repeatability and great possibility of use;
• low loss of information over time, also according to the environmental condi-
tions;
• low influence of background radiation.
In the case of personal dosimeters it must be added:
• handiness to use, in terms of shape and lightness;
• cost-effectiveness;
• coverage of a wide measurement range in terms of equivalent dose (from 0.1
mSv to 10 Sv);
• isotropic angular response;
• independence from the dose rate;
• response accuracy in order to meet the recommendations of the international
commissions.
In this work thesis, neutron passive bubble dosimeters were employed to detect the
neutron dose equivalent (see section 7.2).
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4.5 Neutron photoproduction consequences
Undesirable radiation doses, delivered to patients during radiotherapy treatments,
have been studied since the 1950s. In particular, the NCRP Report No. 79 [43], re-
garding the neutron contamination provided by medical linear accelerators, states
that in the case of irradiation with X-ray there are several sources of absorbed doses
outside the target volume. These sources must be added to the dose due to the pri-
mary beam and considered in the total risk to the patient.
For this reason, several studies have been addressed to the investigation of parasitic
neutrons during radiotherapy treatments, with different dosimetric system (such
as bubble detectors, polycarbonate film, activation detectors, thermoluminescance
dosemeters), both in-field and out-of-field, especially in high-energy medical linear
accelerators (25 MV, 18 MV, 15 MV) [44], [45], [46]. However, there is sparse in-
formation about photoneutrons provided in lower energies, near the GDR reaction
threshold, at 10 MV and 6 MV.
Part of the thesis work (Chapter 9) was thus dedicated to performing measurements
of the parasitic neutrons at low-energy LINAC. Considering the last developments
in radiotherapy in performing more and more lower energy treatments, for example
the 6 MV IMRT or VMAT treatments, also the 6 MV LINAC was taken into account,
giving so a contribution to the present literature in this field [47].
4.5.1 Unaccounted neutron dose during radiotherapy
The undesirable dose components are not completely independent each other and,
from a medical point of view, it must be considered the total risk to the patient.
Sources of extra doses are:
1. photons escaping from the shielding of the accelerator head
2. photons diffused outside the treatment volume
3. neutrons produced by the (g, n) reaction on high Z elements constituting the
LINAC head
4. neutrons produced by the (g, n) reaction on light elements constituting the
human body in the treatment area.
The first point is the best known: the problem of photon diffused from the accelera-
tor head already existed, since the radiotherapy pioneers. The request made by the
International Commission was to obtain a maximum level of diffused photon equal
to 0.1% of the beam dose rate.
The second point, instead, depends on the field size: the component of photons
diffused outside the treatment area is from 5 to 28 times greater than the value of
photons escaping from the accelerator head.
The neutron issue arose when high energy accelerators were employed in radio-
therapy for treating deeper tumours. Looking at the trend of the absorbed dose as a
function of the depth in tissue, it varies according to the photon energy (see Fig. 1.1
or Fig. 3.8): the build-up moves towards greater distances by increasing the photon
energy (2-4 cm for energies range 6-25 MeV).
The side effect of the use of high energy beams is, however, the neutron photopro-
duction, already described in par. 4.2. The neutron production results from the
interaction of bremsstrahlung photons both (1) with high Z nuclei constituting the
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LINAC head (lead, tungsten, iron..) and (2) with light elements constituting the hu-
man body (mainly on carbon, nitrogen and oxygen nuclei).
In the first case, neutrons are produced inside the LINAC gantry, with an isotropic
angular distribution. These neutrons interact then with the human body, without
any discrimination between healthy and sick tissues. While, in the second case, both
the neutron production and transport take place inside the patient body.
Moreover, the photoneutron cross sections reach values of the order of hundreds
of millibarn for heavy elements, and only up to a few tens of millibarn for light
elements (see Fig. 4.4 for photoneutron cross sections and Tab. 4.5 for the (g, n)
threshold energies). As a matter of fact, the predominant neutron dose contribution
is this due to the LINAC head: only 10% of the neutrons are directly produced inside
the patient body in the treatment area.
According to the NCRP report No. 79, the neutron component is been estimated to
be 0.1% - 0.3% of the photon dose.
4.5.2 Relationship between monitor units and unaccounted neutron dose
Photon beam collimation techniques, such as multileaf collimator (MLC), aim at in-
creasing the local tumour control but require a longer time to deliver a certain dose
to the target volume, increasing considerably the number of monitor units.
The Monitor Unit (MU) represents the request time for the LINAC to deliver a cer-
tain dose to the target volume. The monitor unit settings on the LINAC are cali-
brated in order to achieve an output of:
1cGy = 1MU (4.12)
for a standard field size of (10 ⇥ 10) cm2 at 100 cm SSD in a water phantom at build-
up.
When the conditions differ from the reference ones, an accurate evaluation of the
output factor (OF) has to be made:
OF =
Dabs
Dre f
(4.13)
where Dabs is the photon dose absorbed by the patient at build-up, and Dre f is the
reference dose.
In this way, the new MU can be calculated as:
MU =
Dpr
Dr ·OF (4.14)
where Dpr is the prescription dose for the treatment, and Dr = cGy/MU
For example, 100MU are necessary to deliver a dose of 1 Gy at build-up for a photon
field size of (10 ⇥ 10) cm2; to deliver the same dose, keeping opened the secondary
collimators at (10 ⇥ 10) cm2 and by using MLCs in clinical configuration, 103 MU
are necessary because multileaf collimators shield the primary photon beam.
This is what happens during an intensity modulated radiation therapy IMRT, where
the dose is delivered in little segments and the photon beam is semi-shielded by
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the leaves. Therefore, to deliver the prescription dose to the patient by covering the
whole target volume many segments are necessary: this requires a longer treatment
time and, consequently, more MU.
It’s important to point out that monitor units are also related to the parasitic neu-
tron dose: in fact, MLCs are made by high Z elements, increasing thus the neutron
photoproduction.
In Table 4.6 the necessary MUs to deliver 1 Gy at build-up for different kinds of
treatment for a photon field size of (10 ⇥ 10) cm2 are reported.
TABLE 4.6: Monitor units per Gy of photon dose delivered at build-
up for a photon field size of (10 ⇥ 10) cm2.
Treatment Total dose Monitor Unit
[Gy] [MU/Gy]
Traditional 70 100
Traditional + blocks 70 100
Traditional + MLC 60-80 185-290
IMRT 70 1815
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The Boron Neutron Capture
Therapy
During radiotherapy, a large radiation dose is delivered to a tumour aiming at de-
stroying or damaging cancer cells, while the dose to the surrounding healthy tissues
must be limited to a tolerable level. The effectiveness of the treatment depends on
the radiation dose delivered to the tumor target and on the dose accuracy.
One of the technique of high-selectivity radiotherapy is the Neutron Capture Ther-
apy (NCT): the idea behind this therapy is to selectively target tumour cells by high
linear energy transfer (high-LET) heavy particle radiation, which is released when a
tumor-seeking compound is exposed to a neutron field [48].
This chapter gives an overview of the neutron capture therapy on boron-10, describ-
ing its physical, chemical and biological characteristics.
5.1 Therapy of the neutron capture on boron-10
It was the physicist G.L. Locher who proposed the idea of using neutron capture
reactions, in which a 4He nucleus (alpha particle) and 7Li nucleus are emitted when
10B reacts with thermal neutrons, to destroy cancer cells in cancer treatment. It was
1936, four years after the discovery of the neutron. This is the origin of the Boron
Neutron Capture Therapy (BNCT).
BNCT is a two-step procedure:
1. a boron-10 enriched compound is administrated to the patient;
2. the target volume is irradiated by slow neutrons (thermals or epithermals) be-
cause of their high absorption cross section on boron-10.
After losing energy as they penetrate tissue, the neutrons are absorbed by the capture
agent, which subsequently emits high-energy charged particles that can selectively
kill tumor cells that have taken up sufficient amounts of boron-10, [49].
The nuclear reaction
Thermal neutrons are captured by a variety of nuclei, but the probability of capture
by a 10B nucleus (expressed in terms of the capture cross-sectional area in cm2) is
much higher than other elements constituting human tissue, such as hydrogen, oxy-
gen, and nitrogen, since its cross-section (3843 barns at 0.025 eV) is, for example,
about 2.000 times larger than the nitrogen one [4].
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During the neutron irradiation, a nuclear reaction takes place
n+ 10B! 11B⇤ ! a+ 7Li+ 2.79MeV [6%] (5.1)
n+ 10B! 11B⇤ ! a+ 7Li+ g(0.48MeV) + 2.31MeV [94%] (5.2)
producing high-LET heavy fragments from 10B, an a particle (4He) and a 7-lithium
(7Li) nucleus (Figure 5.1).
The track ranges of the two emitted particles are extremely short (of the order of few
µm) and do not exceed the diameter of a typical cell (see Figure 5.2): the destructive
effects are limited to boron-containing cells, thereby selectivity destroying only tu-
mour cells during neutron irradiation if the carrier transporting boron is selective.
[50].
The ionization density produced by the a particle along the path inside the cell gives
birth to an electric field: it segments the two DNA helices at the same height, inacti-
vating the cell itself. Despite the high-LET of 7Li, it rarely causes serious damage to
the nucleus. The destructive effects are thus due to a particles.
FIGURE 5.1: Nuclear reaction in BNCT. Boron neutron capture ther-
apy is based on the nuclear capture and fission reactions that occur
when non-radioactive boron-10, a constituent of natural elemental
boron, 80% of which is in the isotopic form of 11B and 20% as 10B,
is irradiated with low-energy (0.025 eV) thermal neutrons or, alterna-
tively, higher-energy (10 keV) epithermal neutrons. The latter become
thermalized as they penetrate tissues. The resulting 10B(n,a)7Li cap-
ture reaction yields high linear energy transfer a particles and recoil-
ing lithium-7 atoms, emitted in opposite directions.
The nuclear reaction in BNCT is so favourable in radiotherapy because of:
• the high capture cross section for thermal neutrons (3843 barns at 0.025 eV)
• the positive Q-value (Q = 2.792 MeV)
• the reaction products release their energy inside the cell where they have been
created.
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FIGURE 5.2: Schematic representation of the boron fission reaction in-
side the cell. a particle: LET of 163 keV/µm and pathlength of 9-10
µm; 7Li: LET of 210 keV/µm and pathlength of 4-5 µm. The a par-
ticles destructive effects are limited to boron-containing cell. Notice
also that a sufficient amount of 10B must be delivered selectively to
the tumor (⇠20-50 µg/g or ⇠109 atoms/cell) in order for BNCT to be
successful.
• the boron-10 concentration ratio in tumour cells is higher than healthy ones
(typically 3:1, even if it can reach higher uptake values [51]), thanks to the high
boron carrier absorption for cells which replicate faster.
Radiobiological considerations
The radiation doses delivered to tumour and normal tissues during BNCT are due to
energy deposition from three types of directly ionizing radiation, that differ in their
LET (the rate of energy loss along the path of an ionizing particle):
1. low LET gamma rays, resulting primarily from the capture of thermal neu-
trons by normal tissue hydrogen atoms
n+ 1H ! 2H + g (5.3)
2. high LET protons, produced by the scattering of fast neutrons and from the
capture of thermal neutrons by nitrogen atoms
n+ 14N ! p+ 14C (5.4)
3. high LET, heavier charged alpha particles (stripped down helium [4He] nuclei)
and lithium-7 ions, released as products of the thermal neutron capture and
fission reactions with 10B
10B(n, a)7Li (5.5)
Since both tumour and surrounding normal tissues are present in the radiation field,
there will be an unavoidable, nonspecific background dose, consisting of both high
and low LET radiation. However, a higher concentration of 10B in the tumour will
result in it receiving a higher total dose than that of adjacent normal tissues, which
is the basis for the therapeutic gain in BNCT [52]. The total radiation dose in Gy de-
livered to any tissue can be expressed in photon-equivalent units as the sum of each
of the high LET dose components multiplied by weighting factors, which depend
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on the increased radiobiological effectiveness of each of these components (see par.
5.2.1)
Boron delivery agents
Research in the area of development of boron-containing delivery agents for BNCT
started ⇠50 years ago with the investigation of a large number of low molecular
weight boron compounds.
The most important requirements for a BNCT delivery agent are [53]:
1. low toxicity and normal tissue uptake, with a tumor:normal tissue and tu-
mor:blood boron concentration ratios of >3:1
2. tumor boron concentration of ⇠20 µg 10B/g tumor
3. relatively rapid clearance from blood and normal tissues, and persistence in
tumour during neutron irradiations.
The only two BNCT delivery agents currently used in clinical trials are sodium
mercaptoundecahydro-closo-dodecaborate, commonly known as sodium borocaptate (BSH),
and the boron-containing amino acid (L)-4-dihydroxy-borylphenylalanine, known as
boron-phenyl-alanine or BPA [54].
However, with the development of new synthetic techniques and increased aware-
ness of the biochemical requirements needed for effective boron containing agents
and their modes of delivery, a number of new boron agents are emerging: the so-
called "third generation agents". The major challenge in the development of such
agents is the requirement for selective tumour cell targeting, the delivery of thera-
peutic boron levels with minimal normal tissue toxicity, and the ability to exceed the
biological barrier, the blood-brain barrier (BBB), that BPA cannot do.
5.2 Overview of BNCT dosimetry
5.2.1 Dose components
The typical BNCT radiation field produced in normal and tumour tissues consists of
a mixture of several particles, such as neutrons, protons, photons, a particles and 7Li
particles.
In the physical dose estimation, these particles are categorized into four major dose
components [55]:
1. GAMMA DOSE
1H + n  ! 2H + g+ 2.2MeV (5.6)
The gamma dose consists of two components: primary photons accompanying
the neutron beam and secondary photons produced by the thermal neutron
capture reaction on hydrogen in tissue. The gamma dose is written as Dg.
2. BORON DOSE
10B+ n  ! 11B  ! 7Li(0.84MeV) + a(1.47MeV) + g(0.48MeV)(94%)
10B+ n  ! 11B  ! 7Li(1.01MeV) + a(1.78MeV)(6%) (5.7)
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The boron dose is due to the neutron capture reaction by 10B that absorbs a
thermal neutron. The energetic emitted a particle and the recoil 7Li ion result
in locally deposited energy averaging about 2.34 MeV. About 94% of the times
the recoiling 7Li ion is produced in an excited state and de-excites emitting a
480 keV gamma ray. In the remaining events, the 7Li is emitted in the ground
state with no gamma ray emission. The boron dose is written as DB.
3. NITROGEN DOSE or THERMAL NEUTRON DOSE
14N + n  ! 14C+ p+ 0.66MeV (5.8)
The nitrogen dose consists of a locally deposited dose from energetic protons
(660 keV) and recoiling 14C nuclei from the thermal neutron absorption reac-
tion on nitrogen nuclei in tissue. The nitrogen dose is written as DN .
4. HYDROGEN DOSE or FAST NEUTRON DOSE
The hydrogen dose is mainly due to proton recoil reactions at higher neutron
energies (>10 keV) in the tissue. Protons, produced by 1H(n,n’)p reaction,
deposit their energy locally. This dose component is the highest one at the skin
surface and decreases exponentially with depth. The hydrogen dose is written
as DH.
The boron dose accounts for the majority of the biological effect in tumor tissues
[56]. The other dose components deliver background doses to both normal and tu-
mor tissues [57]. The minimum requirement for effective BNCT has been estimated
to be 109 - 1010 boron atoms distributed uniformly throughout a tumour cell [58].
The BNCT dosimetry, therefore, requires a careful analysis of the different compo-
nents of the radiation field.
In order to compare the BNCT dose with the fractionated absorbed dose in photon
radiotherapy, the physical dose needs to be converted to biological dose: each of the
four major dose components is so multiplied by their relative biological effectiveness
(RBE)1 using a weighting factor (wi).
The total BNCT weighted absorbed dose in photon dose equivalent units, weighted Gray
[Gy-eq] can be defined as follows:
DW = wgDg + wBDB + wNDN + wHDH (5.9)
The wi are energy and dose rate-dependent and thus, are also dependent on individ-
ual beam characteristics and scattering conditions (location in the body). In addition,
the biological effectiveness is dependent on the tissue. Moreover, synergy between
the various radiation components is indicated, which results in a greater biological
effect than would be in the case of the independent action of the various radiation
types [59].
Nonetheless, constant values for the wi values are commonly applied, regardless of
the tissue: wg =12, wH and wN = 3.2 [58], [61].
1RBE is defined as the ratio of doses of a reference radiation (currently cobalt-60 gamma rays) to a
test radiation that will produce the same biological endpoint in a given system.
2In other works [60] for long irradiation times (2-3 hours) wg is assumed 0.5 because a cell survival
probability can be enhanced from repair of sublethal damage.
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The wi for DB is called the compound biological effectiveness factor (CBE), since it is
not only dependent on the radiosensitivity of the tissue, but also on the boron car-
rier applied and its micro-distribution inside the cell. In fact, the boron located in
the nucleus is more effective than boron distributed in the cytoplasm, which is in
turn more effective than boron attached to the cell membrane. The CBE factors or
wB usually employed are: 3.8 in the tumor tissue, 1.3 in healthy tissues and 2.5 for
skin, measured by Coderre et al. [58].
Regarding the physical dose components, DH and DN are dependent on the hydro-
gen and nitrogen mass fraction and the mass density of the tissue (most commonly,
elemental compositions of tissues are defined according to ICRU Report 46 [62]).
While for calculation of the physical DB, the boron concentration of tissue needs
to be evaluated: the blood boron concentration during neutron irradiation is com-
monly from about 11 parts per million (ppm) to 30 ppm, depending on the BPA
infusion dose [63].
5.2.2 Dose calculation
The absorbed dose in BNCT is due to nuclear interactions and thus the computa-
tional approximations in use for photon and electron therapy cannot be adopted for
BNCT dose planning. To calculate the neutron interactions within the body, the ele-
mental composition of organs needs to be modeled.
One of the recommended codes for BNCT dosimetric calculations is theMonte Carlo
N-Particle (MCNP) radiation transport code [64].
The dose components are calculated by integrals such as:
Dn,B =
1
rm ·VKn,B
Z
dV
Z
dE · Ecoll · f(E) · ra · sa (5.10)
where:
- V is the cell volume in [cm3], rm is the biological tissue density in [g·cm 3].
Their product is the cell mass expressed in [g];
- Kn,B is a constant depending on the particle type (neutron here) and on the
biological material (normal or borated tissue);
- Ecoll is the energy deriving from the collision inside the biological tissue: for
example for (n,a) reactions with 10B the mean high LET energy released per
event is 2.34 MeV
[7Li(0.84MeV) + a(1.47MeV)] · 94%+ [7Li(1.01MeV) + a(1.78MeV)] · 6%
100%
(5.11)
assumed to be deposited locally;
- f(E) is the neutron fluence in the examined cell in [cm 2 MeV 1];
- ra is the biological tissue density in [atoms barn 1 cm 1]. The unit choice
derives from the eq. (5.10) where the cross section sa is espressed in [barn] and
the neutron fluence f(E) in [cm 2 MeV 1];
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- sa is the microscopic cross section expressed in [barn]
The value of the constant Kn,B is connected to several parameters: kerma factors,
source intensity, RBE and CBE factors, unit of integral Dn,B in [Gy-eq min 1].
The following value for Kn,B is used:
Kn,B = NS · 60 · K2 · Ee f f (5.12)
where:
- NS is the neutron source intensity in [s 1];
- 60 represents [s min  1];
- K2 is a proportional constant equal to 1.602 · 10 10 in order to change the en-
ergy and the mass units from [MeV g 1] to [J Kg 1 = Gy];
- Ee f f is the biological effectiveness (numerically expressed by RBE and CBE
factors) in order to obtain the dose units [Gy-eq].
The dose due to 10B(n, a)7Li in the tumour tissue can be derived from the boron dose
in healthy tissue multiplied by the concentration ratio between tumour and healthy
tissues and then by combining the physical dose with the proper CBE factor.
The biological dose to healthy tissue due to gamma radiation is calculated by an
expression such as:
Dg =
1
M
Kg
Z
dV
Z
dE · Ecoll · f(E) · ra · sa (5.13)
where:
- M is the cell mass in [g];
- Kg is a constant depending on the particle type;
- V, Ecoll , f(E), ra and sa have the same meaning of the equation (5.10).
In order to obtain Dg in [Gy-eq min 1], the value of Kg is fixed at:
Kg = NS · 60 · K2 · Ee f f (5.14)
where Ee f f is 1 for gamma rays and the other terms are the same as those that appear
in equation (5.12) for Kn,B.
The MCNP code allows to calculate the integrals in the eq. (5.10) and (5.13) in a
separate way for the four dose components.
The boron dose cannot be determined or evaluated directly, therefore this compo-
nent is evaluated assuming a homogeneous distribution of the boron in the tissue of
interest. The 10B concentration in tissues is included in the Monte Carlo transport
simulations.
For these reasons, only Monte Carlo-based software programs have been applied in
clinical BNCT.
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5.3 Considerations
The success of BNCT is dependent upon the selective delivery of sufficient amounts
of 10B to the tumour, with only small amounts localized in the surrounding normal
tissues [49]. Thus, normal tissues, if they have not taken up sufficient amounts of
boron-10, can be spared from the nuclear capture and fission reactions.
In theory BNCT is a highly selective type of radiation therapy that can target tu-
mour cells without causing radiation damage to the adjacent normal cells and tis-
sues. Doses up to 60-70 Gy can be delivered to the tumor cells in one or two appli-
cations compared to 6-7 weeks for conventional fractionated external beam photon
irradiation.
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Radiosensitizers in the treatment of
cancer
Radiation therapy has been the mainstay of nonsurgical treatment of cancer for over
a century, while the classic chemotherapy drugs such as cisplatin and 5-fluorouracil
(5-FU) have been in clinical use for almost 50 years. The combination of these modal-
ities is a more recent event that continue to evolve, and it has become the standard of
care for most patients with solid tumours based on improvements in loco-regional
disease control and survival. This effect is known as radiosensitization.
An interpretation of radiosensitization stressed the importance of a differential effect
between tumours and normal tissues, and suggested that only two types of sensitiz-
ers found practical use in clinical radiotherapy [14]:
1. the pyrimidines, based on the premise that tumour cells proliferatemore rapidly
and, therefore, incorporate more pyrimidine analogues than the surrounding
normal tissues;
2. hypoxic cell sensitizer, which increase the radiosensitivity of cells lacking in
molecular oxygen, based on the premise that hypoxic cells occur only in tu-
mours and not in normal tissue.
Although both of these premises were sound, these two classes of drugs turned
out to be less than effective in the clinic for reasons that are probably connected
with pharmacokinetics and drug delivery issues. In fact, the hypoxic cell sensitizers
(e.g., misonidazole), and thymidine analogues (e.g., bromodeoxyuridine) are exam-
ples of "true" radiosensitizers in that they have no inherent cytotoxicity1. However,
the most commonly used radiosensitizers (cisplatin and 5-FU) do have inherent cy-
totoxic activity and can increase damage to normal tissues, with a "true" benefit
achieved only if the increase in antitumor effect is larger than the normal tissue
damage. The result of the combined treatment is at least an additive effect of the
two modalities and at best a synergism effect.
1Cytotoxicity: It is the quality of being toxic to cells. A treatment of cancer often relies on the ability
of cytotoxic agents to kill or damage cells which are reproducing; this preferentially targets rapidly
dividing cancer cells.
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6.1 Combining two agents together: additivity and synergy
A common definition of synergy is that the effect of two agents given together is
more effective than would be predicted based on their individual activity. Thus, if
agent 1 alone causes the surviving fraction to be reduced to 0.5, and agent 2 used
alone also reduces survival to 0.5, then the effect of agents 1 and 2 combined will be
to reduce survival to 0.25 if the effect is additive and to less than 0.25 if the effect is
synergistic. This will only be correct if the survival curves generated by agents 1 and
2, when used separately, are both exponential.
If the response curves are shouldered, more than one scenario is possible. If the
agents are used, both of which have a survival curve with a shoulder followed by
an exponential slope, then there are three possibilities (Figure 6.1):
1. if there is no overlap of damage and the shoulder representing the accumula-
tion of sublethal damage is retained for the second agent;
2. if cells have accumulated maximum sublethal damage from agent 1, the shoul-
der of the survival curve is lost for the second agent;
3. if the final slope of the survival curve is altered, that is, becomes steeper, for
the combined effect of two drugs.
The relationships described imply that there is a range over which two agents can
produce additive effects.
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FIGURE 6.1: The effect of combining two cytotoxic agents together
[65]. Cell survival is indicated following treatment with agent X or
agent Y, each of which has a survival curve with a shoulder followed
by an exponential slope with increasing dose (a and b). Survival (SXY)
after combined use of dose DX of X and dose DY of Y will be equal
to S1 = (SX ⇥ SY) if there is no overlap of damage and the shoulder is
retained for the second agent (c). Survival after combined treatment
SXY will be equal to S2 if cells have accumulated maximum sublethal
damage from the first agent X and the shoulder of the curve is lost for
the second agent Y.
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6.2 Drugs and radiation
Mechanisms of interaction between drugs and radiation can be evaluated at the cel-
lular level on the basis of radiation survival curves prepared with or without the
drug.
Drugs can influence the survival curve in three ways (see Figure 6.2)
1. the curve may be displaced downward by the amount of cell kill produced by
the drug alone;
2. the shoulder on the survival curve may be lost, suggesting that the drug is in
some way preventing the repair of sublethal damage;
3. the slope on the survival curve may be altered, indicating sensitization or pro-
tection by the drug.
FIGURE 6.2: Possibile outcomes of drug treatment on the relationship
between the radiation dose and cell survival [65]. (a) Displacement
of curve; (b) loss of shoulder, indicating the effects of drug on the
repair of sublethal damage; and (c) change in the slope of the curve
indicating sensitization or protection.
Most drug influence radiation response according to the first two modes, a type of
response corresponding to the limits of additivity described in par. 6.1. The third
type of response defines drugs that are radiosensitizers or protectors.
Table 6.1 lists the important interactions between radiation and chemotherapy, which
occur at the cellular and tumor cell population level .
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TABLE 6.1: Mechanisms of Chemotherapy and Radiotherapy interac-
tion
Process Affected Mechanism Example
(Mode of radiosensitization)
Increase DNA damage Drug incorporated into Cisplatin, 5-FU,
(cytotoxic enhancement) DNA/RNA cetuximab,
incorporation
increases
damage susceptibility
Inhibit DNA repair Prevent repair of Halogenated
(cytotoxic enhancement) radiation damage pyrimidines (5-FU)
nucleoside analogues
(gemcitabine,
fludarabine), cisplatin
Cell cycle slowing/arrest Radiation and most Texanes (microtubule
(cytotoxic enhancement) chemotherapy target stabilization)
cycling (proliferating) nucleoside analogues,
cells. Accumulation hydroxyurea
of cells in
radiosensitive G2/M.
Elimination of
radioresistant
S-phase cells
Increase of DNA damage. The majority of chemotherapeutic drugs target DNA and
directly produce damage, which manifests as DNA breaks. For example, the in-
tegration of cisplatin into DNA or RNA close to a radiation-induced SSB can act
synergistically to make the defect significantly more difficult to repair.
Inhibition of DNA repair. Chemotherapy agents have been shown to inhibit the re-
pair of radiation. For example, Fludarabine is a nucleoside analogue which is incor-
porated into DNA and blocks DNA primase, DNA polymerase and DNA ligase.
Cell cycle effects. When administered concurrently, radiotherapy and chemotherapy
often target different phases of the cycle and may cooperate to produce an additive
effect. The radiosensitivity of a cell is dependent on the phase of the cell cycle; cells
in the S phase being the most radioresistant, whereas those in the G2-M phase are
the most radiosensitive.
Because tumors are often defective in one of the cell cycle checkpoints (e.g., the G1/S
checkpoint), inhibiting the remaining checkpoints can shorten the cell cycle, leaving
tumors with less repair time and resulting in greater cell kill than in normal tissues.
The majority of chemotherapeutic agents are inhibitors of cell division and are thus
mainly active on proliferating cells, in addition, many drugs have cell cycle phase
specificity. For example, Gemcitabine, fludarabine, texanes and 5-FU inhibit various
enzymes involved in DNA synthesis and repair in S-phase cells.
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As a consequence of cell cycle phase-selective cytotoxicity of chemotherapeutic agents,
the remaining surviving cells will be synchronized. If radiation could be delivered
when these synchronized cells have reached a more radiosensitive phase of the cell
cycle (e.g., G2/mitosis), a potentiation of the radiation effect might be observed.
In Figure 6.3 is possible to appreciate the effect of radiosensitizers in radiotherapy.
FIGURE 6.3: Radiotherapy plus Cetuximab for locoregionally ad-
vanced head and neck cancer. Overall survival by treatment: 5-year
update [66]. Seven patient was treated. The red curve represents ra-
diotherapy alone, while the blu one radiotherapy coupled with the
Cetuximab radiosensitizer. The overall survival at 5-year is greater in
the combined treatment case.
6.2.1 BNCT as radiosensitizer in radiotherapy
Efforts to improve radiotherapy efficacy have focused on the identification of com-
pounds that can sensitize targeted areas to radiotherapy while limiting bystander
and systematic toxicity, thereby enhancing radiotherapy within tumor cells relative
to normal cell.
For this reason, considering the selective characteristics of BNCT described in the
previous chapter 5, the research work aims at exploiting the boron-10 compound
usually employed in BNCT applications as a localized radiosensitizing drug in ra-
diotherapy. This radiosensitization effect could increase the treatment effectiveness.
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Chapter 7
Materials:
The experimental detection system
In this chapter, the experimental detection system is described, reporting both the
instrumentation used to measure the photon absorbed dose and the neutron dose
equivalent, and the employed anthropomorphic phantoms to detect the dose in
depth in tissue.
7.1 Gafchromic EBT3 films
Radiochromic films have become an important instrument in medical applications
both to verify and to measure two-dimensional dose distributions in external beam
radiotherapy, radiosurgery and brachytherapy [67], [68].
The most popular radiochromic films are the Gafchromic EBT films by Ashland Ad-
vance Materials Inc. (Wayne, NJ, USA) and, at the moment, the third generation
of the film - EBT3 (shown in Figure 7.1), released in late 2011, is available for the
radiotherapy community [69] .
FIGURE 7.1: Gafchromic EBT3 films
by Ashland Advance Materials Inc. (Wayne, NJ, USA), 2011.
Films used in this work are the GAFCHROMIC EBT3 (batch number A10171102),
with sheet dimensions of (20.3⇥25.4) cm2, and they were handled according to the
procedures described in the AAPM TG-55 report [70] and in the user guideline pro-
vided by the manufacturer together with the films [71].
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7.1.1 Description
The EBT3 is a self-developing film, it doesn’t require post-exposure processing, and
it can be read with commercial flatbed RGB (Red Green Blue) color scanners.
The film is tissue equivalent and water resistant, its dose response ranges from 1 cGy
to tens of Gy, and it has got a high spatial resolution (about 25 µm).
The Gafchromic EBT3 dosimetry film is made up of a single active layer, nominally
of 27 µm thick, placed between two transparent polyester substrates of 120 µm thick
each, as represented in Figure 7.2. This symmetric structure allows to no longer keep
track which side is which, eliminating the film face-dependence during scanning.
FIGURE 7.2: Gafchromic EBT3 film structure.
The film is made up of a single active layer, nominally of 27 µm thick,
placed between two polyester substrates, 120 µm thick each.
The atomic mass fraction of the elements constituting the active layer
and the film density are also reported.
The active layer contains the active component, stabilizer, a yellow marker dye and
other additives giving to the film its low energy dependence. The yellow marker
dye, used in conjunction with a RGB film scanner, decreases UV/light sensitivity
and enables multi-channel dosimetry, improving thus the dosimetry results [72].
The polyester substrate, instead, is coated with silica particles. These particles main-
tain a gap between the film surface and the glass window in a flatbed scanner. Since
the gap is nearly ten times the wavelength of visible light, formation of Newton’s
Ring patterns1 is prevented in the scanned image.
1Newton’s rings: it is a phenomenon in which an interference pattern is created by the reflection of
light between two surface: a spherical surface and an adjacent touching flat surface. It is named for
Isaac Newton, who first studied the effect in 1717.
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7.1.2 Principle of operation and use
Like all other Gafchromic films, EBT3 dosimetry films can be handled in interior
room light for short periods without noticeable effects. However, it is suggested that
the film should not be left exposed to room light for hours, but rather should be kept
in the dark when not in use [70].
When the active component in EBT3 film is exposed to radiation, it reacts to form a
blue colored polymer with an absorption maxima at approximately 633 nm.
TheGafchromic EBT3 dosimetry film is recommended to be usedwith a 48-bit flatbed
color scanner: the EPSON Expression 11000XL or 10000XL Photo scanners are the
recommended models due to their large scanning area, measuring the red, green
and blue color components of light transmitted by the film at a color depth of 16-bit
per channel.
In this work, the exposed films were read two days after the irradiation to allow
the stabilization of changes in all the color channel [73], and each film was read
three times with the EPSON Expression 10000XL flatbed scanner on the same day,
to ensure the identical condition of temperature and humidity, minimizing thus the
scanner variability.
The readout process was made according to the manufacturer’s scan guideline [71],
placing the films into the center of the scan area in landscape orientation (a frame
was used to fix the film in a reproducible way), keeping consistent position and ori-
entation in each scan to avoid the lateral scan effect.
RGB-positive images were collected in 48-bit, with a spatial resolution of 72 dpi, in
transmission mode with no colour correction, keeping fixed all the scanner parame-
ters during all the film acquisitions.
The digitized images were then saved in tagged image file format (TIFF) and ana-
lyzed by means of the software ImageJ 1.50i [74], by splitting the film image data into
red, green and blue color channels.
For each scanned image and color channel, a small region of interest (ROI) at the
field centre was selected to obtain the mean pixel value V and its standard deviation
s. Knowing these values and the absorbed dose D by each film, the dose response
curves per each color channel were plotted and analyzed with the software ROOT
[75].
7.1.3 Calibration and sensitivity
Before to use a set of radiochromic films with an identical batch number, one film
needs to be calibrated exposing it to known photon doses.
For this reason, in order to investigate the film performance and to obtain a calibra-
tion curve, several film pieces, each of (4⇥4) cm2, were irradiated at different dose
values, from 0.5 to 90 Gy, with the 15 MV photon beam provided by the Elekta Syn-
ergy Agility LINAC at Maggiore Hospital, Trieste (Italy).
Filmswere placed in awater equivalent slab phantom (RW3 PTW [76]) of (30⇥30⇥12)
cm3 at 1.6 cm depth, in correspondence with the build-up, and irradiated perpendic-
ularly to the radiation beam. The distance from the source to the phantom surface
(SSD) was 100 cm and the field size was (30⇥30) cm2 at isocenter. The RW3 phantom
was centered under the LINAC gantry thanks to its laser alignment system.
The typical dose response for EBT3 film on a RGB scanner is shown in Figure 7.3,
[71]. Note that the response curves slopes are different for each color channel. Each
66 Chapter 7. Materials:The experimental detection system
FIGURE 7.3: Typical response of Gafchromic EBT3 film in all color
channels [71].
of the signals is comprised of a dose-dependent and a dose-independent portion, but
the proportions are different in each color channel. For instance, the response in the
blue channel has a relatively low slope because the signal has weak dose-dependent
while having strong dependence on the thickness of the active layer; instead the re-
sponse in the red channel has a relatively high slope because the signal is highly
dose-dependent.
The recommended equation to fit the calibration curve is:
dx(D) =
a+ b
D  c (7.1)
where dx(D) is the optical density2 of the film in the scanner channel x at dose D,
and a, b, c are the equation parameters to be fitted.
However, in this work, the suggested function to fit the dose response curve has
been empirically modified both to avoid the problem of an impossible ratio when D
is equal to c in equation 7.1 and to provide more precise dose measurements.
The modified calibration function is represented by:
V(D) =
W0 +W1(D/c)
1+ (D/c)
(7.2)
whereV(D) is the pixel value as a function of the absorbed dose D, andW0,W1, c are
the equation parameters to be fitted that depend on the considered color channel.
Moreover,W0 is the pixel value corresponding to D tending to zero (linked, thus, to
the unirradiated film); W1 is the pixel value corresponding to D tending to infinite
(linked to the maximum film dimming); while the parameter c represents the dose
at which the pixel value is half way betweenW0 andW1, [(W0 +W1)/2].
The rational formula 7.2 can be inverted for each of the three RGB colors to pro-
vide three absorbed dose values Dx starting from the film dimming V, with their
associated propagated uncertainty. Then, by weighting the three RGB Dx values, a
2Optical density: it describes the propagation of a wave through a material, and it is calculated as the
logarithmic ratio of the radiation incident on the material to the radiation transmitted by the medium.
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final more precise dose value of an unknown film can be obtained.
Detailed information about the calibration function and the employed procedure can
be found in the recently submitted paper attached in Appendix B.
The described procedures provide dose measurement uncertainty well below 2%
with a precision of about 2.5%, respecting the precision level of 2-4% to be achieved
in film dosimetry [77], [78]).
Notice that other works, such as the recent one by Ref.[79], propose alternative cal-
ibration functions, but often using more complicated expressions not simply to be
handled, inverted and/or suitable for a large dose range like the one here described.
7.2 Superheated Drop (Bubble) detectors
First described by Apfel in 1979 [80], the bubble or superheated drop detectors are
becoming more and more attractive for practical applications in neutron dosimetry.
The most popular bubble detectors are those commercially available from Bubble
Technology Industries (BTI), Chalk River, Canada [81], showed in Figure 7.4.
FIGURE 7.4: Bubble dosimeters representation.
Neutron integral passive bubble detectors from
Bubble Technology Industries (BTI).
In this work two types of their detectors were used, the BD- PND and the BDT. The
BD-PND type has an energy threshold at approx. 100 keV (fast neutrons) and it is
supposed to give a good estimate of dose equivalent above this threshold. While the
BDT was introduced to monitor thermal neutrons, neutrons with energy up to 0.4
eV.
Bubble dosimeters are unique in their high sensitivity to neutrons (up to a few
bubbles per µSv), in their direct reading capability and in their insensitivity to g-
radiation, with an isotropic angular distribution: they are thus suitable to be em-
ployed in mixed radiation fields as in radiotherapy.
Research in this field [82], [42] suggest that the bubble detector is the only type of
personal neutron dosimeter with adeguate sensitivity (i.e., low detection threshold)
to meet the implications of ICRP Publication 103 [22] (the revised ICRP Publication
60 [27]) recommendations for neutron dosimetry.
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7.2.1 Description
A bubble dosimeter consists of a transparent plastic vial of 8 cm3 containing a clear,
elastic hydropolymermedium throughoutwhich 104-105 tiny droplets approximately
20 µm in diameter of a superheated liquid (CCl2F2) have been dispersed.
The polymer in the vial is kept under pressure to prevent the droplets from growing
under normal conditions (i.e., before the detectors are prepared for exposure to neu-
trons). The pressure on the elastic polymer is controlled by a cap assembly on top of
the vial.
The bubble dosimeter from BTI has built-in temperature compensation, which keeps
response sensitivity within±20% between 20 C and 37 C (see Figure 1 in Appendix
A, provided by BTI).
The number of the bubbles obtained from the dosimeter is proportional to the neu-
tron dose over a wide neutron range (see Figure 3 in Appendix A, provided by BTI).
The proportionality constant (i.e., sensitivity) is indicated on the label of every bub-
ble dosimeter.
Each dosimeter is shipped in an airtight aluminum storage tube and with the poly-
mer medium containing the superheated droplets pressurized (i.e., with the cap
screwed onto the top of the dosimeter).
7.2.2 Principle of operation and use
By unscrewing the cap assembly of the bubble dosimeter, the pressure on the poly-
mer is released, and the liquid droplets become superheated. When the dosimeter is
exposed to a neutron flux, neutrons strike the polymer, and the superheated droplets
vaporize due to the high linear energy transfer (LET) recoils from neutron interac-
tions. Small visible bubbles are thus produced instantly in the sensitive medium. A
representation of the process is shown in Figure 7.5.
FIGURE 7.5: How a bubble detector works.
Neutrons interaction with the clear elastic polymer constituting the
dosimeter, in which tiny droplets of a superheated liquid (CCl2F2)
have been dispersed. Neutrons strike the polymer and the super-
heated droplets vaporize due to the recoils from neutron interactions,
making the bubbles visible.
The number of the produced bubbles is proportional to the neutron dose equivalent
as shown in Figures A.2 and A.3 in Appendix A (provided by the manufacturer).
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The bubbles are fixed in the elastic medium and can be subsequently counted visu-
ally or by an automatic image reader. The dose is determined by multiplying the
number of bubbles by the dosimeter’s sensitivity (i.e., the proportionality constant
between the number of the bubbles and delivered dose).
Studies demonstrate that the number of observed bubbles increases with time af-
ter the end of exposure [83]. The increase is approximately (2-4)% in the first 24
hours, then climbs to (4-6)% in the next 24 hours (48 hours after the end of expo-
sure), reaches 10% in the next 24 hours (72 hours after the end of exposure), and
ranges between (10-20)% in the next 72 hours (144 hours after the end of exposure).
This small increase in the number of the bubbles after the end of exposure may be
explained by assuming that some bubbles are too small to be counted immediately
after the end of the exposure but then may gradually increase in size as evaporation
continues due to the fact that the pressure of the gel is insufficient to fully immobi-
lize them. Thus, the bubbles eventually reach sufficient size to be counted some time
after exposure. This effect is relatively small and may be considered to be within the
uncertainties associated with neutron dose determination.
However, the manufacturer recommends keeping the dosimeters under pressure
when not in use (i.e., reading the exposed dosimeters as soon as feasible and re-
pressurizing them as soon as possible): for this reason, in this works the produced
bubbles were read within 1-2 hours after the measurement.
To reuse the dosimeter, the bubbles must first be recompressed into droplets by
screwing the cap assembly back on the dosimeter. The detector is activated again
by unscrewing the cap assembly on the top of the dosimeter. The bubble dosimeter
can be reused several hundred times.
7.2.3 Calibration and sensitivity
The bubble dosimeters are calibrated by the manufacturer with an Am-Be source
having a fluence-weighted average energy equal to 4.15 MeV and a source strength
of 1.13 ⇥ 107 n/s. Dosimeters are calibrated by BTI without the use of a phantom
and with a combination of time and distance from the source that produces approxi-
mately 100-150 bubbles. The source and the dosimeters are held upright and parallel
to each other in a styrofoam jig. The conversion factor used for the Am-Be source is
3.70 ⇥ mrem/(n·cm 2), as calculated from dose equivalent defined in ICRP Report
107 [84] (the revised ICRP Report 38 [85]).
The dosimeters are exposed to the neutron source to determine their detection sen-
sitivities. The detection sensitivity is then indicated on the label of every bubble
dosimeter and a calibration certificate is given together with each detector.
As stated by the BTI manufactures and shown in several studies, the type of the
neutron source used in calibration has only a small effect on the sensitivity value
[86], [87]; in particular, in this work differences between detectors calibration and
the neutron spectrum provided by the e-LINAC are within the 8%.
After sensitivity determination, the necessary temperature compensation compo-
nents are incorporated into the dosimeters, which are then calibrated five times us-
ing the Am-Be source: one calibration each at 20 C, 24 C, 28 C, 35 C, and 37 C. A
bubble dosimeter’s indicated sensitivity is the average response over the tempera-
ture range 20-37 C. The Figure A.1 in Appendix A (provided by BTI) shows the tem-
perature response of the dosimeters; while Figures A.2 and A.3 (provided by BTI)
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indicate that the dosimeter’s linearity with dose is excellent with andwithout repres-
surization of the dosimeters between exposures. The BD-PND bubble dosimeters
provide a good estimate of the dose equivalent for neutrons with energies greater
than 100 keV, as shown in Figure A.4 in Appendix A (courtesy of BTI); while the
BDTs for energies up to 0.4 eV.
However, performing some calibrations in the fast secondary neutron flux provided
by the medical LINAC, it was found that about one-tenth of the fast neutron dose
equivalent contribute to the measured value in thermal dosimeters [47] (see Chap-
ter 9, par. 9.2). This value has been so taken into account and excluded in thermal
neutron measurements.
7.2.4 Longevity of bubble dosimeters
The end of a bubble dosimeter’s useful life occurs when the bubbles can no longer be
compressed back into droplets, when the elastic polymer starts leaking, or when, for
any other reason, the bubble dosimeter does not properly record the neutron dose.
BTI guarantees optimum dosimeter performance for 3 months after receipt, having
a shelf life of at least 6 months (assuming no exposure to neutrons and no depres-
surization). However, several studies indicate that the useful life span of the bubble
dosimeters is longer than the manufacturer’s 3-month warranty. For example, in the
Vanhavere study [88], dosimeters were irradiated over a 2-year period before reach-
ing the end of their useful life. Despite this, the dosimeters employed in this work
were not expired and a calibration check was periodically performed exposing them
to a known neutron field.
7.3 The anthropomorphic phantoms
Anthropomorphic phantoms are employed in radiotherapy in order to evaluate the
dose absorbed by the body: their task is to reproduce, in the better possible way, the
geometry, the sizes and the composition of the human body.
7.3.1 The Trieste anthropomorphic phantom
The Trieste anthropomorphic phantom was specifically developed to be suitable
both for neutron and photon dosimetry. It was designed and built by INFN (Na-
tional Institute of Nuclear Physics) in Trieste following the International Commis-
sion on Radiological Protection indications for neutron dosimetric phantoms (ICRP
103) [22], both about organ positions and tissue substitutes (ICRU 44) [89].
A new phantom was developed because standard phantoms usually employed in
radiotherapy (like RANDO [90]) do not meet all the work needs: to provide suit-
ably large holes to locate bubble dosimeters and to be more tissue equivalent also
for neutrons.
To build a phantom for neutron dosimetry, it’s necessary to consider both the ele-
mental mass fraction of H, C, N and O (which are the main elements involved in
the absorption and scattering reactions) and the neutron energy range involved: the
fine details like surface curvature or squared edges of the phantom geometry are not
so relevant for neutrons. The neutron RBE becomes important at energies higher
than 10 keV and, in this range, the contribution to the absorbed dose comes from the
main elastic scattering on Hydrogen nuclei (up to 97% [89]), while both the scatter-
ing with C, N, O and inelastic scattering and nuclear reactions give a contribution
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of a few percent: for these reasons the phantom was simply made up of polyethy-
lene. In fact looking at the mean human upper part body composition, Hydrogen
is present for 0.10 mass fraction and polyethylene [(C2H4)n], 0.14 Hydrogen mass
fraction, is suitable as material for neutron dosimetry.
The anthropomorphic phantom, represented in Figure 7.6, is thus made entirely in
polyethylene and it approximates dimensions, weight, density and hydrogen con-
tent of an average man [91], as shown in Table 7.1. Moreover, in Figure 7.7 it’s possi-
ble to see how the body proportions known in literature have been exploited to build
the phantom. In fact, it is composed by several modular polyethylene blocks, listed
in Table 7.2 and shown in Figure 7.8, reporting also the external dimensions. The
modular characteristic lets both to place the phantom in the sitting position, making
it suitable for other different dosimetric purposes, and to be easily transported.
FIGURE 7.6: A representation of the Trieste anthropomorphic phan-
tom.
TABLE 7.1: Comparison between the human body and the Trieste
anthropomorphic phantom.
Height Weight Density Hydrogen content
[cm] [kg] [g/cm3] [mass fraction %]
Human body 1.70 73.6 1 0.10
Phantom 1.73 71 0.96 0.14
Inside the phantom several holes, suitable to allocate bubble dosimeters, have been
made in correspondence with critical organs in order to detect the neutron dose
equivalent in depth in tissue. In details, the chest and abdomen area consist of five
polyethylene slabs, in which three slabs present a drawer with arrays (shown in
Figure 7.9) in which bubble dosimeters can be placed. In this way it’s possible to
arrange each dosimeter in the correct organ position and depth, following the ICRP
103 [22] (new ICRP 60 release) recommendations. Moreover, two holes have been
made in the phantom head in order to locate detectors also in correspondence of the
brain position.
Two dosimeters (one for fast neutrons and one for thermal neutrons) were placed
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FIGURE 7.7: Study of the body proportions useful to build the Trieste
phantom.
in the considered organ positions, and holes with no dosimeters inside are filled
with polyethylene cylinders having the same shape of the dosimeter, so no vacuum
areas are present.
The critical organs taken into account for the Trieste phantom are those represented
in Figure 7.10 and reported in Table 7.3.
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TABLE 7.2: The Trieste anthropomorphic phantom, external dimen-
sions.
Height Width Depth
[cm ± 0.1 cm] [cm ± 0.1 cm] [cm ± 0.1 cm]
Head 22.0 15.0 19.0
Neck 7.0 9.0 7.0
Chest 40.0 40.0 15.0
Abdomen 25.0 40.0 15.0
Thighs 40.0 25.0 15,0
Calves 40.0 25.0 12.0
Feet (2⇥) 20.0 10.0 5.0
FIGURE 7.9: Representation of the drawer with five couples of arrays
suitable to host bubble detectors for the chest area of the Trieste phan-
tom.
TABLE 7.3: Considered critical organ positions in the Trieste anthro-
pomorphic phantom.
Position Organs x y z Drawer
[cm ± 0.1 cm] [cm ± 0.1 cm] [cm ± 0.1 cm]
Brain 0.0 84.0 10.0
a-b Thyroid 0.0 60.0 5.0 1
d Lung (right) -10.0 45.0 10.0 2
g Stomach 2.0 45.0 10.0 2
f Liver 2.0 35.0 5.0 1
n Bladder 0.0 5.0 5.0 1
i Kidney (left) -10.0 30.0 15.0 3
Gonads 0.0 -5.0 2.0
7.3. The anthropomorphic phantoms 75
(A) Front projection.
(B) Back projection.
FIGURE 7.10: The Trieste anthropomorphic phantom overlapping the
front and back projection of the human body, with bubble dosimeters
located in correspondence with the considered critical organs. Blue
dosimeters correspond to the BD-PNDs, the red ones to the BDTs.
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7.3.2 The Torino anthropomorphic phantom
Measurements carried out in Torino were performed by using an existing anthropo-
morphic phantom.
The Torino anthropomorphic phantom (Figure 7.11) was designed and made by
INFN sec. Turin in collaboration with the Ispra JRC (Join Research Centre), Varese,
Italy, several years ago [93]. It was specifically developed for neutron dosimetry in
order to evaluate the neutron spectrum and the neutron dose equivalent in tissue
(NCRP 38) [41].
The Torino phantom is made up by different slabs of plexiglass and polyethylene
(seven plexiglass slabs of 1 cm and 2 cm thickness, and one polyethylene slab of 6
cm thickness). There are also 16 cavities in correspondence of critical organs suitable
to locate the integral passive bubble dosimeters (BTI) in order to detect the neutron
dose in depth. Moreover, the phantom has human bone dust inserted in correspon-
dence of the vertebral column, taking so into account the interactions between neu-
trons and calcium nuclei.
The phantomwas designed following the International Commission on Radiological
Protection indications for neutron dosimetric phantom both about organ positions
(ICRP 60) [27] and tissue substitutes (ICRU 44) [89].
The mass fraction composition of materials of the Torino phantom are reported in
Table 7.4, while its external dimensions and organ positions in Table 7.5 and 7.6, re-
spectively.
Moreover, Table 7.7 shows the comparison between the composition of the anthro-
porphic phantom and the reference ICRU sphere3(ICRU 44)[89]. The hydrogen con-
tent inside both phantoms is comparable.
TABLE 7.4: Chemical composition and density of materials constitut-
ing the Torino phantom.
Materials Percentage mass Density
[g/cm3]
Plexiglas 8% H, 32% O, 60% C 1.190
Polietilene 14.4% H, 85.6% C 0.920
Polvero di osso 0.2% H, 41.4% O, 18.5% P, 39.9% Ca 1.930
3ICRU sphere: standard phantom for the definition of operational quantities for dose equivalent. It
is a 30 cm diameter sphere, with a density of 1 g/cm3. The chemical composition, in percentage mass,
is: H (10.1%), C (11.1%), O (76.2%), N (2.6%).
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FIGURE 7.11: The Torino anthropomorphic phantom representation.
Front projection. It is possible to see the holes in correspondence of
critical organs with inside the BTI detectors.
FIGURE 7.12: The reference system for determining the organ posi-
tions in the Torino anthropomorphic phantom. Organs belonging to
slab No.5 are reported.
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TABLE 7.5: The Torino phantom, external dimensions.
Hight Width Thickness
[cm ± 0.1 cm] [cm ± 0.1 cm] [cm ± 0.1 cm]
Head 15.0 13.5 19.0
Neck 10.0 11.0 13.5
Body 59.0 30.0 20.0
(chest)
36.0
(chest + pelvis)
47.0
(chest + pelvis + shoulders)
TABLE 7.6: The Torino phantom, organ positions. The coordinates
were calculated by choosing the origin of the reference system along
the vertical axis of the phantom, on the surface of the first slab (as
shown in Figure 7.12), and the z-axis pointing downwards. The mid-
point of each cavity was chosen to identify the position of the organ.
The slab No.5 is made up of polyethylene, while the remaining ones
of plexiglass.
Organs x y z slabs
[cm ± 0.1 cm] [cm ± 0.1 cm] [cm ± 0.1 cm]
Gonads 0.0 10.0 2.0 2
Bladder 0.0 17.2 6.0 4
Liver -5.0 36.5 6.0 4
Esophagus 0.0 39.7 6.0 4
Right Colon -7.5 26.7 10.1 5
Left Colon 6.5 26.7 10.1 5
Stomach 2.0 35.0 10.1 5
Right Lung -6.0 42.9 10.1 5
Left Lung 6.0 41.0 10.1 5
Thyroid 0.0 62.5 10.1 5
Brain 0.0 77.3 10.1 5
Spleen 9.5 26.0 14.3 6
Left Kidney 4.0 27.8 16.0 7
Right Kidney -5.5 29.0 16.0 7
Bottom Column 0.0 28.8 16.0 7
Half-high Column 0.0 44.0 16.0 7
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TABLE 7.7: Tissue substitutes in percentage mass. Comparison be-
tween tissues substitutes of the Torino phantom and the tissue of the
reference ICRU sphere.
Torino Phantom ICRU Sphere
[w%] [w%]
H 10.2 10.1
C 67.9 11.1
O 18.7 72.2
C + O 86.6 87.7
N 2.6
Bone dust (H, O, P, Ca) 3.2
Density [g/cm3] 1.056 1
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Chapter 8
Simulation methods: the Monte
Carlo codes
The way to analyse in detail complex probabilistic processes, such as the production
and transport of photon, neutrons and other particles, is the Monte Carlo approach.
The name is a reference to theMonte Carlo Casino inMonaco: the use of randomness
and the repetitive nature of the process are analogous to the activities conducted at
a casino.
Numerous software packages for Monte Carlo simulation of nuclear processes have
been developed: the main ones dealing also with no-charged particles interactions
and transport are Fluka, MCNP and GEANT4 [94], [64], [95].
Fluka is a fully integrated particle physics Monte Carlo simulation package born
in CERN, based on Fortran77 programming. It covers an extended range of appli-
cations, from high energy nuclear physics to medical physics and radioprotection.
MCNP, which the acronymous stands for Monte Carlo N- Particles, was instead de-
veloped by Los Alamos National Laboratories. It finds application in several fields,
such as radiation protection and dosimetry, radiation shielding, medical physics, nu-
clear criticality safety, detector design, fission and fusion reactor design, etc. The last
mentioned code is GEANT4, developed by CERN starting from 1998 as the successor
of the GEANT series of software toolkits, and it is based on C++ object-oriented pro-
gramming. It is mainly employed for high energy physics but has recently spread
out in dealing with neutron problems at low energies as well as in medical physics.
The code chosen for the simulation in this work is MCNP release 4B, a quite old
code but available at University. Its main features useful for the application are:
the possibility to follow radiation transport of neutrons, photons and electrons us-
ing cross sections tables from evaluated data libraries for almost all the isotopes on
a wide energy range; the presence of specific libraries for the handling of thermal
neutrons interactions; the availability of variance reduction techniques, the treat-
ment of photo-nuclear (g,n) reactions with specific cross section libraries as well as
the possibility to calculate the dose in BNCT, an important feature for the thesis work
purpose.
Moreover, in the last part of the research work simulations by using the GEANT4
software were performed, with the intent to test the toolkit performance in simulat-
ing the neutron photoproduction in medical LINACs.
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8.1 Monte Carlo simulations: the MCNP4B code
The MCNP4B release allows treating the neutron, photon and electron transport
through 3-dimensional geometries. The particle is followed from the source until
it stops for collisions or until it goes out from the geometry of interest. The interac-
tion of the particle with matter is based on stochastic processes. Each probabilistic
event is simulated in sequence and, only later, the individual probability distribu-
tions which regulate these events are sampled: this gives a precise description of the
phenomenon.
The data necessary for the process description, such as cross sections and thresh-
old energies, are located in suitable folders, called libraries.
The probability of neutron emitted by the source to make a collision in a range l
and l + dl is
p(l)dl = e Ât l ·Ât dl (8.1)
where Ât is the macroscopic cross section of the absorber, and it is considered as the
probability for unit of path length to collision occurs.
Fixed a random number between 0 and 1 such that:
x =
Z 1
0
e Ât ·Ât ds = 1  e Ât l (8.2)
the range l is:
l =   1
Ât
ln(1  x) (8.3)
Since 1  x has the same distribution of x, it can be replaced, obtaining the expression
of the crossed distance by the neutron before a collision:
l =   1
Ât
ln(x) (8.4)
Once the collision has occurred and the target nucleus has been identified, the neu-
tron may undergo an elastic scattering, an inelastic scattering, or a capture process.
Regarding photons, the procedure is based on two different models: the first one,
used with highly energetic photons, considers the photoelectric effect, Compton
scattering and pair production. Thus, the total cross section will be:
st = sph + sc + spp (8.5)
While, the procedure used dealing with low energy photons, or with high-Z ma-
terial, considers the coherent scattering, fluorescence and capture processes. This
model allows to describe interactions of photons with energies lower than the pho-
toelectric threshold one.
The high number of small interactions which characterized the transport of electron
and charged particles do not allow the Monte Carlo code to a full knowledge of the
entire path of a particle, because this requires too many resources in terms of calcu-
lation speed. For this reason, suitable procedures have been included in the code in
8.1. Monte Carlo simulations: the MCNP4B code 83
order to treat charged particles transport, exploiting the main cross sections and the
statistical dependence of the transport. It is so possible to provide an estimation of
the quantity probability distributions, such as the energy loss and angular deflection.
To compile an input file is required the definition of:
1. the three-dimensional geometries, dividing the space into cells bounded by
surfaces of the first and second order as a plane, sphere or cylinder;
2. the density and chemical composition of materials that make up the cells;
3. the source, by specifying the size, shape and energy spectrum;
4. the physical quantities that are to be estimated (such as particle flux, mean
energy deposed, absorbed dose);
5. the variance reduction techniques in order to speed up the calculation time,
such as energy cuts or by increasing the importance of some cells (detailed in
Appendix C).
8.1.1 The MCNP4B-GN code
A routine implemented in theMCNP4B code, theMCNP4B-GN code (NEA 1733/01),
especially developed by INFN (National Institute of Nuclear Physics) of Turin, for
(g, n) reaction was used [96].
MCNP4B-GN is used both to simulate the production of giant dipole resonance pho-
toneutrons in thick layers of high-Z elements, treating so the (g,n) production and
transport in medical accelerator heads, and to study the undesired neutron dose
to patients, employing a single code for both the electromagnetic and the neutron
transport.
In the simulation code, (g, n) and (g, 2n) channels are treated and both evaporation
and direct models of neutron emission from the nucleus are considered.
Since photonuclear cross-sections are more than 2 orders of magnitude lower than
the main atomic processes (Photoelectric, Compton and Pair production), as Figure
4.2 shows, suitable and effective variance reduction techniques were applied.
Evaporation model
According to the evaporationmodel, a photon going deep into the nucleus, gives rise
to a highly excited nucleus. This energy can be considered as the "heat" produced
by the collision of the photon with the nucleus: such "heat" causes the neutron
evaporation. Called E the energy corresponding to the excited level of the nucleus,
the maximum kinetic energy of the emitted neutron is equal to E  Sn, where Sn is
the neutron separation energy from the nucleus.
If the neutron leaves the residual nucleus (Z, A-1) in an excited level Er, the corre-
sponding energy to the emitted particle will be:
En = E  Sn   Er (8.6)
The energy linked to each level Er of the residual nucleus will correspond to the
neutron energy En until the following relation is valid: Er < EM, where EM is the
maximum energy value of the emitted particle, that is when the nucleus stays in its
fundamental state.
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The energy distribution of the particles emitted by the nucleus consists of a set of
peaks. These peaks correspond to the spectrum of the levels of the nucleus (Z, A-1);
the higher energies correspond to the lower excitation states. If the incident particle
energy reaches an enough high value, a greater number of levels of the nucleus can
be excited. Therefore, there will be a continuous energetic distribution of emitted
particles because the Er energies are very close to each other.
Statistical mechanics provides an explanation of the physical behavior of strongly
excited nuclei. The emission of a neutron from the excited nucleus can be compared
to the evaporation of a molecule from a heated liquid: the thermodynamic concepts
of heat, temperature and entropy are thus applied to the nucleus.
The energy spectrum of the emitted particles follows a Maxwellian distribution, and
it depends on the nuclear temperature after the emission.
It is expressed as:
T =
✓
Er
a
◆1/2
(8.7)
where Er is the excited energy of the nucleus (Z, A-1), and a is the level density pa-
rameter.
In calculating the temperature T, the value of Er corresponding to the maximum ex-
citation energy of the residual nucleus is used; while, the parameter a is empirically
calculated. The level density parameter is expressed in MeV, and it depends on the
number of neutrons and protons of the considered nuclide.
The photoneutrons from evaporation process are emitted with an isotropic angular
distribution.
Direct model
In the direct model, the incident particle transfers its energy to a single nucleon. This
one is emitted with a energy that depends on:
- its difference with the incident particle energy;
- the nucleon binding energy with the nucleus;
- the possible excitation energy of the remaining nucleus.
The direct process is characterized by an anisotropic angular distribution of the pho-
toneutrons. It can be expressed according to the following function:
f (q) = 1+ C · sin2(q) (8.8)
where q is the angle between the incident photon and the emitted neutron, while C
is an empirical constant depending on materials as a function of the neutron energy.
The direct effect increases as the incident photon energy increases, and the ratio
between neutrons emitted by direct effect and evaporative effect is of the order of
13-14%.
In literature there is a spare information about the direct photonuclear effect, but an
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algorithm to calculate the percentage of neutrons produced by direct processes is
done by [97].
Fd =
8><>:
0, (Eg   Sn) < 2.5 MeV
0.031, 2.5 MeV < (Eg   Sn) < 9.0 MeV
0.2, (Eg   Sn) > 9.0 MeV
(8.9)
where Fd is the fraction of neutrons directly produced with respect to the total ones:
this quantity will thus increase as the excitation energy of the nucleus increases. Eg
is the incident photon energy, and Sn the binding energy of the neutron.
The Fd value as a function of (Eg - Sn) for different high-Z elements is done by Figure
8.1.
FIGURE 8.1: Fraction of neutrons emitted by the direct process as a
function of the energy available for the emission itself [97].
Photonuclear reactions on light elements
By using this simulation code it is possible to calculate the photoneutron spectrum
and doses due to photon interactions with heavy elements constituting the LINAC
head. However, interactions with light elements constituting the human body must
be also take into account in order to evaluate the neutron spectrum and neutron
doses in tissue: in this way a correct estimation of the neutron contamination in ra-
diotherapy can be achieved.
Photons with energies range between few MeV and tens of MeV interact with light
elements constituting the tissue producing high-LET particles such as neutrons, pro-
tons, 2H, 3H, 4He and other heavier particles, depending on the incident beam en-
ergy.
In the giant dipole resonance energy range (6 - 20 MeV), of interest for this work,
the photonuclear process is dominated by the (g, n) and (g, p) reactions, and the
maximum of the cross sections is included between 10 mb - 20 mb depending on the
considered nucleus (see par. 4.2). For energies higher than 20 MeV the dominated
process is the quasi-deuton effect, consisting in the emission of a couple neutron-
proton.
The light elements considered by the code (listed in Table 8.1), the corresponding
cross sections and the chosen theoretical model refer to the data published by [98].
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The used photonuclear model is greatly simplified, considering only direct channel,
in which the incident photon transfers all its energy to a single particle, which it is
emitted from the nucleus with an energy EN equal to:
EN = (E  Eth   Ee) · (A  AN)A (8.10)
where E is the incident photon energy, Eth is the photonuclear reaction threshold
energy, and Ee is the transition energy between the excited state and the ground
state of the residual nucleus. The factor [(A - AN) / A] takes into account the recoil
of the residual nucleus, in which A is the atomic mass of the residual nucleus and
AN is the atomic mass of the emitted particle.
TABLE 8.1: Light elements considered in theMCNP4B-GN code, pho-
tonuclear reactions and corresponding threshold energies [98]. (g, n0)
e (g, n⇤) indicate the fundamental state and the excited state, respec-
tively, in which the nucleus remains after the neutron emission.
Element Photonuclear reaction Threshold energy
[MeV]
16O (g, n0) 15.7
(g, n⇤) 21.0
(g, np) 23.0
(g, 2n) 28.5
12C (g, n0) 18.7
(g, n⇤) 20.7
(g, np) 27.4
(g, na) 26.0
(g, npa) 38.0
14N (g, n0) 10.5
(g, np⇤) 14.08
18O (g, n) 8.05
(g, 2n) 12.2
13C (g, n) 4.95
(g, 2n) 23.7
23Na (g, n) 12.4
(g, np) 19.2
(g, 2n) 23.5
35Cl (75.5%) (g, n) 12.6
(g, np) 17.8
(g, 2n) 24.2
37Cl (24.5%) (g, n) 10.3
(g, np) 18.3
(g, 2n) 19.0
31P (g, n) 12.3
(g, np) 17.9
32S (g, n) 15.0
(g, np) 21.2
39K (g, n) 13.1
(g, np) 18.2
40Ca (g, n) 15.6
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8.2 Monte Carlo simulations: the GEANT4 code
The acronymous GEANT stands for "GEometry ANd Tracking". The code has been
created exploiting software engineering and object-oriented technology and imple-
mented in the C++ programming language, for modeling and simulating particles
interactions with matter.
It has been designed and constructed to include facilities for handling geometry,
tracking, detector response, run management, visualization and user interface.
• Geometry is an analysis of the physical layout of the experiment, including de-
tectors, absorbers, etc., and considering how this layout will affect the path of
particles in the experiment.
• Tracking is simulating the passage of a particle throughmatter, considering also
possible interactions and decay processes.
• Detector response is recording when a particle passes through the volume of a
detector, and approximating how a real detector would respond.
• Run management is recording the details of each run (a set of events), as well as
setting up the experiment in different configurations between runs.
Because of its general purpose nature, Geant4 is well suited for development of com-
putational tools for analysing interactions of particle with matter in many fields,
including space, medical and nuclear physics applications [99]
8.2.1 How to built a GEANT4 input file
Working with GEANT4 is like making a building set. If "you get the idea, you can
build what you want, tailor it to your requirements, but you have to build it your-
self" [100].
The general receipt for user includes the so-called Mandatory classes (in any user
application) and Action classes (invoked during the execution of the loop).
The mandatory classes, analysed in the next three subsections, are:
1. G4VUserDetectorConstruction, that describes the experimental set-up
2. G4VUserPhysicsList, that selects the physics you want to activate
3. G4VUserPrimaryGeneratorAction, that generates primary events
while the action classes include:
- G4VUserPrimaryGeneratorAction
- G4UserRunAction
- G4UserEventAction
- G4UserTrackingAction
- G4UserSteppingAction
Relationships between action classes are represented in Figure 8.2.
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FIGURE 8.2: Block diagram representing the relationships between
action classes in GEANT4 (from [101]).
1. Detector construction
The simulated detector geometry and materials are defined by a mandatory class
extending G4VUserDetectorConstruction.
Geant4 providesmany pre-programmed shapes that can be assembled in a hierarchy
of volumes. The hierarchy is used as a natural way of embedding volumes within
volumes and as an efficient way of navigating through the geometry. However,
efficiency comes primarily from an automated process of "voxelisation": the space
is divided into slices in three dimensions such that each slice contains only a few
volumes, reducing so the computation time for determining the location of tracks
within the geometrical model.
To understand how to manage the geometry, see Figure 8.3.
Three conceptual layer are present:
- G4VSolid, which gives information about the detector shape and dimensions;
- G4LogicalVolume, for adding information about material (G4Material), sensi-
tivity (G4VSensitiveDetector) and visualization (G4VisAttribute);
- G4VPhysicalVolume, for adding information about its position, rotation, etc.
The G4VSensitiveDetector class should be extended to build a detector; one or more
G4LogicalVolumes classes can be linked to it, and it is invoked when a particle passes
through the associated volume.
The scheme in Figure 8.4 shows how the sensitive detector class works, where the
G4VHit class stores information (e.g.: position and time of the step, energy deposi-
tion of the step, momentum of the track...), while by the G4UserEventAction class it’s
possible to access to the stored hits at the end of events.
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FIGURE 8.3: The geometry management in GEANT4 (from [101]).
FIGURE 8.4: Bock diagram representing the sensitive detector classes
in GEANT4 (from [101]).
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2. Physics implementation
The application builder has to code a second mandatory class, called the physics list,
that assigns appropriate processes to each particle or ion of interest. Each process
can invoke one or more models, depending on the type of particle, energy, etc. Each
process randomly competes to be the one that happens. After something happens,
the probabilities for happening in the future are updated so that proper distributions
are observed.
The user has to choose the correct physics list, and he has to:
- implement all the necessary particles;
- define all the necessary processes and assign the proper particles to them;
- set the energy threshold of the production of the particle.
3. Primary generator action
The last mandatory class is the G4VUserPrimaryGeneratorAction abstract class for the
generation of primaries. Inside it the user has to set the beam parameters: the shape,
the initial energy, the position, the direction, etc.
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Chapter 9
PART 1:
Measurements of the secondary
neutron radiation in radiotherapy
As described in the previous chapters, medical linear accelerators (LINACs) for ra-
diotherapy produce fast secondary neutrons due to photonuclear (g, n) reactions.
Neutron production is governed by the properties of the giant dipole resonance
(GDR) reaction and neutrons are generated when the incident photon energy ex-
ceeds the GDR reaction threshold (6 - 20 MeV), with a mean energy of about 1 MeV
and an isotropic angular distribution. Most of the neutrons are produced by the
interaction of the photon beam on high-Z elements constituting the LINAC head
(target, scattering foils, collimators, jaws, etc.), in addition to being produced in
the bunker walls, floor and ceiling or directly inside the human body. Therefore,
a patient undergoing a radiotherapy treatment is affected by an extra unaccounted
neutron dose that could represent a risk contribution for the patient, causing for ex-
ample radio-induced tumours.
For this reason, the first part of the research work was dedicated to performing mea-
surements of the secondary neutron radiation during radiotherapy sessions, in order
to estimate the total amount of photoneutrons inside and outside the human body.
The chapter describes measurements performed in Trieste, at Maggiore Hospital,
by using the Elekta Synergy Agility LINAC at different megavoltages.
Measurements of the parasitic neutron dose at organs at dif-
ferent LINAC energies
Experimental measurements of the full body parasitic neutron dose equivalent at
critical organs, during single-field conformal radiotherapy sessions, were performed
in order to investigate the neutron photoproduction provided by a LINAC operating
at 15 MV, 10 MV and 6 MV. The aim was to compare the results in terms of, in-field
and out-of-field, neutron photoproduction between different energies with the same
irradiation conditions.
Eachmeasurement was repeated three times, in the same location, in the same set-up
conditions and by using the same LINAC.
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9.1 Materials and methods
The LINAC photoneutron production has been investigated during single-field ra-
diotherapy sessions, measuring the neutron dose equivalent in depth in tissue by
using a tissue equivalent phantom together with bubble dosimeters.
The LINAC employed was the Elekta Synergy Agility operating in photon mode at
15 MV and at energies near the GDR reaction threshold, 10 MV and 6 MV.
The medical LINAC calibration output was carried out by following the Interna-
tional Code of Practice for Dosimetry IAEA TRS-398 [102]. The relationship of the
dose to the number of monitoring units (MU) is 1 cGy = 1 MU at build-up in a water
tank, measured with cylindrical chamber (PTW Farmer), with the SSD (source-to-
surface distance) equal to 100 cm and the field size of (10 ⇥ 10) cm2 at isocenter.
The experimental method
Two different kinds of measurements were performed:
1. The neutron dose equivalent at the patient surface plane, to estimate the total
amount of photoneutrons in the treatment area
2. The neutron dose equivalent at organs, to measure the full body photoneutron
contribution to the patient.
Measurements were carried out with the LINAC gantry at 0 , with an open direct
photon beam of (10 ⇥ 10) cm2 at isocenter.
The patient plane measurements were carried out placing two dosimeters (one for
fast and one for thermal neutrons) on the surface of a cubic polyethylene phantom
(30 ⇥ 30 ⇥ 30 cm3) at isocenter, with the SSD equal to 100 cm. While, the neutron
dose equivalent measurements at organs were performed by using the Trieste an-
thropomorphic phantom, with the photon beam centered on the pelvis region, hav-
ing the SSD equal to 92.5 cm and the isocenter at 7.5 cm depth, in correspondence
with the prostate position. Eight critical organs were taken into account and two
dosimeters (one for fast neutrons and one for thermal neutrons) were placed in each
organ position, for a total of 16 detectors employed.
In Figure 9.1 the experimental setup for the second kind of measurements is repre-
sented.
9.2 Results and discussion
All results are reported in mSv normalized to 100 MU provided by the LINAC, that
is 1 Gy of photon dose absorbed by the patient at build-up in reference conditions.
The typical statistical errors are ⇠5 - 10% due to bubble counting in the range of 300
- 100 bubbles per dosimeter, respectively.
The patient surface plane neutron dose equivalent
Results regarding the patient planemeasurements are shown in Figure 9.2 reporting,
in logarithmic scale, both the fast and the thermal neutron dose equivalent at the
patient surface plane for nominal X-ray energies of 15, 10 and 6 MV. The measured
values are summarized in Table 9.1.
From the obtained results, two important considerations have been drawn:
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FIGURE 9.1: The Trieste anthropomorphic phantom undergoing the
single-field radiotherapy session. The photon beam is centered on the
pelvis region and the isocenter is at 7.5 cm depth, in correspondence
with the prostate. The irradiation is done with the LINAC gantry at
0 , with a direct open field of (10 ⇥ 10) cm2 at isocenter and with the
SSD equal to 92.5 cm.
TABLE 9.1: Patient surface plane neutron dose equivalent per 100MU
for the LINAC operating at 15, 10 and 6 MV. Irradiation setup con-
ditions: field size of (10 ⇥ 10) cm2 at isocenter and SSD of 100 cm.
Measurements performed by using BTI detectors.
Fast neutron dose Thermal neutron dose
[mSv / 100 MU] [mSv / 100 MU]
15 MV 1.98 ± 0.20 0.24 ± 0.02
10 MV 0.91 ± 0.09 0.09 ± 0.01
6 MV 0.07± 0.01 0.006 ± 0.001
• The neutron dose equivalent is reduced by a factor ⇠2 and by a factor ⇠30 of
the measured values at 15 MV for data acquired at 10 and 6 MV, respectively.
• It was found that about one-tenth of the fast neutron dose equivalent con-
tribute to the measured value in thermal dosimeters. This value has been so
taken into account and excluded in thermal neutron measurements.
The measured neutron dose equivalent per unit of 100 MU values at the patient
plane compare reasonably well with those measured by other workers using similar
detector technology, for LINACs operating at 15 and 10 MV [46], [103]. While the
photoneutron production in lower energy LINACs, at 6 MV, is usually ignored.
The parasitic neutron dose equivalent at organs
Results of the BTI measurements at organs during the single-field 15 MV and 10 MV
test irradiations are summarized in Figure 9.3. For each critical organ, the first col-
umn represents the total neutron dose equivalent (fast plus thermal), the second one
is the fast neutron component, while the third column corresponds to the thermal
94 Chapter 9. PART 1:Measurements of the secondary neutron radiation in radiotherapy
FIGURE 9.2: Fast and thermal neutron dose equivalent at the patient
surface plane for a 6, 10 and 15MVLINAC operating in photonmode.
Logarithmic scale. Irradiation setup conditions: photon field size of
(10 ⇥ 10) cm2 and SSD equal to 100 cm. BTI measurements.
component. Results for the 6 MV irradiation are instead reported in Figure 9.4.
At nominal X-ray energies of 15, 10 and 6 MV, the in-field recorded values are 2.05
± 0.2, 0.56 ± 0.06 and 0.031 ± 0.003 mSv/100 MU, respectively. In the remaining
critical organs, the neutron dose equivalent decreases out-of-field and going deep in
phantom, due to neutron moderation and absorption in tissue. Notice that in experi-
mental cases like this one described, the last statement could be slightly not accurate:
neutrons could be also produced in the bunker walls, floor and ceiling, in a complex
and mostly unknown way, giving a contribution to an organ rather than to another
one. Only at 6 MV the out-of-field neutron dose equivalent contribution is less than
0.1% of the photon dose and it may be considered negligible, while photoneutrons
are still present in the treatment area.
In Figure 9.5, all the obtained results are plotted together in logarithm scale. It is so
possible to notice that the total neutron dose equivalent trend at organs is the same
for each simplified direct beam irradiation. Moreover, in the treatment area, in the
prostate position, the neutron dose equivalent to the patient is is maximum at 15
MV, 4 times lower at 10 MV and 72 times lower at 6 MV. This factor increases going
far away from the radiation field, but the neutron dose equivalent is not negligible
except for the 6 MV irradiation.
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(A) Neutron dose equivalent at organs for the 15 MV
LINAC.
(B) Neutron dose equivalent at organs for the 10 MV
LINAC.
FIGURE 9.3: Neutron dose equivalent per 100 MU at organs for the
LINAC operating at 15 MV and 10 MV. Photon field centered on the
pelvis region. SSD: 92.5 cm; isocenter: 7.5 cm depth in phantom in
correspondence with the prostate; field size: (10 ⇥ 10) cm2 at isocen-
ter. BTI measurements.
96 Chapter 9. PART 1:Measurements of the secondary neutron radiation in radiotherapy
FIGURE 9.4: Neutron dose equivalent per 100 MU at organs for the
LINAC operating at 6 MV. Photon field centered on the pelvis region.
SSD: 92.5 cm; isocenter: 7.5 cm depth in phantom in correspondence
with the prostate; field size: (10 ⇥ 10) cm2 at isocenter. BTI measure-
ments.
FIGURE 9.5: Total neutron dose equivalent per 100 MU at organs pro-
vided by a 15, 10 and 6 MV LINAC. Logarithmic scale. Photon field
centered on the pelvis region. SSD: 92.5 cm; isocenter: 7.5 cm depth
in phantom in correspondence with prostate; field size: (10⇥ 10) cm2
at isocenter. BTI measurements.
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9.3 Conclusions
The photoneutron production in the Elekta Synergy Agility LINAC operating at 15,
10 and 6 MVwas investigated for an anthropomorphic phantom undergoing single-
field radiotherapy sessions. The parasitic neutron dose equivalent was measured by
using bubble detectors both at the patient surface plane and inside critical organs,
maintaining the same experimental setup conditions within the two kinds of mea-
surements in order to compare results among the three studied operating LINAC
megavoltages.
Several studies about the photoneutron dose measurements, with different dosimet-
ric system such as bubble detectors, polycarbonate film, activation detectors and
thermoluminescance dosemeters, are present in literature [46], [45], [104]. However,
there is sparse information about photoneutrons provided in lower megavoltages
LINACs, near the GDR reaction threshold, at 10 MV and 6 MV.
The measured neutron dose equivalent per unit of 100 MU values at the patient
plane compare reasonsobly well with those measured by other workers using simi-
lar detector technology, for LINACs operating at 15 and 10 MV [46], [103]. While the
photoneutron production in lower energy LINACs, at 6 MV, is usually ignored.
From this first part of the research work it emerges that a patient undergoing a con-
ventional radiotherapy treatment, with energies E  10 MV, is always affected by an
extra usually unaccounted neutron dose, which could cause radio-induced tumours
representing a risk factor for the patient.
The residual neutron photoproduction is also present at energies near the GDR re-
action threshold. It is ⇠20% and ⇠3% of the measured values at 15 MV for data
acquired at 10 and 6 MV, respectively. These values increase during a treatment
due to neutron thermalization and absorption in the human body, but the neutron
contribution is not negligible at 15 and 10 MV. Although a slight amount of pho-
toneutrons are provided by a 6 MV LINAC, it should not be completely neglected
in clinical applications, especially considering other kind of treatments in which the
use of multileaf collimators or lead blocks could increase the neutron photoproduc-
tion.
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Chapter 10
PART 2:
The BNCT contribution in
radiotherapy
During X-ray radiotherapy treatments by using electron medical linear accelerators
with accelerating potentials above 10 MV, patients undergo an extra unaccounted
neutron dose. Emitted photoneutrons cannot be ignored and represent a risk factor
for patients, since neutrons could cause secondary radio-induced tumours. More-
over, neutrons are moderated by elastic collisions on light elements (H, C, O, N)
constituting the human body: therefore, a consistent thermal neutron field is present
in the treatment area. The research work aims at investigating the possibility to em-
ploy the thermal neutron field to combine a "BNCT contribution" to the traditional
radiotherapy treatment, improving the radiotherapy effectiveness.
The second part of the work was thus focused on performing simulations and mea-
surements quantifying the thermal neutron field in the treatment zone during a con-
ventional radiotherapy treatment in order to calculate the additional BNCT equiva-
lent dose.
This part of the work was performed in Turin, by using the 18 MV Varian 2300CD
LINAC and the Torino anthropomorphic phantomwith inside thermal neutron bub-
ble detectors.
10.1 Materials and Methods
The BNCT contribution in radiotherapywas investigated during a simplified prostate
cancer treatment, by using an open direct field centered on the gonads position at 4
cm depth in phantom.
The irradiation set-up conditions are: LINAC operating in photon mode at 18 MV
accelerating potential; gantry at 0 ; photon field size of (10 ⇥ 10) cm2 at isocenter;
SSD = 96 cm.
The LINAC calibration output is such that 1 cGy = 1 MU at build-up in a water tank,
when the SSD = 100 cm and the photon field size is (10 ⇥ 10) cm2 at isocenter.
The experimental set-up is shown in Figure 10.1, in which it’s possible to see the
Torino anthropomorphic phantom undergoing the radiotherapy session. The total
structure, the LINAC plus the phantom, was considered in the MCNP4B-GN input
file.
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FIGURE 10.1: The Torino anthropomorphic phantom undergoing the
single-field radiotherapy session. The photon beam is centered on the
pelvis region and the isocenter is at 4 cm depth, in correspondence
with the prostate position. The irradiation is done with the LINAC
gantry at 0 , with a direct open field of (10 ⇥ 10) cm2 at isocenter and
with the SSD equal to 96 cm.
10.1.1 Simulation of the experimental set-up
This section describes the data entered into the simulation file for characterizing both
the accelerator and the anthropomorphic phantom.
The 18 MV Varian 2300CD LINAC
The accelerator head components included in the simulation file are summarized in
Table 10.1, for the 18 MV Varian 2300CD LINAC, reporting its materials and their
approximate shapes.
The axes origin was placed in the target centre, with the z-axis pointing downwards,
along the isocenter line.
The representation of the simulated LINAC head is shown in Figure 10.2. Notice
that multileaf collimators were not considered in the input file: MLC is not used for
a conventional radiotherapy treatment like the one here studied.
From an operational point of view the LINAC beam parameters can be summarized
as follow (Table 10.2):
From this parameters it is possible to obtain the effective electron flux impinging on
the target by the relation:
6.25 · 1018 · I · n · T = 1.05 · 1014 e
 
s
(10.1)
where 6.25· 1018 is the inverse of the electron charge. It represents the number of
electrons per second for a current of 1 Ampere.
The effective electron current on the LINAC target is thus of the order of⇠1014 e /s.
This value varies following the energy and technical characteristics of the acceler-
ator, and it is used as a normalization factor for the simulation results (expressed per
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TABLE 10.1: Summary table of the Varian LINAC head components.
Head components Distance from Materials Approximative
the target [cm] shapes
Target source 0.0 Tungsten two coaxial
and Copper cylinders
Primary upper surface: 1.6 Tungsten truncated
collimator lower surface: 7.8 hollow cone
Flattening 12.5 Iron and inverted
filter Tantalum cone
Upper secondary upper surface: 28.0 Tungsten pair of
collimator lower surface: 35.8 parallelepipeds
Lower secondary upper surface: 48.2 Tungsten pair of
collimator lower surface: 53.5 parallelepipeds
FIGURE 10.2: Representation of the Varian 2300 LINAC head simu-
lated by MCNP4B-GN code. The target (made up by tungsten and
copper), flattening filter (iron and tantalum), primary and secondary
collimators (tungsten), are represented. Section on plane y = 0. The
origin of the reference system is placed in the centre of target and the
z-axis is directed downward, along the isocenter line.
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TABLE 10.2: Beam parameters for the 18 MV Varian 2300CD LINAC.
Characteristics of the electron beam impinging on the target.
Technical characteristics Values
Maximum energy 18 MeV
Effective pulse duration, T 2.4 µs
Electron current, I 35 mA
Repetition rate, n 200 Hz
(frequency electron pulse)
Beam power 264 W
a single source electron): the higher is the number of electrons striking on the target,
the higher is the number of X-rays produced by Bremsstrahlung and, consequently,
the amount of neutrons produced by the GDR reaction.
The Torino anthropomorphic phantom
The anthropomorphic phantom was implemented in the simulation input file at 96
cm from the origin of reference system (the LINAC target); the secondary collima-
tors were opened in order to make a 10 cm ⇥ 10 cm square at isocentre. The photon
beam was centered on the gonads position at 4 cm depth in phantom.
The new organs coordinates referred to the simulation reference system (Figure 10.3)
are reported in Table 10.3.
The cavities in correspondence of organs were simulated with spheres, having 1 cm
radius and centre in the position reported in Table 10.3. The chemical composition
of the corresponding tissue/organ, tabulated in the ICRU 44 and reported in Table
10.4, was also inserted.
FIGURE 10.3: Reference system for determining organs position. The
beam is centered on the gonads position.
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TABLE 10.3: Organs positions inside the Torino anthropomorphic
phantom, following the simulation reference system.
Organs x y z
[cm] [cm] [cm]
Gonads 0.0 0 98.0
Bladder 0.0 7.2 102.0
Liver -5.0 26.5 102.0
Esophagus 0.0 29.7 102.0
Right Colon -7.5 16.7 106.1
Left Colon 6.5 16.7 106.1
Stomach 2.0 25.0 106.1
Right Lung -6.0 32.9 106.1
Left Lung 6.0 31.0 106.1
Thyroid 0.0 52.5 106.1
Brain 0.0 67.3 106.1
Spleen 9.5 16.0 110.3
Left Kidney 4.0 17.8 112.0
Right KIdney -5.5 19.0 112.0
Low Column 0.0 18.8 112.0
Half-height Column 0.0 34.0 112.0
TABLE 10.4: Elemental composition (in percentage mass) of organs
according to ICRU 44.
Organs H C N O Density
[w%] [w%] [w%] [w%] [g/cm3]
Gonads 10.6 9.9 2.0 76.6 1.04
Bladder 10.2 14.3 3.4 71.0 1.05
Liver 10.2 13.9 3.0 71.6 1.06
Esophagus 10.2 14.3 3.4 71.0 1.05
Colon 10.6 11.5 2.2 71.5 1.03
Stomach 10.2 14.3 3.4 71.0 1.05
Lung 10.3 10.5 3.1 74.9 1.05
Thyroid 10.4 11.9 2.4 74.5 1.05
Brain 10.7 14.5 2.2 71.2 1.04
Spleen 10.3 11.3 3.2 74.1 1.06
Kidney 10.3 13.2 3.0 72.4 1.05
Bone 3.4 15.5 4.2 43.5 1.92
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10.2 Results
All the results are normalized to 1 Gy of photon dose absorbed by the phantom at
build-up.
Results can be summarized as follows:
• simulation of the neutron spectrum provided by the LINAC at the patient
plane
• simulation of the neutron spectrum in depth in tissue
• simulation of the neutron fluence at organs when the photon beam is centered
in the gonads position
• comparison between simulation and experimental results
• calculation of the additional BNCT equivalent dose at different depth in tissue
Neutron spectrum at patient plane
The typical photoneutron energy spectrum simulated by using the 18 MV VARIAN
2300CD LINAC at patient plane in standard condition during a single-field radio-
therapy treatment is shown in Figure 10.4.
FIGURE 10.4: Neutron fluence per Gy at the patient plane during a
direct single-field radiotherapy treatment. 18 MV VARIAN 2300CD
LINAC. Irradiation conditions: SSD=96 cm; photon field= (10 ⇥ 10)
cm2 at isocenter. Simulation result carried out by the MCNP4B-GN
code. The mean neutron energy is around 1 MeV, in the fast energy
range.
As expected, the mean neutron energy ranges between 700 keV and 1 MeV [37],
in the fast neutron energy range. The dominant energy peak centered around 1
MeV is due to the evaporative mechanism, in which the neutron angular emission
is isotropic, and the energy distribution follows the Maxwellian curve. Moreover, a
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peak can be observed for energies higher than 3 MeV due to direct-reaction neutron
knockout component: in this case the angular distribution is anisotropic, f(q) = a +
b(sinq)2, and the energy distribution is given by the difference between the photon
energy and the binding energy, En = Eg- Eb (see paragraph 8.1.1).
Neutron spectrum in depth in tissue
The photoneutron energy spectrum inside the phantom at isocentre, at 4 cm depth in
tissue, is shown in Figure 10.5: an intense thermal neutron peak of about 1.55 ⇥ 107
cm 2 Gy 1 arises in the lower energy range (between 0.001 eV and 0.4 eV), inside
the treatment zone, due to fast neutrons moderation in tissue.
Moreover, it was simulated how the neutron fluence changes at different depth in
tissue (Figure 10.6): the relative importance of thermal and fast neutron components
change with depth in phantom. Going deeper in tissue, fast neutron component is
thermalized, while thermal component is then absorbed. By considering the ratio
between the thermal and fast neutron component at each depth in phantom, with-
out losing the thermal component, the most favourable depth where more thermal
neutrons are present is between 4-5 cm.
FIGURE 10.5: Neutron fluence per Gy at 4 cm depth in tissue during
a direct single-field radiotherapy treatment. 18 MV VARIAN 2300CD
LINAC. Irradiation conditions: SSD=96 cm; photon field= (10 ⇥ 10)
cm2 at isocenter; isocenter at 4 cm depth in tissue. Simulation result
carried out by the MCNP4B-GN code. The fast neutron component is
thermalized and an intense thermal peak of ⇠ 107 cm 2 Gy 1 arises
in the lower energy range.
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(A) Neutron spectrum at different depth in tissue.
(B) Neutron fluence per Gy at different depth in tissue.
FIGURE 10.6: Neutron spectrum (A) and neutron fluence per Gy (B)
at different depth in tissue, simulated by the MCNP4B-GN code. Ir-
radiation conditions: 18 MV VARIAN 2300 CD LINAC; SSD=96 cm;
photon field= (10 ⇥ 10) cm2 at isocenter. The relative importance of
thermal and fast neutron components change with the depth in tis-
sue.
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Neutron equivalent dose at organs
To study the neutron equivalent dose at organs, the following inputs were imple-
mented in the simulation file:
- fluence-to-dose conversion coefficients, tabulated in the ICRP 116 [40]. (Their
trend as a function of energy is shown in Figure 10.7).
- radiation and tissue/organweighting factors, wR andwT respectively (see par.
2.3.2).
In Figure 10.8A is reported the neutron fluence per Gy in organs for the thermal (neu-
trons with energies up to 0.4 eV) and fast (neutrons with energies above 100 keV)
components; while, in Figure 10.8B the corresponding calculated neutron equiva-
lent dose for the thermal component. In this way it was also possible to make a com-
parison with experimental measurements carried out with thermal neutron bubble
dosimeters BDT, keeping the same the irradiation set-up conditions.
FIGURE 10.7: Fluence to dose conversion coefficients trend as a func-
tion of energy, for different types of radiation [40]. Looking at the
curve corresponding to neutrons, for thermal energies the neutron
curve is quite constant: the fluence to dose conversion coefficient is
about 10 pSv·cm2.
The additional BNCT equivalent dose
To evaluate the additional dose due to BNCT it is necessary to take into account the
various physical dose components, arising from neutrons and gamma interactions
with biological tissues and 10B captured by cells.
As described in section 5.2.1, the total physical dose consists of the gamma dose
(Dg), due to gamma of 2.2MeV from thermal neutron capture reactions on hydrogen
in tissue; the fast neutron dose or hydrogen dose (DH), due to recoil protons from
fast neutron reactions in tissue; the thermal neutron dose or nitrogen dose (DN),
from thermal neutron reactions by nitrogen nuclei, and the boron dose (DB), due to
the neutron capture reactions by 10B that absorbs a thermal neutron.
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(A) Neutron fluence per Gy components at organs for thermal
and fast components. MCNP4B-GN simulation results. Neu-
tron fluence decreases moving away from gonads position and
going deeper in phantom.
(B) Thermal neutron equivalent dose at organs. Compari-
son between BDT measurement and MCNP4B-GN simula-
tion results. Accuracy BDT: 20%. Considering neutron ab-
sorption in depth in tissue, neutron dose distribution is uni-
form at organs. The peak in the irradiation zone is also due
to neutrons directly produced in human body.
FIGURE 10.8: Neutron fluence per Gy in organs (A) and thermal
neutron equivalent dose at organs (B). Irradiation conditions: 18 MV
VARIAN 2300 CD LINAC; SSD=96 cm; photon field= (10⇥ 10) cm2 at
isocenter; isocenter at 4 cm depth in phantom; photon beam centered
in gonads position.
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Remember that, in order to compare the BNCT dose with the fractionated absorbed
dose in photon radiotherapy, the physical dose needs to be converted to biological
dose multiplied by their relative biological effectiveness: the BNCT dose is so mea-
sured in Gy-eq.
All the dose components were calculated by integrals such those described in sec-
tion 5.2.2, considering a thermal neutron total fluence in treatment zone of 1.55 ⇥
107 cm 2 per Gy and a typical healthy-to-tumour tissue 10B concentration ratio of
1:3, with a blood boron concentration of 11 parts per million (ppm) and 30 ppm. By
using these parameters and considering the phantom exposure as in Fig. 10.1, the
BNCT equivalent dose profiles in depth in tissue and its physical dose components
are shown in Figure 10.9, by using the CBE factors of 3.8 in tumour tissues and 1.3
in healthy ones in absence of more accurate values (see section 5.2.1, [52]).
The additional BNCT dose delivered for 1 Gy of photon absorbed dose at 4 cm depth
in phantom, where the treatment target is, is about 1.5 mGy-eq/Gy.
FIGURE 10.9: BNCT equivalent dose profiles in depth in tissue and
its different physical dose components calculated for a thermal neu-
tron fluence of 1.55 ⇥ 107 cm 2 Gy 1 and a healthy-to-tumour tissue
10B concentration ratio of 1:3, with a blood boron concentration of 11
parts per million (ppm) and 30 ppm. MCNP4B-GN simulation re-
sults. It can be observed that the total BNCT dose to tumour tissue,
red line, is mainly due to the boron dose to tumour tissue, blue line.
The total dose to healthy tissue, green line, is mainly due to the fast
neutron component, yellow line, always present during a radiother-
apy treatment; the boron-10 carrier perfusion, violet curve, is negligi-
ible, it does not affect healthy tissue.
In a conventional 70 Gy radiotherapy treatment, the BNCT additional dose is thus
about 0.11 Gy-eq. This value depends on the LINAC characteristics and energy, from
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the collimation system, and from different radiotherapy treatment protocols. This
contribution could considerably increase when the improvement in photon beam
collimation requires a longer time to deliver a certain dose to target volume and also
an accurate evaluation of the LINAC output factor (OF), (par. 4.5.2). As a matter of
fact, a greater number of Monitor Unit (MU), linked to OF, corresponds to a major
neutron flux. For example, during a 70 Gy IMRT radiotherapy treatment (1815 MU
with respect to 100 MU for traditional radiotherapy treatment), patients could un-
dergo an additional BNCT dose component, localized inside tumour cells, of about
3 Gy-eq (i.e. 4% of the therapeutic X-rays dose). This value, calculated by Monte
Carlo simulations, takes into account the total BNCT dose to tumour tissue. This ad-
ditional dose could thus improve radiotherapy, acting as a localized radio-sensitizer.
10.3 Conclusions
In this part of the research work, the possibility to perform a treatment by coupling
conventional high-energy radiotherapy with an additional dose contribution from
thermal neutrons is investigated.
A patient undergoing a conventional radiotherapy treatment is always affected by
an extra unaccounted neutron dose, which presents an intense thermal neutron field
(>107 cm 2 Gy 1 ) localized in the tumour region. If a boron-10 enriched compound
is previously administered to the patient, if the ratio 10B in cancer cells compared to
10B concentration in healthy tissues is sufficiently high and the carrier is uniformly
distributed in cancer cells, this neutron component could produce a localized BNCT
effect with a localized therapeutic dose enhancement, following tumour character-
istics.
This application is a preliminary study of the possibility to use parasitic neutrons
for the enhancement of radiotherapy treatments. In routine photon treatments the
dose is usually delivered in many fractions, so the clinical application at present
seems to be not possible in practice. However, it could be of interest in the future
because of the new trend in radiotherapy, consisting of dose escalation and in dose
hypo-fractioning, i.e. using a very high MU number per Gy (until 2000 MU/Gy)
administering the total therapeutic dose, and consequently the 10B-carrier, in only
few sessions.
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PART 3:
Development of a compact neutron
photo-converter-moderator
The research work is part of the e-LiBANS project. The acronym e-LIBANS stands
for "electron-LINAC Based Actively monitored Neutron Sources". The idea is to
produce neutrons via photonuclear (g,n) reaction and then to moderate them in a
dedicated assembly: the photoconverter [105].
The e-LiBANS project profits of knowledge and experience from previous projects,
first of all, the PhoNeS project [106], whose aim was the developing of a portable
photoneutron source made by a photoconverter suitable to be applied to medical
LINACs for studies on boron neutron capture therapy.
A selection of suitable materials was made on the basis of a cross section analysis
and a radiation protection study, avoiding, for example, the production of radioac-
tive materials [107].
Unlike the e-LiBANS and PhoNeS projects, in this work a compact assembly of the
photoconverter was developed. The intent was to perform a combined treatment, by
coupling the radiotherapy with an additional dose contribution from thermal neu-
trons, and not to produce a pure thermal or epithermal neutron field inside a cavity.
This third and last part of the research work was performed in Trieste, at Maggiore
Hospital. The Elekta Synergy Agility LINAC was used in photon mode with 15
MV accelerating potential, coupled with the photoconverter and a simplified paral-
lelepiped polyethylene phantom.
11.1 Performance of the neutron photo-converter-moderator
assembly
A neutron photo-converter-moderator set-up, with an overall compact size [(20⇥ 20
⇥ 24) cm3], was designed and assembled in order to improve the thermal neutron
field in the treatment region, without compromising the therapeutic photon beam.
This section shows measurements for assessing the photoconverter performance.
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11.1.1 Materials and Methods
The photoconverter geometry is shown in Figure 11.1. It is made up by a 10 cm thick
[(10 ⇥ 10) cm2 wide] lead neutron target (2 lead blocks of 5 cm thick each), followed
by 4 cm thick polyethylene and by 10 cm thick [(20 ⇥ 20) cm2 wide] of carbon fiber
box filled with heavy water moderator.
Photoneutron cross-section on lead shows a maximum of 600 mb for Eg = 13.5 MeV.
The convolution of this peak with the bremsstrahlung spectrum gives the theoret-
ically expected amount of emitted neutrons, which have an energy spectrum char-
acterized by a most probable energy around 1MeV. Neutrons can then be thermal-
ized mainly through elastic scattering in moderator materials: heavy water was thus
chosen for its high moderation power combined with its low neutron capture cross
section.
FIGURE 11.1: Plot of the photo-converter-moderator assembly. On
the left, a longitudinal view, where the beam direction is bottom-top.
On the right, a 3D view.
Measurements, by using lead blocks of 5 cm and 10 cm thick, were carried out in
order to assess the neutron photo-converter-moderator performance.
Two kinds of measurements, for each configuration, were performed in depth in
phantom:
1. the photon absorbed dose, by using radiochromic films EBT3;
2. the neutron dose equivalent, by using passive bubble dosimeters for thermal
and fast neutrons (BDT and BD-PND respectively).
Measurements were performed by using the Elekta Synergy Agility LINAC in pho-
ton mode, operating at 15 MV accelerating potential, coupled with the photocon-
verter and a simplified parallelepiped polyethylene phantom of (30 ⇥ 30 ⇥ 22) cm3
dimensions.
The phantom is made up by several slabs, and bubble dosimeters and EBT3 ra-
diochromic films were located inside it at different depth.
The irradiation was performed by using an open direct field of (10 ⇥ 10) cm2 at
isocentre; the isocentre was at 10 cm depth in phantom; SSD = 90 cm; LINAC gantry
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= 90 .
Each measurement was repeated three times, in the same location, in the same set-
up conditions and by using the same LINAC.
The experimental set-up is shown in Figure 11.2.
11.1.2 Results
Results are reported in mSv normalized to 100 MU provided by the LINAC. The
typical statistical errors are ⇠ 5-10% due to bubble counting in the range of 300-100
bubbles per dosimeters, respectively.
The photon absorbed dose in depth in phantom
Regarding the in-phantom photon absorbed dose as a function of depth, the depth-
dose curves (PDDs) are reported in Figure 11.3, both for the configuration with-
out the photoconverter and for the photoconverter with 5 cm and 10 cm thick lead
shield.
By calculating the tissue-phantom ratio (TPR), it was possible to know which mega-
voltage photon beam corresponds the found PDDs (see section 3.2.1, eq. 3.5 and
Table 3.1). Both for 5 cm and 10 cm thick lead, the calculated TPR20,10 is about 0.67,
which corresponds to a 6MV photon beam: this is due to the minimum photon cross
section on lead (see Fig. 4.2).
The attenuation factor at build-up was also calculated. The photon beam is attenu-
ated by a factor of ⇠8 between the configuration without the photoconverter assem-
bly and the photoconverter with 5 cm thick lead shield, and by a further factor of⇠9
between the photoconverter with 5 cm and 10 cm thick lead shield.
Moreover, the photon beam profiles were measured checking for the beam deteri-
oration after using the photoconverter. Figure 11.4 shows the photon beam cross
profiles at different depth in phantom for a photon field size of (10 ⇥ 10) cm2 at
isocentre by using the photoncervert with 10 cm thick lead shield. The photon pro-
files are very similar to the ones measured by Dawod et al. [108] for the same field
size and the same megavoltage LINAC. The photon beam is not so spread out with
the photoconverter, it is still well collimated: the photon field is not deteriorated.
By using the photo-converter-moderator assembly, the photon field ismodifiedwith-
out degrading the quality of the therapeutical beam.
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(A) Set-up for the neutron dose
equivalent measurements. Bubble
dosimeters were placed in suitable
holes inside the phantom at 0 cm,
3 cm, 8 cm, 23 cm depth. Two
dosimeters, one for fast and one
for thermal neutrons, were located
in each position.
(B) Set-up for the photon absorbed
dose measurements. Gafchromic
EBT3 films were placed between
the phantom slabs at 2 cm, 4 cm,
and then every 3 cm up to 22 cm
depth.
FIGURE 11.2: Experimental set-ups for assessing the photo-
converter-moderator performance. 15 MV Elekta Synergy Agility
LINAC; photon field = (10⇥ 10) cm2 at isocentre; SSD = 90 cm; isocen-
tre at 10 cm depth in phantom; LINAC gantry at 90 .
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FIGURE 11.3: Percentage depth dose curves of the photon beam. Con-
figuration without the photoconverter assembly, and with the photo-
converter with 5 cm and 10 cm thick lead. Both for 5 cm and 10 cm
thick lead shield, the calculated TPR20,10 is about 0.67, which corre-
sponds to a 6 MV photon beam [32].
FIGURE 11.4: Photon beam cross profile at different depth in phan-
tom, for a photon field size of (10 ⇥ 10) cm2 at isocentre. Configura-
tion with the photoconverter assembly by using 10 cm thick lead. The
beam profile is not degraded after the photoconverter: it is still well
collimated.
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The neutron dose equivalent in depth in phantom
Regarding the neutron dose equivalent measurements, the fast and thermal neutron
doses were investigated both in absence of the photoconverter and with the photo-
converter with 5 cm and 10 cm thick lead, in front of the phantom and at different
depth.
Figure 11.5 shows the ratio between the thermal and fast neutrons dose equivalent
for each configuration. In general, more thermal neutrons are produced by using the
photoconverter, especially with 10 cm lead thickness at 8 cm depth in phantom.
Moreover, the thermal neutron doses per unit photon dose in each configuration
were calculated and represented in Figure 11.6. Neutrons are absorbed going deeper
in phantom, and thermal neutrons per photon gain a factor of about 3 between 5 cm
and 10 cm thick lead at 3 cm depth, and a factor of about 7 between the configuration
without the photoconverter and the photoconverter with 10 cm thick lead. While,
at 8 cm depth in phantom, these values increase due to neutron thermalization and
absorption in tissue.
By the photon and neutron dose measurements, it emerges that the best photo-
converter-moderator assembly is by using a 10 cm thick lead shield. This config-
uration was so used for the next investigations.
FIGURE 11.5: Ratio between thermal neutron dose equivalent and
fast neutron dose equivalent at different depth in phantom. Config-
uration without and with the photoconverter assembly. In general,
more thermal neutrons are present by using the photoconverter as-
sembly, especially at 8 cm depth with 10 cm thick lead.
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FIGURE 11.6: Thermal neutron dose equivalent per unit photon ab-
sorbed dose at 3 cm and 8 cm depth in phantom.
11.2 The angular neutron dose distribution
An angular neutron dose distribution measurements around the photo-converter-
moderator was carried out. For this purpose, a suitable structure to allocate upon
the photoconverter was designed and assembled.
11.2.1 Materials and Methods
The structure, in alveolar polycarbonate, is made up by several holes at different
q angles suitable to host neutron bubble detectors. The structure can also rotate
around the photoconverter along the f direction, making thus possible the angular
distribution. Its dimensions perfectly suit the photoconverter geometry.
A 3D sketch of the support is represented in Figure 11.7.
Measurements were carried out by using bubble detectors for fast and thermal neu-
trons in the same experimental conditions of the previous ones: 15 MV Elekta Syn-
ergy Agility LINAC, single-open direct field of (10 ⇥ 10) cm2 at isocentre, SSD = 90
cm, LINAC gantry = 90 , and by using the photoconverter in the configuration of 10
cm thick lead shield.
The angle (0 , 0 ) of the alveolar polycarbonate structure is set in correspondence of
the isocentre, at 100 cm from the source, centred with the beam direction axis.
Measurementswere performedwith andwithout the photoconverter assembly, com-
paring the two configurations. Figure 11.8 shows the experimental set-up.
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FIGURE 11.7: 3-D representation of the alveolar polycarbonate struc-
ture upon the photoconverter. Plot made bymeans of the open source
software SketchUp [92], a computer graphics application for 3D mod-
eling. The structure has got a pair of holes every 15 , from 0  to 90 
suitable to host two bubble detectors (one for fast and one for thermal
neutrons) per each angle.
11.2.2 Results
As usual, results are reported inmSv normalized to 100MUprovided by the LINAC.
The typical statistical errors are ⇠ 5-10% due to bubble counting in the range of 300-
100 bubbles per dosimeters, respectively.
Figure 11.9 shows the angular neutron dose equivalent distribution around the pho-
toconverter, at different q and f angles: 0 , 30 , 60 , 90 , both for thermal and fast
neutrons. In general, neutrons are spread out around the photoconverter, without
any preferential direction. For this reason, a specific direction was better investi-
gated also without the photoconverter: the fast neutron component was investi-
gated at different q angles maintaining fixed the f angle at 0  (see Figure 11.10). In
the forward direction (0 , 0 ), the most relevant one for the therapy, fast neutrons are
reduced by over a factor 16; while, in the remaining angles no noticeable differences
with respect to the configuration without the photoconverter are observed.
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FIGURE 11.8: Experimental set-up for the angular neutron dose dis-
tribution. Configuration with the photoconverter assembly with 10
cm thick lead shield. The alveolar polycarbonate structure can rotate
around the photoconverter along the f direction, and bubble dosime-
ters are located in suitable holes at different q angles. In the picture,
the detectors are placed at (0 , 30 ) and (30 , 30 ).
FIGURE 11.9: Graphical representation of the angular neutron doses
distribution around the photoconverter. Values are reported in
mSv/100 MU. The blue data correspond to the fast neutron dose
equivalent measures, while the red ones to the thermal neutrons. In
general, neutrons are spread out around the photoconverter, without
any preferential direction.
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FIGURE 11.10: Fast neutrons dose equivalent angular distribution.
Comparison between the configuration with and without the photo-
converter assembly at f = 0 . In the forward direction (0 , 0 ) fast
neutrons are reduced by over a factor 16; while, in the remaining an-
gles no noticeable differences with respect to the configuration with-
out the photoconverter are observed.
11.3 GEANT4 simulations
Monte Carlo simulations, by using the GEANT4 code (release 10.4), were performed
in order to test the toolkit performance in simulating the photoneutron production
in medical LINACs.
The 15MV Elekta Synergy Agility LINAC, the photoconverter with 10 cm thick lead,
and the simplified polyethylene phantom were simulated in the set-up conditions
previously described (see section 11.1.1).
The physics list used was QGSP-BERT-HP, the recommended one in simulating ra-
diotherapy treatments [109].
A cut in energy was also done to speed up the simulation runs: all photons with
energies lower than 7 MeV were cut. This choice was done considering the pho-
tonuclear reaction threshold energy on lead and tungsten nuclei.
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11.3.1 Simulation of the experimental set-up
This paragraph describes the data entered into the simulation file for characterizing
the linear accelerator, the photoconverter and the simplified phantom.
The 15 MV Elekta Synergy Agility LINAC
The included accelerator head components in the simulation file are summarized in
Table 11.1, reporting their materials and shapes in an approximative way due to a
non-disclosure agreement for the Synergy Agility LINAC technical manual. For this
reason, components dimensions, their distance from the target, and beam parame-
ters, such as the electron current, the pulse duration, the frequency, etc., could be
neither reported.
The origin of the reference system was placed in correspondence of the LINAC tar-
get, with the z-axis pointing along the isocenter line.
TABLE 11.1: Summary table of the Elekta Synergy Agility LINAC
head components.
Head components Approximative Approximative shapes
materials
Target source Tungsten pair of
and Copper parallelepipeds
Primary Tungsten truncated hollow cone
collimator
Flattering Copper alloy inverted cone
filter
Upper secondary Iron alloy pair of
collimator parallelepipeds
Lower secondary Iron alloy pair of
collimator parallelepipeds
MLC Tungsten set of parallelepipeds
Monitor chamber Kapton six cylinders
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The photo-converter-moderator
The photoconverter was placed at 61 cm from the LINAC target, following exactly
the dimensions, shapes, and materials of the real one (see Figure 11.1).
The simplified phantom
The polyethylene simplified phantom was implemented in the simulation input file
at 90 cm from the origin of the reference system (the LINAC target), and the sec-
ondary collimators were opened in order to make a 10 cm ⇥ 10 cm square at isocen-
tre, at 10 cm depth in phantom.
The simplified phantom was simulated as a parallelepiped of (30 ⇥ 30 ⇥ 22) cm3
dimensions, divided in 220 slabs of 1 mm thick each in order to obtain a continuous
neutron dose distribution as a function of the depth in phantom.
The total simulated structure (LINAC + photoconverter + phantom) is shown in
Figure 11.11
FIGURE 11.11: Simulation plot of the experimental set-up. It’s possi-
ble to see the linac head, the photoconverter assembly and the sim-
plified parallelepiped phantom.
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11.3.2 Results
Results can be summarized as follows:
1. Simulation of the X-ray energy spectrum provided by the LINAC.
2. Simulation of the neutron equivalent dose in depth in tissue (to be compared
with experimental results).
1. Simulation of the X-ray energy spectrum
Aiming to validate the simulation code, the first step was studying the photon beam
spectrum provided by the LINAC in order to:
• make a qualitative comparison between the simulated 15 MV X-ray spectrum
with the ones present in literature;
• calculate the ratio between photons with energies higher, ghigh, and lower,
glow, than the cut in energy (to be used to reconstruct the MU provided by
the LINAC);
• verify the incident photon beam symmetry.
Several runs were launched. The obtained spectra follow the typical trend of a
bremsstrahlung spectrum, providing the first test on the simulation reliability. In
Figure 11.12 one of the obtained X-ray spectra is shown.
FIGURE 11.12: X-ray energy spectrum provided by the 15 MV Elekta
Synergy Agility LINAC. The spectrum shows a maximum energy of
15 MeV and a peak at 0.6 MeV as espected [110].
Starting from the energy spectra, it was possible to calculate the ratio between pho-
tons with energies higher than the cut and the total produced photons as:
R =
ghigh
gtot
(11.1)
A weighted mean was done over all the runs, by assuming that the counts follow a
Poisson distribution1. The resulting R value was 0.113037.
1If the number of counts is N, the statistical error on the counts will be
p
N
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The incident photon beam symmetry was then evaluated. Figure 11.13 shows the
spatial distribution of the photon beam. The symmetry was confirmed: the beam
uniformity is within 0.6 s.
2. Simulation of the neutron dose equivalent in depth in phantom and compari-
son with experimental results
The neutron fluence in depth in phantom was evaluated both for thermal and fast
neutrons. Thanks to fluence-to-dose conversion coefficients trend reported in Figure
10.7 (ICRP 116), it was possible to calculate the neutron dose equivalent.
Aiming to compare simulation results with the experimental ones, the number of
generated photons by the simulation have to be converted in MU given experimen-
tally by the accelerator.
Remembering the relationship between monitor units and absorbed dose, 1 MU = 1
cGy2, and the fluence-to-dose conversion coefficients trend for photons, it was found
that
1MU = 2 · 109g/cm2 (11.2)
for photon energies of the order of MeV.
The run output gives the number of photons ghigh, therefore:
gtot/cm2 =
ghigh/cm2
R
(11.3)
Consequently, the total number of monitor units given during a run simulation is:
MUtot =
1MU · gtot/cm2
2 · 109g/cm2 (11.4)
where gtot is the total number of simulated photons, R is the ratio between ghigh and
gtot, and MUtot are the total simulated monitor units.
Figure 11.14 shows the simulated neutron dose equivalent as a function of depth
in tissue for the thermal and fast components, while Figure 11.15 the comparison
with experimental data.
A better correspondence between experimental and simulation data is present for
the thermal dose with respect to the fast one (smax = 0.8 and smax = 2.3, respectively).
This is due to the higher statistic available for the thermal component in the simula-
tion: the ratio of the number of neutrons entering in the phantom between thermal
neutrons and fast neutrons is 3.01 ± 0.04 nth/n f ast. As wanted, the photoconverter
moderates fast neutrons.
2at build-up for a field of 10 cm x 10 cm square and SSD= 100 cm
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(A) Photon beam spatial distribution. 3D view.
(B) Photon beam spatial distribution. 2D view. To evaluate the
beam symmetry, the image was divided in 4 equal regions.
FIGURE 11.13: Spatial distribution of the X-ray beam on the photo-
converter lead block. Geant4 calculations. The beam uniformity is
within 0.6 s.
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(A) Thermal neutron dose equivalent.
(B) Fast neutron dose equivalent.
FIGURE 11.14: Thermal and Fast neutron dose equivalent in depth in
phantom by using the photonconverter assembly. Simulation results.
The black dots represents the experimental values.
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(A) Thermal neutron dose equivalent.
(B) Fast neutron dose equivalent.
FIGURE 11.15: Thermal and fast neutron dose equivalent in depth in
tissue, by using the photoconverter assembly. Comparison between
experimental and simulation results.
128 Chapter 11. PART 3:Development of a compact neutron photo-converter-moderator
11.4 Summary
A compact photo-converter-moderator assembly [(20 ⇥ 20 ⇥ 24)] cm3 was devel-
oped: it modifies the photon field and increases the neutron photoproduction, ab-
sorbing and thermalizing fast neutrons.
Measurements were performed by using the 15 MV Elekta LINAC in photon mode,
coupled with the photoconverter and a simplified polyethylene phantom of (30 ⇥
30 ⇥ 22) cm3 dimensions. The photon dose and the neutron dose equivalent at dif-
ferent depths in phantom were measured by using radiochromic films and neutron
bubble detectors, respectively. Results show that the photon field is modified: a 15
MV photon field produces a dose profile very similar to that would be produced by
a 6 MV field in absence of the photoconverter assembly. Moreover, the photon beam
profile is not so compromised by the scattering of the photons on lead, the beam is
still collimated.
As far as the neutron field is concerned, neutrons are still spread around the pho-
toconverter, without any preferential direction. No appreciable differences with re-
spect to the configuration without the photoconverter are present, except in the di-
rection of the incident photon beam, where fast neutrons are reduced of a factor of 16.
Moreover, in phantom measurements show that more thermal neutrons are present
by using the photoconverter assembly; thermal neutrons per photon increase of a
factor 3 to 12 according to the depth in phantom and to different photoconverter ge-
ometries.
GEANT4 simulations were performed to verify the toolkit performance in simulat-
ing photoneutron production in medical LINACs, by comparing also the obtained
results with the experimental ones. Simulation and experimental data are in agree-
ment: the GEANT4 simulation is completely validated.
Moreover, from the simulation it emerges that a greater amount of thermal neutrons
are present after the photoconverter with respect to the fast component (nth/n f ast '
3).
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Conclusions
This work investigated the possibility of using the parasitic neutron field, produced
by high-energy radiotherapy LINACs, to deliver an additional BNCT therapeutic
dose to the patient under treatment. The following steps illustrate the idea:
- Patients udergoing radiotherapy with high-energy electron LINACs are ex-
posed to an intense photoneutron field;
- The patient is a very efficient moderator, thus the neutron field in the internal
organs and tissues has in important thermal fraction;
- If a tumour seeker boron-10 drug is subministered to the patient, an additional
BNCT treatment can be superposed to the conventional radiotherapy;
- This radiosensitization effect could be increased by modifying the treatment
field by using a specifically designed neutron photo-converter-moderator as-
sembly.
The idea was investigated experimentally, by using radiochromic films and super-
heated bubble dosimeters, and with Monte Carlo simulations.
The study consists in three part:
1. Measurements of the parasitic neutron field in organs during single-field ra-
diotherapy with different energies.
The patient wasmimicked by a simplified phantom, suited for dosimetric mea-
surements. For a 10 cm ⇥ 10 cm square photon field at isocentre (at 7 cm
depth in phantom) with accelerating potentials 6 MV, 10 MV and 15 MV, the
measured neutron dose equivalent in phantom was 0.07 mGy/Gy (neutron
dose equivalent / photon absorbed dose at isocentre), 0.99 mGy/Gy and 2.22
mGy/Gy, respectively.
2. Simulation of the potential BNCT dose contribution during single-field radio-
therapy.
For a 10 cm ⇥ 10 cm square photon field at isocentre (at 4 cm depth in phan-
tom) with 18 MV accelerating potential, Monte Carlo simulations quantified
the thermal neutron field in the treatment zone in 1.55 ⇥ 107 cm 2 Gy 1. As-
suming a BNCT-standard 10B concentration in tumour tissue, the calculated
additional BNCT dose at 4 cm depth in phantom would be 1.5 mGy-eq/Gy.
This value depends on the LINAC characteristics and energy, from the collima-
tion system, and from different radiotherapy treatment protocols, reaching 43
mGy-eq/Gy for an IMRT treatment (corresponding to 4% of the 70 Gy photon
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dose). The thermal neutron component could thus produce a localized BNCT
effect, with a localized dose enhancement, following tumour characteristics.
3. Development of a compact neutron photo-converter-moderator assembly to
improve the thermal neutron field in the treatment region without compro-
mising the therapeutic photon field.
When a specifically designed compact neutron photo-converter-moderator as-
sembly is applied to the LINAC to enhance the thermal neutron field, the pho-
ton field is modified. Particularly, a 15MV photon field produces a dose profile
very similar to that would be produced by a 6MV field in absence of the photo-
converter-moderator assembly, without compromising the therapeutic photon
beam. As far as the thermal neutron field is concerned, in general more ther-
mal neutrons are present with the photoconverter, and thermal neutrons per
photon increase of a factor 3 to12 according to its different geometries and to
the depth in phantom. By contrast, the photo-converter-moderator assembly
was found to reduce fast neutrons of a factor 16 in the direction of the incident
beam.
Although this work is only preliminary, the quantitative estimations suggest that:
- A patient undergoing a radiotherapy treatment is always affected by a
parasitic thermal neutron field in the treatment region, of variable intensity
depending both on the used collimation techniques and on the performed type
of treatment.
- The thermal neutron component could be exploited to produce localized addi-
tional therapeutic doses if the 10B-carrier was administered to the patient.
- This radiosensitization effect could be increased by modifying the treatment
field by using the specifically designed neutron photo-converter-moderator as-
sembly.
This work is a feasibility study of the possibility to employ the neutron contami-
nation in radiotherapy for the enhancement of the treatment effectiveness, it is not
a clinical application. However, the methodology here proposed could be of inter-
est for clinical applications in the future, considering both the ongoing research on
newer boron delivery agents, able to be more selective in tumour cell targeting with
minimal normal tissue toxicity, and the new trend in radiotherapy consisting of dose
escalation and dose hypofractionation.
The next work steps will be:
- to evaluate how the photoconverter assembly changes the total BNCT dose in
healthy and tumour tissues, having a higher fraction of thermal neutrons;
- the development of a holder for the photoconverter, to be fixed to the LINAC
head, to perform real treatments with multiple fields.
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Appendix A
Superheated Drop (Bubble)
detectors: Features provided by BTI
In this appendix, graphs provided by the manufacturer BTI about the performance
of BD-PND bubble detectors are reported.
FIGURE A.1: Temperature response of BD-PND dosimeters.
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FIGURE A.2: Dynamic range for BD-PND dosimeter -
with recompression.
FIGURE A.3: Dynamic range for BD-PND dosimeter -
without recompression between measurements.
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FIGURE A.4: Energy response of BD-PND dosimeters.
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New RGB algorithm for dose
measurements with EBT3 films
tested in 15 MV X-ray beams
Recently submitted in: Physics and Imaging in Radiation Oncology
number ID: PHIRO_2018_28
The work investigates the dose-response of EBT3 films in 15 MV X-ray beams up to high-
dose levels, 90Gy, with a fit function able to provide more precise dose measurements in
the whole range by weighing the three RGB (Red-Green-Blue) color channels together,
comparing also results with two different scanners. A consistent dose response was ob-
served, no deviation from the known response curves is shown, only some difference in
the recorded pixel values was detected using different scanners. The absorbed dose of
unknown films was found to be within 1-1.5% of the true absorbed dose, with a precision
of about 2.5%.
Key-words:
Gafchromic EBT3 film; Radiochromic film; Dosimetry; Dose response curve; Calibration
function; Scanner dependence
Introduction
Radiochromic films have become an important instrument in medical applications
both to verify and to measure two-dimensional dose distributions in external beam
radiotherapy, radiosurgery and brachytherapy [1], [2]. Themost popular radiochromic
films are the Gafchromic EBT films and, at the moment, the third generation of the
film (EBT3), released in late 2011, is available for the radiotherapy community. Sev-
eral studies have been published about the film properties, such as the scanning ori-
entation dependence [3], [4], the energy dependence [5], the film homogeneity [6],
and its use in different applications (IMRT [7], stereotactic radiotherapy [8], electron
beam therapy [9], in vivo dosimetry [10], IORT [11]). However, there is a little in-
formation about both the film response to high dose levels and calibration functions
usable in an extended dose range. Only few recent works deal with these aspects
([12], [13, [14]), but using greyscale images or not all the three RGB (Red, Green,
Blue) color channels together to give the absorbed dose, and/or using a small exper-
imental data set to test the calibration functions. For this reason, this work aims to
studying the dose response of Gafchromic EBT3 films in a 6 MV x-ray beam up to
very high dose levels, 90 Gy, above the recommended 40 Gy value, with a modified
calibration function able to provide more precise dose measurements by weighting
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the three RGB scanned image colors together. Moreover, a comparison between two
different flatbed scanners was performed.
Materials and Methods
Measurements were carried out exposing the Gafchromic EBT3 dosimetry films to a
15 MV Elekta Synergy Agility LINAC x-ray beam.
The medical LINAC calibration output was carried out by following the Interna-
tional Code of Practice for Dosimetry IAEA TRS398.
Gafchromic EBT3 film
Films used are Gafchromic EBT3, lot #03171501, by Ashland Advance Materials Inc.
(Wayne, NJ, USA) [15], and they were handled according to the procedures de-
scribed in the AAPM TG-55 report [16] and in the user guideline provided by the
manufacturer together with the films [17].
The EBT3 is a self-developing film, it doesn’t require post-exposure processing, and
it can be read with commercial flatbed color scanners. The film is tissue equivalent
and water resistant, its dose response ranges from 1 cGy to tens of Gy, and it has got
a high spatial resolution (about 25 µm).
The Gafchromic EBT3 dosimetry film is made up of a single active layer, nominally
of 27 µm thick, placed between two polyester substrates, 120 µm thick each. This
symmetric structure allows to no longer keep track which side is which, eliminating
the film face-dependence during scanning.
The active layer contains the active component, stabilizer, marker dye and other
additives giving to the film its low energy dependence; while the yellow dye de-
creases UV/light sensitivity and enables multi-channel dosimetry. The polyester
substrate, instead, is coated with silica particles to prevent Newton’s ring patterns
in the scanned image.
Irradiation Process
In order to investigate the film performance at high dose levels and to obtain a cal-
ibration curve, 22 film pieces, each of 4⇥4 cm2, were irradiated at different dose
values, from 0.5 to 90 Gy. Each film piece was marked on the upper edge in order to
know its orientation relative to the original 20⇥25 cm2 sheet.
Films were placed in a water equivalent slab phantom (RW3 PTW) of 30⇥30⇥12
cm3 at 1.6 cm depth, in correspondence with the build-up, and irradiated perpen-
dicularly to the radiation beam. The distance from the source to the phantom surface
(SSD) was 100 cm and the field size was 30⇥30 cm2 at isocenter. The RW3 phantom
was centered under the LINAC gantry thanks to its laser alignment system.
The film homogeneity was also investigated as a part of the calibration process, ex-
posing 4 film pieces, each of 4⇥4 cm2, in different positions in the radiation field
prior to irradiation in the same conditions above described.
Readout Process
The exposed films were read two days after the irradiation, to allow the stabiliza-
tion of changes in all the color channels [18], by means of two different commer-
cial flatbed color scanners: the Epson 1680Pro (Scanner A), with a scan window of
22⇥31 cm2 (A4 paper size), and the Epson Expression 10000XL (Scanner B), with a
scan window of 31⇥44 cm2 (A3 paper size).
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Each film piece was read three times with both scanners on the same day, to ensure
the identical condition of temperature and humidity, minimizing the scanner vari-
ability.
The readout process was made according to the manufacturer’s scan guideline [17],
placing the films into the center of the scan area in landscape orientation (a frame
was used to fix the film in a reproducible way), keeping consistent position and ori-
entation in each scan to avoid the lateral scan effect.
RGB-positive images were collected in 48-bit, measuring the red, green and blue
color components of the light transmitted by the film at a color depth of 16-bit per
channel with a spatial resolution of 72 dpi, in transmission mode with no color cor-
rection. All the scanner parameters have been kept fixed during all the film acquisi-
tions.
Analysis Process
The digitized images were saved in tagged image file format (TIFF) and analyzed
by means of the software ImageJ 1.50i [19], by splitting the film image data into red,
green and blue color channels. For each scanned image and color channel, a small
region of interest (ROI) at the field centre was selected to obtain the mean pixel
value V and its standard deviation s. Knowing these values and the absorbed dose
D by each film, the dose response curves per each color channel were plotted and
analyzed with the software ROOT [20].
Four different conditions have been taken into account:
• Films read with the Scanner A, in the recommended dose range 0-40 Gy
• Films read with the Scanner A, in the extended dose range 0-90 Gy
• Films read with the Scanner B, in the recommended dose range 0-40 Gy
• Films read with the Scanner B, in the extended dose range 0-90 Gy
The suggested function to fit the dose response curve of the EBT3 film [21] has
been empirically modified, providing more precise dose measurements. The modi-
fied calibration function is represented by:
V(D) =
W0 +W1(D/c)
1+ (D/c)
(B.1)
where V(D) is the pixel value as a function of the absorbed dose D, and W0,W1, c
are the equation parameters to be fitted that depend on the considered color channel.
Moreover,W0 is the pixel value corresponding to D tending to zero (linked, thus, to
the unirradiated film); W1 is the pixel value corresponding to D tending to infinite
(linked to the maximum film dimming); while the parameter c represents the dose
at which the pixel value is half way betweenW0 andW1, [(W0+W1)/2].
The rational formula B.1 be inverted for each of the three RGB colors to provide
three absorbed dose values Dx of an unknown film starting from the film dimming
V, with their associated propagated uncertainty:
Dx = c · W0  VV  W1 (B.2)
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This last expression can be used to give a final more precise dose value in the whole
range, by weighting the three RGB scanned image colors together:
Df =Â
x
Dx/sx2
1/sx2
(B.3)
with its standard deviation:
Df =
s
Â
x
1
1/x2
(B.4)
Results
For each of the four conditions taken into account, the dose response curves per each
color channel were plotted and fitted with the equation B.1, by means of ROOT.
Results are shown in Figure B.1. The flattest curve is linked to the blue channel,
the curve with a steep slope at low doses corresponds to the red channel, while the
curve with a reasonable good response at low, medium, and high doses corresponds
to the green channel.
Once the calibration has been carried out and the fitting parameters W0, W1 and
c, have been evaluated in each condition, the equation B.2 was used to give the
three RGB absorbed dose values Dx. Then, by taking the weighted mean of the
three RGB colors together, the final absorbed dose value Df was calculated with the
equation B.3, giving the absorbed dose of an unknown film. Finally, residuals have
been evaluated by calculating the ratio between the calculated absorbed doses and
the original absorbed doses D.
Both the Df values and residuals as a function of the original absorbed dose D are
reported in Figure B.2 , for the extended dose range 0-90 Gy and for the Scanner B.
Comparable results have been obtained for the Scanner A: for this reason, results
were reported in the text but not shown in graphical representations.
Discussion
As far as the film homogeneity check is concerned, the deviation in all color channels
was less than 1%: no evidence was so found for films inhomogeneity.
Looking at Figure B.1, the estimated fit parameters for the two dose ranges (0-40 Gy
and 0-90 Gy) are in agreement within 2s, except for the parameter W1 in the green
and blue channels in the Scanner A and Scanner B, respectively, within 3s. SinceW1
is linked to the maximum film dimming, the value obtained for the extended dose
range is considered nearer to the true one, and thus the correct value to be taken into
account.
The simple parametric dependence has allowed to estimate the dose response er-
ror: relative errors range 0.4-0.8% for the green and red channels, and 1.0-2.8% for
the blue one. This is due to the blue curve general flatness, giving a higher error
value; while the slope of the other two curves is still pronounced around c, provid-
ing smaller errors.
The modified calibration function fits well in the whole dose range: it’s so usable
both in the recommended dose range values and at higher ones. A consistent dose
response was thus observed in EBT3 films, no deviation from the typical response
curves is shown [17].
However, some difference in the recorded pixel values was detected by using two
different flatbed scanners, mostly in the blue channel, despite films were positioned
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FIGURE B.1: EBT3 DOSE RESPONSE CURVE
for the Epson 1680Pro - Scanner A (upper graphs) and the Epson Ex-
pression 10000XL - Scanner B (bottom graphs).
Images on the left show the film response per each RGB color channel
in the recommended dose range 0-4000 cGy, while the right ones for
the extended dose range, up to 9000 cGy. In the upper right side of
both images, the estimated fit parameters W0, W1, c and the reduced
chi-square 2 values are reported for each of the three color channels.
The upper box shows results for the red channel, the middle one for
the green channel, and the last box for the blue channel.
FIGURE B.2: Calculated weighted absorbed dose Df (on the left) and
residuals for the weighted RGB absorbed dose Df (on the right in
logarithm scale in the x axes) as a function of the true absorbed dose
D. Films irradiated in the extended dose range 0-9000 cGy, and read
with the Epson Expression 10000XL flatbed scanner (Scanner B).
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in exactly the same way. The different responses have to be related to the dissimilar
light source and sensor system of the scanners. It is known that Gafchromic film is
a polarizer, like the mirror system in the scanner, and both influence the same light
ray before it reaches the CCD sensor: the Scanner A and the Scanner B have differ-
ent dimensions (width and height), thus differences in the angle of incidence on the
mirrors can be expected between the scanners, introducing an off-set in the calibra-
tion curve. This problem has been largely discussed in a recent work [22], and here
confirmed.
Regarding results obtained for the inverse of the calibration function, the graph on
the left in Figure B.2 shows the linearity of the calculated absorbed doses Df versus
the real ones for the Scanner B. The reduced chi-square value is 1.40: with 20 degrees-
of-freedom and a p-value equal to 0.05, the null hypothesis can be accepted. Com-
parable results have been obtained for the Scanner A, where the chi-square value is
1.42.
Moreover, looking at residuals in the graph on the right in Figure B.2, data are well
arranged around the reference value 1 by weighting the three RGB colors together,
and both relative errors and the chi-square value are lower than those found consid-
ering channels separately. Also in this case, analogous results have been obtained
analyzing data for the Scanner A.
Starting from the dispersion of residuals it was possible to calculate the film preci-
sion: it was noted that precision level of 2-4% has to be achieved in film dosimetry
[14, 23]. In this work the reached precision level is 2.5%, slightly better than the re-
ported 2.6% for a 6MV photon beam [24] and much better than the 3.7% reached in
other works for the same beam energy [14].
From this work it emerges that the calibration function fits well in the whole dose
range, and its inverse function can be used to give the absorbed dose Df of an un-
known film, within the 1.5% and the 1% accuracy with respect to the true absorbed
dose D for the Scanner A and Scanner B, respectively, by weighting all the three
color channels together.
Notice that other works, such as the recent one by Ref. [12], propose alternative
calibration functions, but often using more complicated expressions not easily to be
handled, inverted and/or suitable for a large dose range like the one here discussed.
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Appendix C
MCNP: Variance reduction
techniques
A lot of variance reduction techniques are available in the MCNP code. They reduce
the needed machine time to get statistically significant results, improving thus the
accuracy and efficiency.
The efficiency of a Monte Carlo calculus depends both on the kind of the wanted
result and on the random walk histories of particles. When a result is requested, for
example a flux in a tally, the code provides a number coming from the reproduction
of a series of particles that statistically give rise to the correct density of N particles
at that point, N(~r, v, t).
Several methods are present to statistically reproduce a correct particle density: the
analog and no-analog techniques. The analog techniques reproduce simply the events
according to their natural probability to occur, by estimating the number of physical
particles that walk a certain path. The no-analog techniques, instead, do not directly
simulate the nature of a particle: the statistical properties of a process can be mod-
ified, and the particle can walk any histories, as long as the correct particle density
N(~r, v, t) is, at the end, calculated. This can be obtained by modifying the statistical
weight of each particle and histories simulated. The statistical weight can be thought
as the number of physical particles corresponding to the simulated particle; there-
fore, the correspondence with the nature of a particle can be recovered by acting on
the particle weight, lost altering the sampling process.
Summarizing, the estimated relative error accompanying any tally result is propor-
tional to 1/
p
N, where N is the number of particle histories, which is proportional to
the computer time T. Since it is often impossible to improve the simulation precision
by increasing the number of histories, other strategies like the tally choices and/or
the sampling choices are employed.
The main techniques to reduce the computer time can be divided into four classes,
meshing more non-analog techniques together:
1. Truncation methods. They speed up calculation by truncating parts of phase
space do not contribute significantly to the solution, e.g., the energy cut-off
and time cut-off.
2. Population control methods. They use particle splitting and Russian roulette
to control the number of samples taken in various regions of phase space. In
important regions, many samples of low weight are tracked; while, in unim-
portant regions, few samples of high weight are tracked. A weight adjustment
is thus made to ensure that the problem solution remains unbiased.
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3. Modified sampling methods. They alter the statistical sampling of a problem
by increasing the number of tallies per particle. For any Monte Carlo event, it
is possible to sample by any arbitrary distribution rather than by the physical
probability, as long as the particle weights are adjusted to compensate. For
example, sampling can be done by distributions that send particles in desired
directions or into other desired regions of phase space, such as time or energy,
or force a desired type of collisions.
4. Partially deterministic methods. They do not use the normal random walk
process but apply deterministic-like techniques, such as the next event estima-
tors used for point detectors.
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